<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2711234558
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LENALIDOMIDE SPC 10 mg Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LENALIDOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14505.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sudair Pharma Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sudair Pharma Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What lenalidomide SPC is</strong><br /><strong>Lenalidomide SPC</strong> capsules contains the active substance &lsquo;lenalidomide&rsquo;. This medicine belongs to a group of medicines which affect how your immune system works.<br /><strong>What lenalidomide SPC is used for</strong><br />Lenalidomide SPC is used in adults for:<br />&bull;&nbsp;&nbsp; &nbsp;Multiple myeloma<br />&bull;&nbsp;&nbsp; &nbsp;Myelodysplastic syndromes (MDS)<br />&bull;&nbsp;&nbsp; &nbsp;Mantle cell lymphoma (MCL)<br />&bull;&nbsp;&nbsp; &nbsp;Follicular lymphoma (FL)<br /><strong>Multiple myeloma</strong><br />Multiple myeloma is a type of cancer which affects a certain kind of white blood cell, called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys.<br />Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a &lsquo;response&rsquo;.</p><p><br /><strong>Newly diagnosed multiple myeloma &ndash; in patients who have had a bone marrow transplant</strong></p><p>lenalidomide SPC is used on its own as maintenance therapy after patients have recovered enough following a bone marrow transplant.<br /><strong>Newly diagnosed multiple myeloma &ndash; in patients who cannot have a bone marrow transplant</strong><br />Lenalidomide SPC is taken with other medicines. These may include:<br />&bull;&nbsp;&nbsp; &nbsp;a chemotherapy medicine called &lsquo;bortezomib&rsquo;<br />&bull;&nbsp;&nbsp; &nbsp;an anti-inflammatory medicine called &lsquo;dexamethasone&rsquo;<br />&bull;&nbsp;&nbsp; &nbsp;a chemotherapy medicine called &lsquo;melphalan&rsquo; and<br />&bull;&nbsp;&nbsp; &nbsp;an immunosuppressant medicine called &lsquo;prednisone&rsquo;.<br />You will take these other medicines at the start of treatment and then continue to take lenalidomide SPC on its own.<br />If you are aged 75 years or older or have moderate to severe kidney problems - your doctor will check you carefully before starting treatment.<br /><u>Multiple myeloma &ndash; in patients who have had treatment before</u><br />Lenalidomide SPC is taken together with an anti-inflammatory medicine called &lsquo;dexamethasone&rsquo;. Lenalidomide SPC can stop the signs and symptoms of multiple myeloma getting worse. It has also been shown to delay multiple myeloma from coming back following treatment.<br /><strong>Myelodysplastic syndromes (MDS)</strong><br />MDS are a collection of many different blood and bone marrow diseases. The blood cells become abnormal and do not function properly. Patients can experience a variety of signs and symptoms including a low red blood cell count (anemia), the need for a blood transfusion, and be at risk of infection.<br />Lenalidomide SPC is used alone to treat adult patients who have been diagnosed with MDS, when all of the following apply:<br />&bull;&nbsp;&nbsp; &nbsp;you need regular blood transfusions to treat low levels of red blood cells (&lsquo;transfusion-dependent anemia&rsquo;)<br />&bull;&nbsp;&nbsp; &nbsp;you have an abnormality of cells in the bone marrow called an &lsquo;isolated deletion 5q cytogenetic abnormality&rsquo;. This means your body does not make enough healthy blood cells<br />&bull;&nbsp;&nbsp; &nbsp;other treatments have been used before, are not suitable or do not work well enough.<br />Lenalidomide SPC can increase the number of healthy red blood cells that the body produces by reducing the number of abnormal cells:<br />&bull;&nbsp;&nbsp; &nbsp;this can reduce the number of blood transfusions needed. It is possible that no transfusions will beneeded.<br />&nbsp;<br /><strong>Mantle cell lymphoma (MCL)</strong><br />MCL is a cancer of part of the immune system (the lymph tissue). It affects a type of white blood cell called &lsquo;B-lymphocytes&rsquo; or B-cells. MCL is a disease where B-cells grow in an uncontrolled way and build up in the lymph tissue, bone marrow or blood.<br />Lenalidomide SPC is used alone to treat adult patients who have previously been treated with other medicines.<br /><strong>Follicular lymphoma (FL)</strong><br />FL is a slow growing cancer that affects the B-lymphocytes. These are a type of white blood cells that help your body fight infection. When you have FL, too many of these B-lymphocytes may collect in your blood, bone marrow, lymph nodes and spleen.<br />Lenalidomide SPC is taken together with another medicine called &lsquo;rituximab&rsquo; for the treatment of adult patients with previously treated follicular lymphoma.<br /><strong>How Lenalidomide SPC works</strong><br />Lenalidomide SPC works by affecting the body&rsquo;s immune system and directly attacking the cancer. It works in a number of different ways:<br />&bull;&nbsp;&nbsp; &nbsp;by stopping the cancer cells developing<br />&bull;&nbsp;&nbsp; &nbsp;by stopping blood vessels growing in the cancer<br />&bull;&nbsp;&nbsp; &nbsp;by stimulating part of the immune system to attack the cancer cells</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must read the package leaflet of all medicinal products to be taken in combination with lenalidomide SPC before starting treatment with lenalidomide SPC.</strong></p><p><strong>Do not take Lenalidomide SPC:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant, think you may be pregnant or are planning to become pregnant, <strong>as Lenalidomide SPC is expected to be harmful to an unborn child </strong>(see section 2, &lsquo;Pregnancy, breast-feeding and contraception&ndash; information for women and men&rsquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are able to become pregnant, unless you follow all the necessary measures to prevent you from becoming pregnant (see section 2, &lsquo;Pregnancy, breast-feeding and contraception &ndash; information for women and men&rsquo;). If you are able to become pregnant, your doctor will record with each prescription that the necessary measures have been taken and provide you with this confirmation.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lenalidomide SPC or any of the other ingredients of this medicine listed in section 6. If you think you may be allergic, ask your doctor for advice.</p><p>If any of these apply to you, do not take lenalidomide SPC. Talk to your doctor if you are not sure.</p><p><strong>Warnings and precautions</strong></p><p><strong>Talk to your doctor, pharmacist or nurse before taking lenalidomide SPC if:</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had blood clots in the past - you have an increased risk of developing blood clots in the veins and arteries during treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any signs of an infection, such as a cough or fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have ever had previous viral infection, particularly hepatitis B infection, varicella zoster, HIV. If you are in doubt, talk to your doctor. Treatment with lenalidomide SPC may cause virus to become active again, in patients who carry the virus, This results in a recurrence of the infection. Your doctor should check whether you have ever had hepatitis B infection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems - your doctor may adjust your dose of lenalidomide SPC</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a heart attack, have ever had a blood clot, or if you smoke, have high blood pressure or high cholesterol levels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had an allergic reaction whilst taking thalidomide (another medicine used to treat multiple myeloma) such as rash, itching, swelling, dizziness or trouble breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have experienced in the past a combination of any of the following symptoms: widespread rash, red skin, high body temperature, flu-like symptoms, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes &ndash;these are signs of a severe skin reaction called Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome. (see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>If any of the above apply to you, tell your doctor, pharmacist or nurse before starting treatment.</p><p>At any time during or after your treatment, tell your doctor or nurse immediately if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML). If you had these symptoms prior to treatment with lenalidomide, tell your doctor about any change in these symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience shortness of breath, tiredness, dizziness, pain in the chest, a faster heartbeat, or swelling in the legs or ankles. These may be symptoms of a serious condition known as pulmonary hypertension (see section 4).</p><p><strong>Tests and checks</strong></p><p>Before and during the treatment with Lenalidomide SPC you will have regular blood tests. This is because lenalidomide SPC may cause a fall in the blood cells that help fight infection (white blood cells) and help the blood to clot (platelets).</p><p>Your doctor will ask you to have a blood test:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Every week for the first 8 weeks of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then at least every month after that.</p><p>&nbsp;</p><p>You may be evaluated for signs of cardiopulmonary problems before and during the treatment with Lenalidomide SPC.</p><p><strong>For patients with MDS taking Lenalidomide SPC</strong></p><p>If you have MDS, you may be more likely to get a more advanced condition called acute myeloid leukaemia (AML). In addition, it is not known how Lenalidomide SPC affects the chances of you getting AML. Your doctor may therefore do tests to check for signs which may better predict the likelihood of you getting AML during your treatment with Lenalidomide SPC.</p><p><strong>For patients with MCL taking Lenalidomide SPC</strong></p><p>Your doctor will ask you to have a blood test:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Every week for the first 8 weeks (2 cycles) of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then every 2 weeks in cycles 3 and 4 (see Section 3 &lsquo;Treatment cycle&rsquo; for more information)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after this it will happen at the start of each cycle and</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At least every month</p><p><strong>For patients with FL taking Lenalidomide SPC</strong></p><p>Your doctor will ask you to have a blood test:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Every week for the first 3 weeks (1 cycles) of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then every 2 weeks in Cycles 2 to 4 (see Section 3 &lsquo;Treatment cycle&rsquo; for more information)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After this it will happen at the start of each cycle and</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At least every month.</p><p>&nbsp;</p><p>&nbsp;</p><p>Your doctor may check if you have a high total amount of tumor throughout the body, including your bone marrow. This could lead to a condition where the tumors break down and cause unusual levels of chemicals in the blood which can lead to kidney failure (this condition is called &lsquo;Tumor Lysis Syndrome&rsquo;).</p><p>Your doctor may check you for changes to your skin such as red spots or rashes.</p><p>Your doctor may adjust your dose of Lenalidomide SPC or stop your treatment based on the results of your blood tests and on your general condition. If you are newly diagnosed, your doctor may also assess your treatment based on your age and other conditions you already have.</p><p><strong>Blood donation</strong></p><p>You should not donate blood during treatment and for 7 days after the end of treatment.</p><p><strong>Children and adolescents</strong></p><p>Lenalidomide SPC is not recommended for use in children and adolescents under 18 years.</p><p>&nbsp;</p><p><strong>Elderly and people with kidney problems</strong></p><p>If you are aged 75 years or older or have moderate to severe kidney problems, your doctor will check you carefully before starting treatment.</p><p>&nbsp;</p><p><strong>Other medicines and Lenalidomide SPC</strong></p><p>Tell your doctor or nurse if you are taking or have recently taken any other medicines. This is because Lenalidomide SPC can affect the way some other medicines work. Also, some other medicines can affect the way Lenalidomide SPC works.</p><p>In particular, tell your doctor or nurse if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to prevent pregnancy such as oral contraceptives, as they may stop working</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used for heart problems &ndash; such as digoxin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to thin the blood &ndash; such as warfarin</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and contraception - information for women and men Pregnancy</strong></p><p><strong><u>For women taking Lenalidomide SPC</u></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must not take Lenalidomide SPC if you are pregnant, as it is expected to be harmful to an unborn baby.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must not become pregnant while taking Lenalidomide SPC. Therefore you must use effective methods of contraception if you are a woman of childbearing potential (see &lsquo;Contraception&rsquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do become pregnant during your treatment with Lenalidomide SPC, you must stop the treatment and inform your doctor immediately.</p><p><strong><u>For men taking Lenalidomide SPC</u></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your partner becomes pregnant whilst you are taking Lenalidomide SPC, you should inform your doctor immediately. It is recommended that your partner seeks medical advice.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must also use effective methods of contraception (see &lsquo;Contraception&rsquo;).</p><p><strong>Breast-feeding</strong></p><p>You must not breast-feed when taking Lenalidomide SPC, as it is not known if Lenalidomide SPC passes into breast milk.</p><p><strong>Contraception</strong></p><p><u>For women taking Lenalidomide SPC</u></p><p>Before starting the treatment, ask your doctor if you are able to become pregnant, even if you think this is unlikely.</p><p>&nbsp;</p><p>If you are able to become pregnant</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you will have pregnancy tests under the supervision of your doctor (before every treatment, at least every 4 weeks during treatment, and at least 4 weeks after the treatment has finished) except where it has been confirmed that the fallopian tubes have been severed and sealed, to stop eggs from reaching the uterus (tubal sterilisation)</p><p>AND</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you must use effective methods of contraception for at least 4 weeks before starting treatment, during treatment, and until at least 4 weeks after stopping treatment. Your doctor will advise you on appropriate methods of contraception.</p><p><u>For men taking Lenalidomide SPC</u></p><p>Lenalidomide SPC passes into human semen. If your female partner is pregnant or able to become pregnant, and she does not use effective methods of contraception, you must use condoms during treatment and for at least 7 days after the end of treatment, even if you have had a vasectomy.</p><p><strong>Driving and using machines</strong></p><p>Do not drive or operate machines if you feel dizzy, tired, sleepy, have vertigo or blurred vision after taking Lenalidomide SPC.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lenalidomide SPC must be given to you by healthcare professionals with experience in treating multiple myeloma, MDS, MCL or FL<br />&bull;&nbsp;&nbsp; &nbsp;When Lenalidomide SPC is used to treat multiple myeloma in patients who cannot have a bone marrow transplant or have had other treatments before, it is taken with other medicines (see section 1 &lsquo;What Lenalidomide SPC is used for&rsquo;).<br />&bull;&nbsp;&nbsp; &nbsp;When Lenalidomide SPC is used to treat multiple myeloma in patients who have had a bone marrow transplant or to treat patients with MDS or MCL, it is taken alone.<br />&bull;&nbsp;&nbsp; &nbsp;When Lenalidomide SPC is used to treat follicular lymphoma, it is taken with another medicine called &lsquo;rituximab&rsquo;.<br />Always take Lenalidomide SPC exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />If you are taking Lenalidomide SPC in combination with other medicines, you should refer to the package leaflets for these medicines for further information on their use and effects.<br /><strong>Treatment cycle</strong><br />Lenalidomide SPC taken on certain days over 3 weeks (21 days).<br />&bull;&nbsp;&nbsp; &nbsp;Every 21 days is called a &lsquo;treatment cycle&rsquo;.<br />&bull;&nbsp;&nbsp; &nbsp;Depending on the day of the cycle, you will take one or more of the medicines. However, on some days you do not take any of the medicines.<br />&bull;&nbsp;&nbsp; &nbsp;After completing every 21-day cycle, you should start a new &lsquo;cycle&rsquo; over the next 21 days.<br />OR</p><p>Lenalidomide SPC taken on certain days over 4 weeks (28 days).<br />&bull;&nbsp;&nbsp; &nbsp;Every 28 days is called a &lsquo;treatment cycle&rsquo;.<br />&bull;&nbsp;&nbsp; &nbsp;Depending on the day of the cycle, you will take one or more of the medicines. However, on some days you do not take any of the medicines.<br />&bull;&nbsp;&nbsp; &nbsp;After completing every 28-day cycle, you should start a new &lsquo;cycle&rsquo; over the next 28 days.<br /><strong>How much Lenalidomide SPC to take</strong><br />Before you start treatment, your doctor will tell you:<br />&bull;&nbsp;&nbsp; &nbsp;how much Lenalidomide SPC you should take<br />&bull;&nbsp;&nbsp; &nbsp;how much of the other medicines you should take in combination with Lenalidomide SPC if any<br />&bull;&nbsp;&nbsp; &nbsp;on what days of your treatment cycle to take each medicine<br /><strong>How and when to take Lenalidomide SPC</strong><br />&bull;&nbsp;&nbsp; &nbsp;swallow the capsules whole, preferably with water.<br />&bull;&nbsp;&nbsp; &nbsp;do not break, open or chew the capsules. If powder from a broken Lenalidomide SPC capsule contact with the skin, wash the skin immediately and thoroughly with soap and water.<br />&bull;&nbsp;&nbsp; &nbsp;healthcare professionals, caregivers and family members should wear disposable gloves when handling the blister or capsule. Gloves should then be removed carefully to prevent skin exposure, placed in a sealable plastic polyethylene bag and disposed of in accordance with local requirements. Hands should then be washed thoroughly with soap and water. Women who are pregnant or suspect they may be pregnant should not handle the blister or capsule.<br />&bull;&nbsp;&nbsp; &nbsp;the capsules can be taken either with or without food.<br />&bull;&nbsp;&nbsp; &nbsp;you should take Lenalidomide SPC at about the same time on the scheduled days.<br /><strong>Taking this medicine</strong></p><p>To remove the capsule from the blister:<br />&bull;&nbsp;&nbsp; &nbsp;press only one end of the capsule out to push it through the foil<br />&bull;&nbsp;&nbsp; &nbsp;do not put pressure on the center of the capsule, as this can cause it to break.</p><p>&nbsp;<img alt="" width="308" height="190" src="data:image/jpeg;base64,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" /><br /><strong>Duration of the treatment with Lenalidomide SPC</strong><br />Lenalidomide SPC is taken in treatment cycles, each cycle lasting 21 or 28 days (see above &lsquo;Treatment cycle&rsquo;). You should continue the cycles of treatment until your doctor tells you to stop.<br /><strong>If you take more Lenalidomide SPC than you should</strong><br />If you take more Lenalidomide SPC than was prescribed, tell your doctor immediately.</p><p><strong>If you forget to take Lenalidomide SPC</strong><br />If you forget to take Lenalidomide SPC at your regular time and:<br />&bull;&nbsp;&nbsp; &nbsp;less than 12 hours have passed - take your capsule immediately.<br />&bull;&nbsp;&nbsp; &nbsp;more than 12 hours have passed - do not take your capsule. Take your next capsule at the usual time the next day.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Lenalidomide SPC can cause side effects, although not everybody gets them.</p><p><strong>Stop taking Lenalidomide SPC and see a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong><br />&bull;&nbsp;&nbsp; &nbsp;Hives, rashes, swelling of eyes, mouth or face, difficulty breathing, or itching, which may be symptoms of serious types of allergic reactions called angioedema and anaphylactic reaction.<br />&bull;&nbsp;&nbsp; &nbsp;A serious allergic reaction that may begin as a rash in one area but spread with extensive loss of skin over the whole body (Stevens-Johnson syndrome and/or toxic epidermal necrolysis).<br />&bull;&nbsp;&nbsp; &nbsp;Widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome). See also section 2.</p><p><strong>Tell your doctor straight away if you notice any of the following serious side effects:</strong><br />&bull;&nbsp;&nbsp; &nbsp;fever, chills, sore throat, cough, mouth ulcers or any other symptoms of infection including within the bloodstream (sepsis)<br />&bull;&nbsp;&nbsp; &nbsp;bleeding or bruising in the absence of injury<br />&bull;&nbsp;&nbsp; &nbsp;chest pain or leg pain<br />&bull;&nbsp;&nbsp; &nbsp;shortness of breath<br />&bull;&nbsp;&nbsp; &nbsp;Bone pain, muscle weakness, confusion or tiredness that might be due to high level of calcium in the blood.</p><p>Lenalidomide SPC may reduce the number of white blood cells that fight infection and also the blood cells which help the blood to clot (platelets) which may lead to bleeding disorders such as nosebleeds and bruising.<br />Lenalidomide SPC may also cause blood clots in the veins (thrombosis).</p><p><strong>Other side effects</strong><br />It is important to note that a small number of patients may develop additional types of cancer, and it is possible that this risk may be increased with Lenalidomide SPC treatment, therefore your doctor should<br />&nbsp;<br />carefully evaluate the benefit and risk when you are prescribed Lenalidomide SPC.<br /><strong>Very common side effects (may affect more than 1 in 10 people):</strong><br />&bull;&nbsp;&nbsp; &nbsp;A fall in the number of red blood cells which may cause anemia leading to tiredness and weakness<br />&bull;&nbsp;&nbsp; &nbsp;Rashes, itching<br />&bull;&nbsp;&nbsp; &nbsp;Muscle cramps, muscle weakness, muscle pain, muscle aches, bone pain, joint pain, back pain, pain in the extremities<br />&bull;&nbsp;&nbsp; &nbsp;Generalised swelling including swelling of your arms and legs<br />&bull;&nbsp;&nbsp; &nbsp;Weakness, tiredness</p><p>&bull;&nbsp;&nbsp; &nbsp;Fever and flu like symptoms including fever, muscle ache, headache, earache, cough and chills<br />&bull;&nbsp;&nbsp; &nbsp;Numbness, tingling or burning sensation to the skin, pains in hands or feet, dizziness, tremor</p><p>&bull;&nbsp;&nbsp; &nbsp;Decreased appetite, change in the way things taste<br />&bull;&nbsp;&nbsp; &nbsp;Increase in pain, tumour size or redness around the tumour<br />&bull;&nbsp;&nbsp; &nbsp;Weight loss<br />&bull;&nbsp;&nbsp; &nbsp;Constipation, diarrhoea, nausea, vomiting, stomach pain, heartburn<br />&bull;&nbsp;&nbsp; &nbsp;Low levels of potassium or calcium and/or sodium in the blood<br />&bull;&nbsp;&nbsp; &nbsp;Thyroid functioning less than it should be<br />&bull;&nbsp;&nbsp; &nbsp;Leg pain (which could be a symptom of thrombosis), chest pain or shortness of breath (which may be a symptom of blood clots in the lungs, called pulmonary embolism)<br />&bull;&nbsp;&nbsp; &nbsp;Infections of all types, including infection of the sinuses that surround the nose, infection of the lung and the upper respiratory tract<br />&bull;&nbsp;&nbsp; &nbsp;Shortness of breath<br />&bull;&nbsp;&nbsp; &nbsp;Blurred vision<br />&bull;&nbsp;&nbsp; &nbsp;Clouding of your eye (cataract)<br />&bull;&nbsp;&nbsp; &nbsp;Kidney problems which include kidneys not working properly or not being able to maintain normal function<br />&bull;&nbsp;&nbsp; &nbsp;Abnormal liver test results<br />&bull;&nbsp;&nbsp; &nbsp;Increase in liver test results<br />&bull;&nbsp;&nbsp; &nbsp;Changes to a protein in the blood that can cause swelling of the arteries (vasculitis)<br />&bull;&nbsp;&nbsp; &nbsp;Increases in your blood sugar level (diabetes)<br />&bull;&nbsp;&nbsp; &nbsp;Decreases in your blood sugar levels<br />&bull;&nbsp;&nbsp; &nbsp;Headache<br />&bull;&nbsp;&nbsp; &nbsp;Nosebleed<br />&bull;&nbsp;&nbsp; &nbsp;Dry skin<br />&bull;&nbsp;&nbsp; &nbsp;Depression, mood change, difficulty sleeping<br />&bull;&nbsp;&nbsp; &nbsp;Cough<br />&bull;&nbsp;&nbsp; &nbsp;A fall in blood pressure<br />&bull;&nbsp;&nbsp; &nbsp;A vague feeling of bodily discomfort, feeling bad<br />&bull;&nbsp;&nbsp; &nbsp;Sore inflamed mouth, dry mouth<br />&bull;&nbsp;&nbsp; &nbsp;Dehydration</p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong><br />&bull;&nbsp;&nbsp; &nbsp;Destruction of red blood cells (haemolytic anaemia)<br />&bull;&nbsp;&nbsp; &nbsp;Certain types of skin tumour<br />&bull;&nbsp;&nbsp; &nbsp;Bleeding of the gums, stomach, or bowels<br />&bull;&nbsp;&nbsp; &nbsp;Increased blood pressure, slow, fast or irregular heart beat<br />&bull;&nbsp;&nbsp; &nbsp;Increase in the amount of a substance which results from normal and abnormal breakdown of red blood cells<br />&bull;&nbsp;&nbsp; &nbsp;Increase in a type of protein that indicates inflammation in body<br />&bull;&nbsp;&nbsp; &nbsp;Darkening of your skin, discoloration of your skin resulting from bleeding underneath, typically caused by bruising, swelling of skin filled with blood, bruise<br />&bull;&nbsp;&nbsp; &nbsp;Increase in uric acid in the blood<br />&bull;&nbsp;&nbsp; &nbsp;Skin eruptions, redness of skin, cracking, flaking or peeling skin, hives<br />&bull;&nbsp;&nbsp; &nbsp;Increased sweating, night sweats<br />&bull;&nbsp;&nbsp; &nbsp;Difficulty swallowing, sore throat, difficulty with voice quality or voice changes<br />&bull;&nbsp;&nbsp; &nbsp;Runny nose<br />&bull;&nbsp;&nbsp; &nbsp;Production of much more or much less urine than usual or the inability to control when to urinate<br />&bull;&nbsp;&nbsp; &nbsp;Passing blood in the urine<br />&bull;&nbsp;&nbsp; &nbsp;Shortness of breath especially when lying down (which may be a symptom of heart failure)<br />&bull;&nbsp;&nbsp; &nbsp;Difficulty getting an erection<br />&bull;&nbsp;&nbsp; &nbsp;Stroke, fainting, vertigo (problem with inner ear which leads to feeling that everything is spinning), temporary loss of consciousness<br />&bull;&nbsp;&nbsp; &nbsp;Chest pain spreading to the arms, neck, jaw, back or stomach, feeling sweaty and breathless, feeling sick or vomiting, which may be symptoms of a heart attack (myocardial infarction)<br />&bull;&nbsp;&nbsp; &nbsp;Muscle weakness, lack of energy<br />&bull;&nbsp;&nbsp; &nbsp;Neck pain, chest pain<br />&bull;&nbsp;&nbsp; &nbsp;Chills<br />&bull;&nbsp;&nbsp; &nbsp;Joint swelling<br />&bull;&nbsp;&nbsp; &nbsp;Bile flow from liver slowed or blocked<br />&bull;&nbsp;&nbsp; &nbsp;Low levels of phosphate or magnesium in the blood<br />&bull;&nbsp;&nbsp; &nbsp;Difficulty speaking<br />&bull;&nbsp;&nbsp; &nbsp;Liver injury</p><p>&bull;&nbsp;&nbsp; &nbsp;Impaired balance, difficulty moving<br />&bull;&nbsp;&nbsp; &nbsp;Deafness, ringing in the ears (tinnitus)<br />&bull;&nbsp;&nbsp; &nbsp;Nerve pain, unpleasant abnormal sensation especially to touch<br />&bull;&nbsp;&nbsp; &nbsp;An excess of iron in the body<br />&bull;&nbsp;&nbsp; &nbsp;Thirst<br />&bull;&nbsp;&nbsp; &nbsp;Confusion<br />&bull;&nbsp;&nbsp; &nbsp;Toothache<br />&bull;&nbsp;&nbsp; &nbsp;Fall which may result in injury</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people):</strong><br />&bull;&nbsp;&nbsp; &nbsp;Bleeding within the skull<br />&bull;&nbsp;&nbsp; &nbsp;Circulatory problems<br />&bull;&nbsp;&nbsp; &nbsp;Loss of vision<br />&bull;&nbsp;&nbsp; &nbsp;Loss of sex drive (libido)<br />&bull;&nbsp;&nbsp; &nbsp;Passing large amounts of urine with bone pain and weakness, which may be symptoms of a kidney disorder (Fanconi syndrome)<br />&bull;&nbsp;&nbsp; &nbsp;Yellow pigmentation to the skin, mucus membrane or eyes (jaundice), pale coloured stools, dark coloured urine, skin itch, rash, pain or swelling of the stomach &ndash; these may be symptoms of injury to the liver (hepatic failure)<br />&bull;&nbsp;&nbsp; &nbsp;Stomach pain, bloating, or diarrhoea, which may be symptoms of inflammation in the large intestine (called colitis or caecitis)<br />&bull;&nbsp;&nbsp; &nbsp;Damage to the cells of the kidney (called renal tubular necrosis)<br />&bull;&nbsp;&nbsp; &nbsp;Changes to the colour of your skin, sensitivity to sunlight<br />&bull;&nbsp;&nbsp; &nbsp;Tumour lysis syndrome - metabolic complications that can occur during treatment of cancer and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and may include the following: changes to blood chemistry; high potassium, phosphorus, uric acid, and low calcium consequently leading to changes in kidney function, heart beat, seizures, and sometimes death.<br />&bull;&nbsp;&nbsp; &nbsp;Increase in blood pressure within blood vessels that supply the lungs (pulmonary hypertension).</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong><br />&bull;&nbsp;&nbsp; &nbsp;Sudden, or mild but worsening pain in the upper stomach and/or back, which remains for a few days, possibly accompanied by nausea, vomiting, fever and a rapid pulse &ndash; these symptoms may be due to inflammation of the pancreas.<br />&bull;&nbsp;&nbsp; &nbsp;Wheezing, shortness of breath or a dry cough, which may be symptoms caused by inflammation of the tissue in the lungs.<br />&bull;&nbsp;&nbsp; &nbsp;Rare cases of muscle breakdown (muscle pain, weakness or swelling) which can lead to kidney problems (rhabdomyolysis) have been observed, some of them when Lenalidomide SPC is administered with a statin (a type of cholesterol lowering medicines).<br />&bull;&nbsp;&nbsp; &nbsp;A condition affecting the skin caused by inflammation of small blood vessels, along with pain in the joints and fever (leukocytoclastic vasculitis).<br />&bull;&nbsp;&nbsp; &nbsp;Breakdown of the wall of the stomach or gut. This may lead to very serious infection. Tell your doctor if you have severe stomach pain, fever, nausea, vomiting, blood in your stool, or changes in bowel habits.<br />&bull;&nbsp;&nbsp; &nbsp;Viral infections, including herpes zoster (also known as &lsquo;shingles&rsquo;, a viral disease that causes a painful skin rash with blisters) and recurrence of hepatitis B infection (which can cause yellowing of the skin and eyes, dark brown-colored urine, right-sided stomach pain, fever and feeling nauseous or being sick).<br />&bull;&nbsp;&nbsp; &nbsp;Rejection of solid organ transplant (such as kidney, heart).</p><p><br /><strong>Reporting of side effects</strong><br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not Store above 30&deg;C.<br />Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date, which is stated on the blister and on the carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.<br />&bull;&nbsp;&nbsp; &nbsp;This product does not require any special storage conditions.<br />&bull;&nbsp;&nbsp; &nbsp;Do not use this medicine if you notice any damage or signs of tampering to the pack.<br />&bull;&nbsp;&nbsp; &nbsp;Do not throw away any medicines via wastewater or household waste. Please return unused medicines to your pharmacist. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lenalidomide 5 mg SPC capsules, hard: Each capsule contains 5 mg of Lenalidomide.</p><p>Lenalidomide 10 mg SPC capsules, hard: Each capsule contains 10 mg of Lenalidomide.</p><p>Lenalidomide 15 mg capsules, hard: Each capsule contains 15 mg of Lenalidomide.<br />Lenalidomide 20 mg capsules, hard: Each capsule contains 20 mg of Lenalidomide.</p><p>Lenalidomide 25mg SPC capsules, hard: Each capsule contains 25 mg of Lenalidomide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lenalidomide 5 mg SPC capsules, hard:
White to off-white colored powder filled in size ‘4’ hard gelatin capsules with opaque white colored cap imprinted ‘SPC’ with black ink and opaque white colored body imprinted ‘5mg’ with black ink.

Lenalidomide 10 mg SPC capsules, hard:
White to off-white colored powder filled in size ‘2’ hard gelatin capsules with pale green colored cap imprinted ‘SPC’ with black ink and pale-yellow colored body imprinted ‘10mg’ with black ink.

Lenalidomide 15 mg capsules, hard:
White to off-white colored powder filled in size ‘1’ hard gelatin capsules with blue colored cap imprinted ‘SPC’ with black ink and white colored body imprinted ’15 mg’ with black ink.

Lenalidomide 20mg capsules, hard:
White to off-white colored powder filled in size ‘0’ hard gelatin capsules pale green colored cap imprinted ‘SPC’ with black ink and pale blue colored body imprinted ’20 mg’ with black

Lenalidomide 25mg SPC capsules, hard:
White to off-white colored powder filled in size ‘0’ hard gelatin capsules with opaque white colored cap imprinted ‘SPC’ with black ink and opaque white colored body imprinted ‘25mg’ with black ink.

Alu-Alu blisters. Pack size of 21 capsules.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MANUFACTURING AND MARKETING AUTHORIZATION HOLDER:</strong><br />Sudair Pharma Company (SPC)<br />King Fahad road, Riyadh Gallery - Building A1, Riyadh, Saudi Arabia Tel: +966-11-920001432<br />Fax: +966-11-4668195<br />Email: info@sudairpharma.com<br />Mailing: P.O. Box 12363 Riyadh, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو ليناليدوميد اس بي سي ؟</strong></p><p dir="RTL">يحتوي ليناليدوميد <strong>اس بي سي </strong>على المادة الفعَّالة &quot;ليناليدوميد&quot;. ينتمي هذا الدواء إلى مجموعة من الأدوية التي تؤثر على طريقة عمل جهاز المناعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي استخدامات ليناليدوميد اس بي سي ؟</strong></p><p dir="RTL"><strong>يُستخدم ليناليدوميد اس بي سي</strong><strong> </strong><strong>&nbsp;للبالغين &nbsp;في علاج الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورم النخاعي المتعدد (المايلوما المتعددة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمات خلل التنسج النقوي (MDS)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا مانتل الليمفاوية(MCL)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الغدد الليمفاوية الجريبى(FL)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الورم النخاعي المتعدد (المايلوما المتعددة</strong><strong>)</strong></p><p dir="RTL">الورم النخاعي المتعدد (أو الورم النقوي المتعدد أو المايلوما المتعددة) هو نوع من أنواع السرطانات الذي يؤثر على نوع معين من خلايا الدم البيضاء، تسمى خلية البلازما. تتجمع هذه الخلايا في نخاع العظام ثم تنقسم، فتصبح خارجة عن السيطرة.</p><p dir="RTL">قد يضر ذلك العظام والكلى. لا يمكن الشفاء من الورم النخاعي المتعدد بشكل عام. ومع ذلك، فيمكن أن تقل العلامات والأعراض إلى حد كبير أو تختفي لفترة من الزمن. وهذا ما يُدعى &quot;استجابة&quot; للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الورم النخاعي المتعدد حديث التشخيص </strong>في المرضى الذين خضعوا لزرع نخاع العظام، يُستخدَم ليناليدوميد <strong>اس بي سي</strong><strong> </strong>- وحده باعتباره علاج مداوم بعد تعافي المرضى بمدة كافية عقب عملية زراعة نخاع العظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الورم النخاعي المتعدد حديث التشخيص </strong>في المرضى الذين لا يمكنهم الخضوع لزرع نخاع العظام، يُستخدَم ليناليدوميد اس - بي سي مع أدوية أخرى و ذلك يتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء للعلاج كيميائى يسمى&quot;بورتيزوميب&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;دواء مضاد للالتهابات يسمى &quot;ديكساميثازون&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء للعلاج الكيميائي يسمى &quot;ميلفالان&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;دواء مثبط للمناعة يسمى &quot;بريدنيزون&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتناول هذه الأدوية الأخرى في بداية العلاج، ومن ثم تستمر في تناول ليناليدوميد اس بي سي وحده وسوف يفحصك الطبيب المعالج لك بعناية قبل بدء العلاج إذا كنت تبلغ من العمر 75 عامًا أو أكثر أو إذا كنت تعاني من مشكلات في الكلى تتراوح شدتها بين متوسطة وخطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الورم النخاعي المتعدد </strong>المصاب به المرضى الذين قد تلقوا علاجًا من قبل، يستخدم ليناليدوميد اس بي سي بجانب علاج مضاد- للالتهابات يسمى &quot;ديكساميثازون&quot;.</p><p dir="RTL">يستطيع ليناليدوميد اس بي سي منع علامات الورم النخاعي المتعدد وأعراضه من أن تزداد سوءًا. ثَبُتَ أيضًا أنه يستطيع تأخير عودة الورم النخاعي المتعدد عقب العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متلازمة خلل التَّنسج النخاعي </strong>هي عبارة عن مجموعة من عدة أمراض في الدم ونخاع العظام المختلفة. تصبح خلايا الدم غير طبيعية وغير قادرة على أداء وظائفها بشكل ملائم. قد يعاني المرضى من مختلف العلامات والأعراض، بما في ذلك: نقص خلايا الدم الحمراء (الأنيميا) والحاجة إلى نقل دم وخطورة التعرض للإصابة بعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم ليناليدوميد اس بي سي وحده لعلاج المرضى البالغين الذين تم تشخيصهم بالإصابة بمتلازمة خلل التَّنسج النخاعي، عندما تنطبق الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت في حاجة إلي نقل دم بشكل دوري لعلاج انخفاض مستويات خلايا الدم الحمراء (&quot;فقر الدم المعتمد على نقل الدم&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اختلال خلايا في نخاع العظام يسمى &quot;الخلل الوراثي الخلوي المتعلق بالنفاد الصبغي 5 ( 5q ) المنعزل&quot;. يعنى ذلك أن جسمك لا ينتج خلايا دم صحية بما يكفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اُستخدمت أدوية أخرى من قبل، لكنها لم تكن ملائمة أو لا تظهر فعالية كافية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يزيد ليناليدوميد اس بي سي من أعداد خلايا الدم الحمراء التي ينتجها الجسم من خلال تقليل أعداد الخلايا غير الطبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي ذلك إلى تقليل عدد مرات نقل الدم التي تحتاجها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي ذلك إلى عدم الحاجة إلى نقل الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سرطان خلايا مانتل الليمفاوية </strong>هو سرطان يحدث في جزء من الجهاز المناعي (الأنسجة الليمفاوية). يؤثر على نوع من خلايا الدم البيضاء تسمى &quot;الخلايا اللمفاوية البائية&quot; أو &quot;الخلايا البائية&quot;. سرطان خلايا مانتل الليمفاوية هو مرض حيث تنمو الخلايا البائية بطريقة خارجة عن السيطرة، ثم تتراكم في الخلايا الليمفاوية أو نخاع العظام أو الدم.</p><p dir="RTL">يستخدم ليناليدوميد اس بي سي وحده لعلاج المرضى البالغين الذين تلقوا علاجًا بأدوية أخرى.</p><p dir="RTL"><strong>سرطان الغدد الليمفاوية الجريبي (</strong><strong>FL</strong><strong>)</strong></p><p dir="RTL">هو سرطان بطيء النمو يؤثر على الخلايا الليمفاوية B و هو نوع من خلايا الدم البيضاء التي تساعد جسمك على محاربة العدوى. فى هذه الحالة قد يتجمع الكثير من هذه الخلايا اللمفاوية B في الدم ونخاع العظام والغدد الليمفاوية والطحال.</p><p dir="RTL">يؤخذ ليناليدوميد اس بي سي جنبا إلى جنب مع دواء آخر يسمى &quot;ريتوكسيماب&quot; لعلاج المرضى البالغين الذين يعانون من سرطان الغدد الليمفاوية الجريبي الذى تمت محاولة علاجه مسبقا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية عمل ليناليدوميد اس بي سي</strong></p><p dir="RTL">يعمل ليناليدوميد اس بي سي عن طريق التأثير على الجهاز المناعي لجسم المريض، ومهاجمة السرطان مباشرة. يعمل بعدة طرق مختلفة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عن طريق منع الخلايا السرطانية من التكوُّن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عن طريق منع الأوعية الدموية من النمو في الخلايا السرطانية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عن طريق تحفيز جزء من الجهاز المناعي لمهاجمة الخلايا السرطانية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك قراءة النشرات الخاصة بجميع المنتجات الطبية التي يجب تناولها مع ليناليدوميد اس بى سي قبل بدء استخدام ليناليدوميد اس بي سي.</p><p dir="RTL"><strong>لا تتناول ليناليدوميد اس بي سي في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فمن المتوقع أن يضر ليناليدوميد اس بي سي بالجنين) انظري القسم رقم 2 ، &quot;الحمل والرضاعة ووسائل منع الحمل معلومات للنساء والرجال-.&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديكِ القدرة على الحمل، إلا إذا اتبعت كافة التدابير اللازمة لمنع الحمل (انظري القسم رقم 2 ، &quot;الحمل والرضاعة ووسائل منع الحمل معلومات للنساء والرجال&quot;). إذا كانت لديكِ القدرة على الحمل، فس يُسَ جل الطبيب - المعالج لك مع كل وصفة طبية أنه قد تم اتخاذ التدابير اللازمة وسيؤكد لكِ ذلك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ليناليدوميد اس بي سي أو أي من المكونات الأخرى الداخلة في تركيب هذا الدواء والمدرجة في القسم 6. استشر الطبيب المعالج لك إذا كنت تعتقد أنك قد تكون مصابًا بحساسية. ولا تتناول ليناليدوميد اس بي سي ، إذا انطبق عليك أي من هذه الحالات. إذا لم تكن متأكدًا، فيُرجى التحدُّث إلى الطبيب المعالج لك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><strong>تحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك أو الممرض(ة)المعالج(ة)لك قبل تناوُل ليناليدوميد اس بي سي ، في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت سابقًا من تجلطات بالدم، حيث أنك أكثر عرضة لخطر الإصابة بجلطات الدم في الأوردة والشرايين أثناء العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من أي علامات تدل على الإصابة بعدوى مثل: السعال أو الحمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني مصابًا أو أُصبت من قبل بعدوى فيروسية، خاصة التهاب الكبد الوبائي (بي) و الحماق النطاقى وفيروس نقص المناعة البشرية. تحدث إلى الطبيب المعالج لك إذا لم تكن متأكدًا من مثل هذه الحالات. قد يعيد العلاج بليناليدوميد اس بي سي تنشيط الفيروس لدى المرضى الذين يحملون الفيروس مما يؤدى إلى تكرر العدوى. يجب على الطبيب المعالج لك التحقق مما إذا كنت قد أُصبت بعدوى التهاب الكبد الوبائي &quot;بي&quot; في أي وقت مضى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشكلات في الكلى، قد يعدل الطبيب المعالج لك جرعتك من ليناليدوميد اس بي سي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من نوبة قلبية أو من جلطة دموية في أي وقت مضى أو إذا كنت تدخن أو إذا كنت تعاني من ارتفاع ضغط الدم أو ارتفاع مستويات الكوليسترول في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من تفاعل تحسسي عند تناول ثاليدوميد اس بي سي )دواء آخر يستخدم لعلاج الورم النخاعي المتعدد( مثل: طفح جلدي أو حكة أو تورم أو دوخة أو صعوبة في التنفس.</p><p dir="RTL">&bull; &nbsp;اذا عانيت في الماضي من مزيج من أي من الأعراض التالية: طفح جلدي واسع النطاق ، احمرار البشرة ، ارتفاع درجة حرارة الجسم ، أعراض تشبه الإنفلونزا ، ارتفاع إنزيمات الكبد، اضطرابات فى عدد خلايا الدم (فرط الحمضات)، تضخم العقد الليمفاوية (وهي علامات على تفاعل جلدي حاد يسمى تفاعل الدواء مع فرط الحمضات والأعراض الجهازية) والذي يُعرف أيضًا باسم DRESS أو متلازمة فرط الحساسية للأدوية. ، انظر أيضًا القسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان أي مما سبق ينطبق عليك ، أخبر طبيبك أو الصيدلي أو الممرضة قبل بدء العلاج.</p><p dir="RTL">في أي وقت أثناء أو بعد العلاج ، أخبر طبيبك أو ممرضك على الفور إذا كنت:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من عدم وضوح الرؤية أو فقدان الرؤية أو ضعف الرؤية أو صعوبة في التحدث أو ضعف في الذراع أو الساق أو تغير في طريقة المشي أو مشاكل في التوازن ، خدر مستمر ، انخفاض الإحساس أو فقدان الإحساس ، فقدان الذاكرة أو الارتباك. قد تكون كل هذه أعراض حالة دماغية خطيرة ومميتة تُعرف باسم اعتلال بيضاء الدماغ التقدمى متعدد البؤر (PML). إذا كان لديك هذه الأعراض قبل العلاج باستخدام ليناليدوميد ، أخبر طبيبك عن أي تغير في هذه الأعراض.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعرت بضيق في التنفس ، أو إرهاق ، أو دوار ، أو ألم في الصدر ، أو تسارع في ضربات القلب ، أو تورم في الساقين أو الكاحلين. قد تكون هذه أعراض لحالة خطيرة تعرف باسم ارتفاع ضغط الدم الرئوي (انظر للقسم 4).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاختبارات والفحوصات</strong></p><p dir="RTL">ستخضع لاختبارات دم دورية قبل العلاج بليناليدوميد اس بي سي وأثناء العلاج، إذ قد يؤدي ليناليدوميد اس بي سي إلى انخفاض عدد&nbsp;خلايا الدم التي تساعد على مكافحة العدوى (خلايا الدم البيضاء) وتساعد الدم على التجلط (الصفائح الدموية).</p><p dir="RTL">سيطلب منك الطبيب المعالج لك إجراء اختبارات دم:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل أسبوع ولمدة الأسابيع الثمانية الأولى من العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم مرة كل شهر بعد ذلك على الأقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتم فحصك بحثًا عن أعراض مشاكل القلب والرئة قبل وأثناء العلاج بليناليدوميد اس بي سي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للمرضى الذين يعانون من متلازمة خلل التنسج النقوي </strong><strong>MDS)</strong><strong>) الذين يتناولون ليناليدوميد اس بي سي</strong></p><p dir="RTL">إذا كنت مصابًا بمتلازمة خلل التنسج النقوي ، فقد تكون أكثر عرضة للإصابة بحالة أكثر تقدمًا تسمى ابيضاض الدم النخاعي الحاد (AML). بالإضافة إلى ذلك ، من غير المعروف كيف يؤثر ليناليدوميد اس بي سي على فرص حصولك على AML.</p><p dir="RTL">لذلك قد يقوم الطبيب المعالج لك بإجراء فحوصات للتحقق من العلامات التي قد تتنبأ بشكل أفضل باحتمالية إصابتك بابيضاض الدم النقوي الحاد<strong> </strong>(AML) أثناء علاجك بـليناليدوميد اس بي سي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اللمرضى الذين يعانون من سرطان خلايا مانتل الليمفاوية ويتناولون ليناليدوميد اس بي سي</strong></p><p dir="RTL">سيطلب منك الطبيب المعالج لك إجراء اختبارات دم:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل أسبوع ولمدة الأسابيع الثمانية الأولى (خلال دورتين) من العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم كل أسبوعين خلال الدورتان الثالثة والرابعة (انظر القسم رقم 3 &quot;دورة العلاج&quot; للمزيد من المعلومات&quot;(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد ذلك سيُجرى الاختبار في بداية كل دورة علاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على الأقل مرة كل شهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للمرضى الذين يعانون من </strong><strong>سرطان الغدد الليمفاوية الجريبى:</strong></p><p dir="RTL">سيطلب منك طبيبك إجراء فحص دم فى الاوقات التالية:</p><p dir="RTL">&bull; قبل العلاج</p><p dir="RTL">&bull; كل أسبوع في الأسابيع الثلاثة الأولى (1 دورة) من العلاج</p><p dir="RTL">&bull; ثم كل أسبوعين في الدورات العلاجية من 2 إلى 4 (انظر القسم 3 &quot;دورة العلاج&quot; لمزيد من المعلومات)</p><p dir="RTL">&bull; بعد ذلك سيكون الفحص فى بداية كل دورة علاجية.</p><p dir="RTL">&bull; على الأقل مرة كل شهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتحقق الطبيب المعالج لك مما إذا كنت تعاني من ارتفاع الكمية الكلية للأورام في كافة أنحاء الجسم، بما في ذلك نخاع العظام.</p><p dir="RTL">قد يؤدي ذلك إلى حالة تتكسر فيها الأورام وتسبب اضطراب مستويات المواد الكيميائية في الدم، والذي من شأنه أن يؤدي إلى الفشل الكلوي) وتسمى هذه الأعراض &quot;متلازمة تحلل الورم&quot;(. قد يفحصك الطبيب المعالج لك تحسبًا لوجود اضطرابات في للجلد مثل: بقع حمراء أو طفح جلدي.</p><p dir="RTL">قد يُعدِّل الطبيب المعالج لك جرعة ليناليدوميد اس بي سي أو يوقف العلاج بناء على نتائج اختبارات الدم وحالتك الصحية العامة.</p><p dir="RTL">إذا تم تشخيصك حديثًا، قد يقيِم الطبيب المعالج لك العلاج بناء على عمرك وظروف أخرى تعاني منها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التبرع بالدم</strong></p><p dir="RTL">يحظر عليك التبرع بالدم خلال العلاج ولمدة أسبوع واحد بعد انتهاء العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينصح باستخدام ليناليدوميد اس بي سي للأطفال والمراهقين تحت سن 18 عامًا.</p><p dir="RTL"><strong>كبار السن والذين يعانون من مشكلات في الكُلى</strong></p><p dir="RTL">سوف يفحصك الطبيب المعالج لك بعناية قبل بدء العلاج إذا كنت تبلغ من العمر 75 عامًا أو أكثر، أو إذا كنت تعاني من مشكلات في الكلى تتراوح شدتها بين متوسطة وخطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع ليناليدوميد اس بي سي</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب المعالج لك أو الممرض(ة) الخاص(ة) بك إذا كنت تتناول أو قد تناولت مؤخرًا أي أدوية أخرى. لأن ليناليدوميد اس بي سي قد يؤثر على آلية عمل بعض الأدوية الأخرى. وبالمثل، فقد تُؤثر بعض الأدوية الأخرى على آلية عمل ليناليدوميد اس بي سي. أخبر الطبيب المعالج لك أو الممرض(ة) الخاص(ة) بك إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لمنع الحمل مثل: تناول وسائل منع الحمل التي تتناوَل عن طريق الفم، حيث إنه قد لا يظهر مفعولهم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج مشكلات القلب مثل ديجوكسين.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بعض الأدوية المستخدمة لتسييل الدم مثل وارفارين.</p><p dir="RTL"><strong>حالات الحمل والرضاعة الطبيعية ومنع الحمل معلومات للنساء والرجال</strong><strong> </strong>-<strong>الحمل</strong></p><p dir="RTL"><strong>خاص بالسيدات اللاتي يتناولن ليناليدوميد اس بي سي</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم تناول ليناليدوميد اس بي سي في حالة الحمل، لأنه من المتوقع أن يضر بالجنين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا تحملي خلال فترة تناول ليناليدوميد اس بي سي. لذا يجب عليكِ استخدام وسائل فعالة لمنع الحمل إذا كنتِ امرأة لديها القدرة على الحمل (انظري &quot;منع الحمل&quot; أدناه).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التوقف عن تناول العلاج وإبلاغ الطبيب فورًا إذا أصبحتِ حاملًا خلال فترة العلاج بليناليدوميد اس بي سي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>خاص بالرجال الذين يتناولون ليناليدوميد اس بي سي</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك إخبار الطبيب المعالج لزوجتك على الفور إذا أصبحت زوجتك حاملًا خلال فترة العلاج بليناليدوميد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُوصى بأن تحصل زوجتك على مشورة طبية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يجب عليك استخدام وسائل فعالة لمنع الحمل (انظر &quot;منع الحمل&quot; أدناه(.</p><p dir="RTL"><strong>الرَّضاعة الطبيعية</strong></p><p dir="RTL">يجب تجنب الرضاعة الطبيعية عند تناول ليناليدوميد اس بي سي ، فمن غير المعروف ما إذا كان ليناليدوميد اس بي سي يفرز في حليب الأم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>منع الحمل</strong></p><p dir="RTL">للسيدات اللاتي يتناولن ليناليدوميد اس بي سي قبل بدء العلاج، استشيري الطبيب المعالج لك إذا كانت لديك القدرة على الحمل، حتى إذا كنت تعتقدين أن ذلك مستبعد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا كنتِ قادرة على الحمل</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستخضعين لاختبارات حمل تحت إشراف الطبيب المعالج لك (قبل كل جلسة علاج ولمدة لا تقل عن 4 أسابيع خلال العلاج و مدة مماثلة بعد انتهاء العلاج )، إلا إذا تم التأكد من أن قطع أو انسداد أنبوبتي فالوب لمنع البويضات من الوصول إلى الرحم (التعقيم الأنبوبي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام وسائل فعالة لمنع الحمل لمدة لا تقل عن 4 أسابيع قبل بدء العلاج وخلال تلقى العلاج وحتى ما لا يقل عن 4 أسابيع بعد وقف العلاج.</p><p dir="RTL">سيخبركِ الطبيب المعالج لك بوسائل منع الحمل المناسبة لكِ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>خاص بالرجال الذين يتناولون ليناليدوميد اس بي سي</strong></p><p dir="RTL">يفرز ليناليدوميد اس بي سي في السائل المنوي البشري. إذا كانت زوجتك حاملًا أو قد تصبح حاملًا ولا تستخدم وسائل فعالة لمنع الحمل، فيجب عليك استخدام واقي ذكرى خلال فترة العلاج وبعد أسبوع على الأقل من انتهاء العلاج، حتى إذا كانت القناة الدافقة لديك مقطوعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقود السيارة أو تشغل آلات إذا كنت تشعر بدوخة أو تعب أو نعاس أو إذا كنت تعاني من دوار أو ضعف الرؤية بعد تناول ليناليدوميد اس بي سي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عدم استخدام ليناليدوميد اس بي سي إلا عن طريق أخصائي الرعاية الصحية &nbsp;من ذوي الخبرة في علاج الورم النخاعي المتعدد،</p><p dir="RTL">متلازمة خلل التَّنسج النخاعي، سرطان خلايا مانتل الليمفاوية او سرطان الغدد الليمفاوية الجريبى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند استخدم ليناليدوميد اس بي سي لعلاج الورم النخاعي المتعدد لدى المرضى الذين لا يمكنهم الخضوع لزرع نخاع العظام أو كانوا يتناولون علاجات أخرى من قبل، يتم تناول الدواء مع أدوية أخرى (انظر القسم 1 &quot; فيم يستخدم ليناليدوميد اس بي سي&quot;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناول ليناليدوميد اس بي سي وحده في حالة استخدامه لعلاج الورم النخاعي المتعدد في المرضى الذين خضعوا لزرع نخاع العظام أو لعلاج المرضى الذين يعانون من متلازمة خلل التَّنسج النخاعي أو سرطان خلايا مانتل الليمفاوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عند استخدام ليناليدوميد اس بي سي لعلاج الأورام اللمفاوية الجريبية ، يتم تناوله مع دواء آخر يسمى &quot;ريتوكسيماب&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول ليناليدوميد اس بي سي دائمًا وفقًا لتعليمات الطبيب المعالج لك. استشر الطبيب المعالج لك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول ليناليدوميد اس بي سي مع أدوية أخرى، يجب عليك الرجوع إلى نشرة العبوة الخاصة بتلك الأدوية للحصول على المزيد من المعلومات عن استخدامها وآثارها.</p><p dir="RTL"><strong>&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الدورة العلاجية:</strong></p><p dir="RTL">- يؤخذ ليناليدوميد اس بي سي في أيام معينة على مدى 3 أسابيع (21 يومًا).</p><p dir="RTL">&bull; كل 21 يومًا تسمى &quot;دورة العلاج&quot;.</p><p dir="RTL">&bull; اعتمادًا على يوم الدورة ، ستأخذ واحدًا أو أكثر من الأدوية. ومع ذلك ، في بعض الأيام قد لا تتناول أيًا من الأدوية.</p><p dir="RTL">&bull; بعد الانتهاء من كل دورة مدتها 21 يومًا ، يجب أن تبدأ &quot;دورة&quot; جديدة خلال الـ 21 يومًا القادمة.</p><p dir="RTL">- او فإن ليناليدوميد اس بي سي قد يؤخذ في أيام معينة على مدى 4 أسابيع (28 يومًا).</p><p dir="RTL">&bull; كل 28 يومًا تسمى &quot;دورة العلاج&quot;.</p><p dir="RTL">&bull; اعتمادًا على يوم الدورة ، ستأخذ واحدًا أو أكثر من الأدوية. ومع ذلك ، في بعض الأيام قد لا تتناول أيًا من الأدوية.</p><p dir="RTL">&bull; بعد الانتهاء من كل دورة مدتها 28 يومًا ، يجب أن تبدأ &quot;دورة&quot; جديدة خلال الـ 28 يومًا القادمة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي الكمية التي يجب عليك تناوُلها من ليناليدوميد اس بي سي</strong></p><p dir="RTL">سيخبرك الطبيب المعالج لك بالتالي قبل بدء العلاج:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما هي الكمية التي عليك تناوُلها من ليناليدوميد اس بي سي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما كمية الأدوية الأخرى التي ينبغي عليك تناولها مع ليناليدوميد اس بي سي ، إن وجدت.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في أي يوم من أيام دورة العلاج مسموح بتناول كل دواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>طريقة وموعد تناوُل ليناليدوميد اس بي سي</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولة كاملة، يُفضَّل بلعها ببعض الماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكسر الكبسولة أو تفتحها أو تمضغها. إذا لمس مسحوق ليناليدوميد اس بي سي الناتج من كبسولة تالفة جلدك، اغسل الجلد فورًا جيدًا بالماء والصابون.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على المتخصصين في ومقدمي الرعاية الصحية وأفراد الأسرة ارتداء القفازات التي تستخدم لمرة واحدة عند التعامل مع الشريط أو الكبسولة. يجب نزع القفازات بعناية لمنع تعرض الجلد للشريط أو الكبسولة ، ووضعها في كيس بلاستيكي قابل للغلق من البولي إيثيلين والتخلص منها وفقًا للمتطلبات المحلية. يجب بعد ذلك غسل اليدين جيدًا بالماء والصابون. يجب على النساء الحوامل أو المشتبه في أنهن حوامل عدم التعامل مع الشريط أو الكبسولة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول الكبسولات مع الطعام أو بدونه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تتناول ليناليدوميد اس بي سي في الوقت نفسه من كل يوم مقرر فيه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>طريقة تناول هذا الدواء لإزالة الكبسولة من الشريط</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط على نهاية واحدة فقط من الكبسولة لدفعها خارج الشريط.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تضغط على وسط الكبسولة، لأن هذا يمكن أن يؤدي إلى تلفها.</p><p><img alt="" width="308" height="190" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAC+ATQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopKAFopit82KfQAUUUUAFFFJmgAY4pFbNBYHoaARQA6kNIWHrSbvegDI8Valc6ToN9e2llJqVzawvNHZwsFe4KqT5YJ7nGPrisj4Y+PrH4keE7DxDpzt9mu4xvhlGJIJRw8Tjsyngj1FdLqEYe3fcCVxn8q8C8QyH4B/E7/AISKHdH4F8V3CQatHj91pt+wAjuyOyyn5XP97aaAPomis6xkIKrvLrtGeQRn6+uKvc7vagB9FJRQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHcHEZOdp7HGakqObPlnFAHBeIviFL4b+I/hbw9Naj7HrglC3Zf7kqLkJj3ruYXbzApycgt2wOa8b/aS0udfAdr4jtI1a78PX0OphsfOI1OJMd/uk16roeqRaxa2l7buzwXcCXCNkFSGUEVktwNeiiitQK18zLbkocPnC/WvJPFnx9tfD/iB/D2iWF14z8TLy+maWFAhGMAyyMQsfPbJPtXovjzWF0DwZrWosCfstpLKNvXIQnj3rgv2b/Clr4d+E/h+4EEZ1DU4F1G8uiPnnklG/ex7nDAVjNu+gGVar8cvFWJZLzwv4MhfkWyQSX9xGP8AafKoT9KVvDnxu0fL2/jfw3rr54g1LSntw3+zuRjt+uDXtUcaRjCqFHoKR0Hvk+lVdgeJ6X+0JdeHdcg0X4l+HZPBd3O3lW2qRSNcabct/wBdto8sf74Fex2dyLjYVkV1Zd2VwQwPRh6g+tUfEXh7TPEGjXGn6vYwX9hONksNxGJAwPqD1rxKbwz4v/Z+mkvfB8dx4t8FLmS48MXE267sE7m0dj8wHXyz26YpAfQzxrIpDcrxWD4w8J6d4y8M6nomqQLd2F/G0E0bDqG6Ee4PIPqKzPh38SNI+JmkxatoV8t5ZHKSxsmya3kHVJUPKMOm0iusmAki5IKnk9qtgeNfAvxJqGh3mofDbxRMZ/EOgRhrG7ZhnUtNJIimz3ZQCj+617NbtuY4bI6g46g9K8b+PnhG+jtdO8eeHITJ4q8KuLtIoOPtloCDcWwPcsgJUH+ID1r0jwV4l03xn4b0vXdIl+0aZqFss9vIp42MAQD+vH1qY7gdEcf3aKXpmitAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTZBuUg96dRQBlaxo9nq2k3dldRq9vcQvDIrcjawwa8q/Zp1C5sfDmoeDNRc/2t4TvHsXDnl4GO+Fx7bSB+FeyXn/AB7vztOOD6GvCPHEjfDH4x6J42w0Wj60i6NrDn7kRz+4lb33cZ9DUS3QHvQIzx606s+0dvN+f+6NvPbt+Oc1bnm2qMHnIHAzVAYHxI0x9a8B6/YRf624spUUep2niuW/Z31iLXvhB4SuEbCx6els0Z/heP8AdsPwKEfhXcySmaPJfzoWU524z17V4R4P14fA74jan4T1uU6f4X1q8a90PUZhiESyf621Zv4G3YZSeuSKy3YH0UqgHinVStZCzMOeDjmrfXrWiQCSIHAyM45qCaFAq5T5c+nSrPSkbDcGnYDwL4teCb74b61cfFPwRb5voU369pFuMJq1uOXYL/z2VRlT7EV654R8SWXjDQdO1mwn+1afqEC3EL9irDIPt6Y9q0tSggkt3EwDQD7wJ4x0rwr4EauNF/Z7uL3+1oNGsILy/Wxv7wfuoYPPdYmI7qD2rKbswPebrbHHuCgqDkj19q8R+GbN8KPi1rfw8yU0LWI5Ne8PluEiYvm7tlHbazBwOwkA7Vk6L40+Jt9HGmkeL/h/42DAfuVlNtPJ6AbWPXHpV/4xm+tbb4ZeKr6yj03XLLxHapcRxv5gRbjdDJGG7j5gT/uCmB7o10keCxZtw3DjsaKarcvtVnUNgDI+XHGP0z+NFAGhRRRWoBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUmaAEYBlwelcz8QPBth448G6roV+mbW+hMbMOqH+Fx6FTgj6V09Q3So0JDfd+vFAHkPwJ8bXuoaLc+FvEbgeL/DshtL1WODNEP9XcL6hl2/jmq3xw8X6oV0vwJ4akx4k8S7oVcMQ9raL/rrjPqAcD3YVP8AFjwDri+ItN8eeDFt28UadEYJ7SZtkeoW55MTt7dj61H4J+KnhTxd4ikFzpzeHvHYg8h9P1NQlwVBzshY8OpPOV6+lZXA2LzXtO+DujeEfDsMdxqk95LDpdrFuLzO2CWkcnnAALE/Wr/i5fC/iu8/4QnXY4r1r2xkvHs5BkiNWVSwPVWDMMGuQ0Hwn4l1X4g3/jfxbBbxSabBLaaBpFpIX2K3Jlcn+NsYHoCaf8JfDOuan4s1zx94wtUstT1SBbSw00EM1laK2djerMfmP0pAUvhfrWp/CvxhD8NfEd5Ne2M8bS+GtWuDueWIctbSuesidj3H0r3OGZpW4+71B/HGK86+LHgGz+JXhm40y1u1tfEFpIt5p91EQZLS5XmN8ZyB0B9jTfg38SpvH/hNZLyNbXxNp0jWGrWJ6w3CH5mx/dcDcPY+1UB6h3qve7miG04wcnBweO1Zlh4ksdRungg1C0uZozteO3uEkdfYgHINP1fVodN0u6vruVbe0tkaaSTP3VQZYn6CqewHlf7QHjO/t9Hs/Bfh52bxd4rdrW2wfltrYgC4uG9AiE49yK6C88Btovwst/CXhmKx3WtoltaJq0AnhkKjkyL3yRk/WuW+AujzeLtS1T4na7Gw1PXsxaZbzjJtNPUnywvp5g+c/UV7PJCix44CDuD096yA+TNX0zwtpeLL4pfCyPQ2YbU8UeGYnaDfz82Y8PFz061sed4f8aat8NPA/gzWLjXdGivz4ivNQkmaZoobfIjDs3ILTEJg/wB017R8VPH+nfDjwhc6jqSC6ZmENtp8YzJd3DfchjHdicVz/wABfhfc+EYNT8Ra+luPGPiOQXeox26gR2qD/VW0f+yi9T/E2T3qkB6ordcyeXz0Az9f1op8duqqFUEheOvNFWBboooqgCiiigAopNw9aM0ALRRSZHrQAtFFJuHrQAtFJuHrRketAC0UUUAFI3SjI9aCaAG7vrQrc0m4etLuoAfRTFb5sU7NAC0UlIXHY57UAKxwKjeQBSen4USMdpx1rjvirr1/4d+GvifU9LDTajZ6dNLAq9fMCErxUSlYDppNWtI5vLa6t1kzna0qhvyzUokErDkFX6beQa/nQ134o+MvFHiG61jUPE2pnVJpDJLIt04AIbkAA/KK9z+Bn/BQT4p/B28t47jVG8UaCrgS6fqL72299j9Qa51XV7F8jP2/8tccDnpXGfEj4XeHviLpbwazpkczgYju0+SeH/aWQcqR2xXEfs4/tTeFP2kPCv8AaegXIt72IEXOm3DATW59SO6/7Vew211DcRrJDOlxCeN8bBhnvyK2upCaaPCSvxH+C8OY1m+I3hWLgJKQNTt0HAG//loAPXn3o1j9prQr7RIYPBYGu+ML4m3stClUxTxTdSZlP3UTOSx9OK99kWNYztUEHqM9q8k+KnwB0PxzdRa7YhtA8XWq/wCia9poEU0foCRww9c9akk4PUPgAvhHwNP4lh1+7sPiDZRvqM/iAykxz3HLtGyE48r+HHoa8K/bG+K2ufDP4U6R8R/D3/Eg1bx5oiaZqEUZI2zFA6yr/tL8wB67Wrv/ABR4o8T6jqp8F/GjVo9A8O2aLLJcaXDJ5fiABsgM6g7OANyDr61S+OXw41D9qz4eeJ7uHR7jSPD+jaPL/wAIzBcw+W93ckZ84J/CiqCqg880ne2hUbXVz8oPDPxC8T+EddTWtG8Qahpupq5uGuVuG3O5PfnkfWv0Z+E/7dT/AB7+Anizwf4qmisvHFrpm0XMXyJqERIEjD0cLnIr8yHRoZNsiSRzIWjdJP4dvGCOxzmpbG8n0e4S9tZmgmi/5aK2OD1z+FcccRKLszr9mpO6P30+IHjy6+Hvw28MW3hqCOXWtWa00jR4ZuY9zRriRsfwqoJ4rAuPi142+GMcrfEfSIbnw/Eu6TxRonMMSZ+9NAeVwe6npzXzZ8Kfj5c+Nvgf8PNR1aSGHxV4Puhd2y6g3l2urWqqY3CS8qJQh6HoQK9YsPG2q/theRpen6NqPhr4axSrc61eX3yyaqqnCW0OP4CQN7dCAMd67IyUlc5JdjvvhPpM/wAavFqfE3X4W/sO3LJ4T02UfIsRxuvnX+/L1XPKrive4YESQuq4J6mqei28FrbxQ28KwRQosSpGAFRVGAox6DitMEVrHUkaciil9aKsB9FFFABTZPun6U6kbpQB4n8Rv2tPhh8JfFs/hvxR4st9I1a3iS4ktplOTGwyCOMVzh/b/wDgQvJ8fWSDurBifwGK7P4xfAnwj8SPDviOS98Oaffa3eafKiX00CvKGCMEAYj6V8p/s0X3wi8M/sc2Pi34geGtFEvh6a40zUJprVGmkmikKbTkcseKw5mnqVa577H/AMFAfgRJjHj+wOf9l/8ACnf8N9/Alunj2x/75f8A+Jr80/iv+25puvX93b+Avhh4X8O6duKxzXOnxy3Ei9nORha8S1H45eKNQmE0n9lxtnO1LCNVP04rKVdI09mz9l3/AG/vgWCN3juzC5+9tbH8qST/AIKAfArO0ePbPJ/2G/wr8lfCP7WHiPwrMguvDfhfxBagbjBfaZGDgdRuAr7y/ZI+OnwV/aQ1AaDqXw70Hw/4qWMSJbfZUMVwB18okZJHcVUaykRyNHucn/BQH4FBGZvH9mE7MFbnHXHy817h4U8Vad408P6drek3QutNv41mt5VGBIp5yK+L/wBlL4Q+CfiN8ZvjX4kn8K6XdaFHq66bptu1spiQRDDlR05avuDSdEsdDsbaxsLSO0s7VRHDDEu1UUdAAK2gyDRpJPuGnUjdOma0AwPGHi7TfAvh6+1vWrwWemWcRlmmIJCKOpOK8MuP2/PgdDDKy+OLaRlQuI44nYuf7qjHJr6D1bSbTWtPns761jvLWZSskMqhlYehBr4f/aO+Gvhv4b/tR/CPXbLw5ptrpesR3GkyRG3VYhOVzESOmc45rGTaGdj4H/bt0fVNU1fUfF4tvBfhBlB0l9Um23tyO7NEOVB9xXnfjX/gpevhPx5eHSLfSvFngg7PInsbkpex+u5GHP4V+aXxhtNWt/il4otvEYmfWI7+ZZo5gePmOCuei46AVxkQ8sMEwo/vY5rkliLPQ7Y0otH7Z+B/+CkHwZ8Vad595rk/h+4Xg2+oQndnvgjORXT/APDe3wQB58e2oHfMT/8AxNfiZ4D+IWqfD/XrfVNKe380Ljyb22WeJ8diCOhr9Of2Pv2kPhd8f3Tw14k8FaBofi+OP5R9mj8u9Pcpx7dK3p1lLc55w5We8P8At7fAxoWdPHtr67vLcf8AsvSup+GP7UXw4+L3iRdE8JeJodX1Dynn+zRqwIRerZI6V4N+3x4J8JeH/gxZaTpnhjTLHV/EGqW+m27W9sqyDc43YwPTNfTnw3+Ffhz4f6bpa6ZoVhY3sNnHbvdQQKsj4QAksB3IojKXNrsYnczLlSPXHbNfIv7dHxi8K6T4A1XwmfHf/CL+NkiF3bQgsvmqP4Gx1Vhxj3r67mwyMD0r5d/b6+Gej+If2dPGesLo9rNrVnbpOl55CtOFRgcBuorV66Bex+QXxE8CyWeiaX4y0+LzPD2sMzebECEt7n+OBv7pz83PUGuB2lflB4HG5em761+8fgr4W+BPi3+zfoOnXeg2L6RrWlQXEqW8YX94YwDIMfxA96/Nz9o7/gm343+E+oXWqeC7eXxf4W5ZFgH+kWy5ztZR976iuKpRe6O2nNNanzZ8L/iZr3wl8Y2uv6BcNb3CnyZo1Yok8JGGV8diCa/Q39n/AOPVz8BNI0bXby7vdb+Bvigs9vfSZmuPD92WzJDKeSV3Z5PbFfmfeabeaTcm3vbC5srhXw0NzCyuuPVcZxX6tf8ABLPwLqF18B9etvFek+foeoaj51pa6jD8jgD5nVGHAJAp0OcK3JbQ9sH7fHwQj3E+OLZSOT+7crx6cVZtP25Pgpq1/DY23jW1uLqeRbeOLY3zM3RenXmvQtW+EPw90vS7y6k8G6GkcEbyu32KMAYBOelfNv8AwT++GHhzxN4H8V+NtS8PaZcTa34ku7my32ynyYUbamw44HHau6NziPry7sbW/t/3ttBcgEvEZYwVXgEHBr5G/bq+O3hvw14TvPDuj+PP+Ed8faM9vqsOnoXUXUanPktgY2uARjpX2aYVGQEGM8DFfOP7cPwZ0Tx1+z944votDtJPEUFibmC8EA+0ZjO4Dd1xweKt2sNbn5WftO/D2C8t9N+L3ha2z4R8YZublYlwmm33Amt29Pm5BPY14TGgkkBwVVnKhOvboc9c1+7fwf8ACfgv40fss+GbW70SybQNa0mJrm1hjVVEuwB2H+1uBOa+CPjd/wAEsfG3h3W3uvh3c2/iPRJSzJa3MvlTQrnIUHvXnVKLvdHVTqJXizu/+CXNhpvxS+EfxL8AeI7SO+0yOZJ4zMoYw+fGVk2f3Tx2r1HwP8TtV/Yj8VRfDf4mTTXPw0nLDwz4qZC/2ZByLebA7eprsf8Agnv+yrq37NvgvWpfE7RN4k12ZZJYYGDRwxKPlTPc819Ra74R0TxVarba1pdrqsCnIiu4hIufXBrqjGySOeUrtng0X7efwMhJJ8cWsbbQzHY+MnjrjvW14S/bS+EPjLxFY6FpXjG2vtUv5vs8FvHGwZnOeOntXZa38I/h1ouk3d4/hDQYIbWMzuzWMYAVeTnj2r51/wCCdfw10HVPhbqvj660CyOoa/4kv9TsZHgUtBD5pSMIccDC549aL8rIPstZG55YEcEYziipE+UEDgZorawEtFFFMApG6UtRsx2nHXFAEJCqOeePu+or8qvih8DdY8Wa58b/AILaE5Gp2utx+M9Gs2OFu4ZFxKgHse3rX398TPi5eeHNe07wx4c00634vv4jcRWbPtt4Igdplnf+FfQHrXzb+0H8KfjjpfirSvjN4fm8PSeKPDtnLA9nZLIHubZjyj7uHOemKxNVKx+UPiLw9qXhLVp9M1rTbzR7+NvLeG6jKcj69vpWa0pKnlSP9nnFfquPDvx1/aH8L2OtXfhP4a+IdOv4g6TXkWWPqCfvBgcgjsRXCX37AfxIv7x52+HXgCJ26iO8kRPwFc06Lt7upt7Q/ODzA0gDFiccAHJI9h1r6i/ZR+E/ijwjqF/8ZdXtrrQ/DHhWzuLyO5nQxtd3BjKIseeSCWGe3FfT3hP9kv4v+A5km0v4a/DRZlI2zzZmb8mr0HxH8D/2gvjoukeE/iJP4Z0PwHBeQ3N7DoZxLcKnPlqBwFJxkUoUXHVC9orHqn7CHgWfwX+z3oFxqCMmq648msXJYYJeZi3P0GK+j1rJ0XS4dF0+0sbWIxW9uqxRRjoiquAK11rsicvUWkpaa/3TWgDW+6fpXy3/AMFAPC97q3wPi8SabAz6t4T1K31e3VELsVVhvAx6ivpHWtYt9H027vLqdILa1iaSWSQ4EagZJP4V4fYfEL4i/FSzkvvDOkaTo/hdhthudeVmlvEzjeIwPlQ+hrJgfM3xX+FPwn/b00Oz13wT4ls9I+Jdvar59rJmN5n2gmOROuc/xV8CfFL9nf4g/BrUpbPxP4YvLcL0u4kMkDD1VlHP41+jfxQ+E8fjzxcmkDR9P+H/AMY7dfteheI9EJjstQKkHyZOnOOxrq59K/a6vrBLS/03wDexqio4uQJfMOMHgg4rmnS59kbKofjh5wVsbj8o24HFdh8Jf7buviR4YHhRJ5dajvYmg+z5LZ3jg47etfotrv7KPxj8R3Bnvvhh8L5JmOWkXchY/QEVveBfgX+0B8MJPP8ADfgX4aaTKBgNCCX+oYjIpRoNSTNPaJ7nWfFySb4uftZfCDwNNtm/4R22bX9WQNlRIEAAP49M19lRqN2BkjOQfWvnX9mD4EeIvAfiDxP44+IN7b6p488Ryj7RJbjMVtEv3Y4yecV9HqAK61uYSt0H7a5X4leFYfGngHxDoU4/dahZS25JHTKkA108km1Sa5P4jePLH4e+Eb/W9QzMsC7YoE5eaU8JGo7kmra0J66nwJ4K1j9ob4c/DXS/Blxqui/DvQ9NkktbPUNQTz768hDHaY4l68dK3vD+mfEXxDqyR2H7Rd/aeInGILDWdK+yxSt7AgAg19QfCj4ZzTXh8b+MoY7/AMY6knmRQTfPHpkP8MMQPQgHkjvWh8fPCmneNPBcmjS2yPqV4fKsZ1UedbyDnzEbqCMVnctyVtDxH4O+OptU+K0nw1+NPg/Q18dLG1xYazb2kfk6rGOpUkZ3DA4FfW9na2tlbrDawxQRLxGsKhVUZ6ACvjnxx8M/HXx2+G/wv8a+D7rTm+IvhLUZEN5ePsjmWMmNwx99oJFao/4bGXawt/BCH5shpD1Jz+VGvQz3PSP21PiM3w3/AGdvFlzFIBfX0H9m2iqfmaaUhFA9Tzmum/Zj+H4+GHwO8F+HGi8q4tdPRpv+ujgM2ffLfpXgMXwJ+Nvxr8feF7n4zXehWvhHQLtdQGl6M2/7VOoO3d7A19lwwhJVIBAUFQO2Cc8U1FpgWdorN8QaXFrui32mzqrw3cDwOG6YZSD/ADrS55qG4yse4A5q2Fz5G/4J963Jofgfxj8M9Tcx6h4J1y4tVjlOD9mdi0Zwe2K7/wCJ37ZHws+F+oSaZfeIF1PWkBB0/SUM8qn0IXODXmvx2/ZN8da98W5/E3wz8VJ4XtvFEC2Hifs5jX/ltH/t44r2H4K/sy/D/wCDOnpZ6N4etpb8ruuNTvUWee5kP3nLtzknnHas7yC55SP+Ch2hLH5qfDbxw1qF3ed/Zb4ZR3A712Hw/wD27PhV461KLTJNbfw3qkuAtlrsLWrsT0A3DGc19DfZU+VfLGxRgAKMCvOPit+z74B+LmhzWHifwvY3iyDaLhYljmjOc7lkGCDwOaLPcDgv23PiaPAP7M/iqezuFfUNagGk6eiEFpZpyI8IR1IBJ/CvRP2d/h6nwp+C3gvwooZX03S4Y5Axz+8Kgv8A+PE18w+Df2IfHEfxQ0HTfFnjD/hIvhJ4Vv21bRbC6YvctIcFEkJ6hOa+37fG84GDgNyPXtSs7gTLRS0VvYB9FFFIArM1PVINL0+5u7mVY7a3jeaRyeAiglifwFaR4BNeMftLalKvw9t/D+m5Gp+KL2DRIAp+YLK+ZTn02A5NAFP9n7R5tcsNW+IGqW4GqeLrtrpFk5MNmh2W8Qz0BUbiPU13/jpVXR7e0QnzLy8ht8qecbtxOPYLWXpfg3VvBen2ll4c1FZ7GzhSKGwvl+XaoxhW7Vbs7DWNY1+xvtWto7S3slZ4oopQ4aU8En2ArHqBxnwbtl8K/E74j+EYYzFYw3cWq2cKnCpHcLucAdvmB/OvbEQNyRXj/hyNF/ah8ZuDhm8P2JI7ffcV7CMqBWsQFMa9SKaY1J+6PyqWimAwRgHNPoooAQ9KjckqRgmpD0qKc/ujtyx6cUAeI/HqafxfrXhD4eWUhjXXLlrnUZB/z5wnLL/wJsCvW7XS4La2htooFiiiUJHEBwqAYC14j4V0OT4l/GDxl4sg1Ga1TSmTRLC6t8Mu5OZflPB5NelNN4v01ZIgLHUkK4SZSY5N3TLDp+VZLcDzD426GdU8N+I/EFtEsNzoF/a3VnPHwf3RAc59wSDXuWg3g1TTbG6Ays8KSg/VQSf1rz34maC2m/AvxVbTSZlNhK8zK2cseetdj8Nf+RD8MnOT/Z8HzevyCiPxMDqNoOOKGQHtTqD1rRAM8lPSnYHJoLVBdzGK3d15K9vX2osAXEirEckAHoW6V873uny/tBfE+ZorySDwl4NnxE8fS61IdSf7yp6Vv/Fv4g6hq2oQ/D/wdKsvivVI/wDSJwdyaXbNw80hHRsZCg966n4a2fhrwbY2/g7RbyF5tMRVlhY4mdzyXbPUk5JNQtWA+18W3WhzG28RWwt1z8mpQAmCb6nqp9jUOm3o1x9R8T3MbR2FnBJHZLIu3KBTuk59e1d5dWcNzbmN4VkQ/ejbBBrzP9oLXl8N/CHXBaN5V5qEaafbogwS8zBF2j1GT+VVJaAQfsv2hj+D+k3DKUN5NcXe08cPKxH6V6+I1btXM/D/AMOr4T8IaJo2cmztIoumAcKMn8811C96UdgG+Uo6cGl8sbs45p38VLVgJ3pHUMMGnUUARtGvHy5pI4UVshAuKlooAaowKSSNZFwyhh6Gn0UARLCqnIUKcY4p6oAfwxTqKAE2iilooAKKZk+9Ju3ZA5NABu7Z5rwFb2Pxz+0BcXRkjHhf4e2rCSfdlG1KYEuCf+mcf6tWp8V/ipqmn6pB4I8ErDqnj3UovlO79zpUPQ3Nx/dUdl6sa0vB/wANbn4efD+00PQbqKXUPMMt9faknmNeyO26WR1HXc2cZ6Cstbgdp4f8T6T4mt3l0vUrfUYc43W7htvPQ85Fb7QKg+T5Wx+FeCaxouhw6pGviTSpPB+qFT9m1/RHMULnPGdvAPs4/GvSvAtr4h0/T54dd1mHWVWUCC+hTYTDjjeOhPuK1SA4/wAD/wCmftLfEW6QF4rfTdPtC/8AdbaXK/rXtB6CvFP2c5G10+NPF5Qga/rtw9v6fZ4iI4z+IBNe1+goAdRRRQAUUlIzDaeePrQAN90844rz34sePF+HfgPV9YdvMuNnkWca8mWd/ljRR65Ofwrqtc8Qad4d0e81LVLyOy0+GNpJriZ8Iigc5NeE+FodR+O3iyw8Xavby6Z4F0l/M0HT5kKzX8o4F1Ip/hA+6O9AHYfC+3034T+CtE0LVtTtbXWblDdXCzShPNmkO5iSe+TXqFrIt1GCCpVxkMMfMPYjrXnPinRda1H7SL7RNH8U6Xk4tmTbdBR6E8H8DXN+FdFi+2C48A+IJtMKSYvvD+qOzqoz820Nyh+nFZR3A6f9oO8jtfgn4qaQkCSz8sY7lmAArr/AVl9h8G6DbknMNlEm09R8grzP9oa6k1TSvC3hS2UCfX9WgRucjyY/3jn6YAr2Czh8mQBVCKo247ccD9KI/EwLrdqZI4C/ex9OtMu2ZYjjJPsM14/4qh+KXi7XLnTdMvtP8I+HY8KNUUC4vZx6Kn3V+prV7Adl48+KHh/4d2Rutd1aGxUjKQyHMknsqDkmvNF8YfEX40QiDw5p0ngbwxOMHW9UTF3cRnr5MPVMju1db4I+AvhnwlqX9qXEE3iHxA4zLq+tP9onLeqg/Kn4CvThGM5IzWa3A828I/CfSfhx4dvdP0OaSC+uf3l3q9z+9uZ3/vSM3X6dMVxfiKwi1DVrSw8XtHY3kuRpni7S/wByvmdBGx/vex4Ne6atDHNaTI6rtdCrEjIweteVR/DO7sdan0nyU1TwLqkZ8+zu5MvZSgZV4WPO0+natANTwBrni2HULnQPFFoJpbZP9H1u3X9zeR9mx/A47jvXL+NFHxK+OHh7wnDzpvhxf7a1PIyDN92FPrnLYrovFHiq1+C/w6+0XVzc37Wq/ZrSFvnluZGOIoh3LZx+ApfgT4Ev/COh3Go6+Vn8U67Kb/VZ852s33Il/wBlFwKzV29QPTY/mfOOc5z6VMn3jSqoXPFL+FaALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFFrgKpAY/c3cHp9a8U8UfFnXvHWsXHhH4YbJ7yBjDqfieZN9npfsv/PWb/ZHA71s/ErwL4h+IWoafpL6+dE8FkZ1GKyJS9vH3Y8gSD/Vx47rzXd+GPCOk+DdDtNJ0awh0vTLcbI7eFdoBHf3Puaz1uBzPw1+Fem/DHTZYrENfaheSefqGp3j77i+mOMu7+n+x0Fdxc6bHcWslsVJjkBDtnBwRjj8KurGqgAKtPIIzgVaVgPLLP4c3vh/UhDp+o/b/DN1uW+0bVB567T3ic/Nn2PA7VR+NniFPh58MX07w9b7dV1J10nSbOMnPmy/Jkf7KqWY/QV6ZeXdvpttLdXEyRW8MbNJKx+WMD5mZj6CvEPh+k3xv+JH/CwruKVPCOih7Tw1byDat0zcS3vPY/dX25pgeq/DXwjB4D8D6HoFscxWFvHCx/vNj5yfctzXY1Xit9jZwOTk/wCNWaACiiigCGR9ucfyrkPiF8SNC+Guiyalreoi3jZvLigRfMlmftHGg5LE8Cul1oXn9l3n9niFr/ym+zi4JEfmY+XcR2zivKvAHwbFlrx8XeNdTHi3xg52wzyJi1sVzxHDH0B/2utAHOaL4G8QfG7WLTXfiFbnSPDULiXTvCBOWc5ysl3jgt0IToO9e9R2qQqqRoFRBhVUYC+gA7cVMsYVgwXJzy2KlZVKn0oA4vxn4DtfFkcE/wBtvdL1G2yYLuwm2MhPqOje+ar+F/C9wv2W98RR2N/rlsWiS/tUKPMmeCw9a7eZUaMg4ryL40fEq58K2tp4c0FBd+M9cZrfTrZRuMK4w87eiqO/rWS3AoeHZF+Jn7Qmo63GwfSPCdsdPt+6SXT8yMPdRxXuCr1AGK4z4W+Abf4b+D7DRIP3ssfz3N0fvTzt8zufqa7bvWoCMoYdKj8lT1QH8OKmooAYsYVs4XP0p1DdKguGZYHKglscAUWAdMQ3BGR6YrlfHPjjQ/h7ocmr63dR2lrGu1VkGXkbsqKOWJ9BWR8T/idp/wAL/Dx1G+Sa9upmENhptuN093OeFjjXvk9SeBXH/Dv4W6n4o8QQeM/iUDe+If8AWWOi532ekKedqjo8oGMufwosBF8P/Cus/FLxlaeOvGlm9nZWwMnh/QbhcNbr0+0TL0MhH3fQV7qkWGHyn1Jz3psdvtkVyvzc4J5Iz1qxQAY5zS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVHtPMPKqefT8asGMbcYz3p9FACVGWwpOM+1S1h61rEeg6Pf6peEi2s7eWeUD+6gJ/UCgDxn4oSXHxY8fQ/C3T5ZE0eCJL7xPdRsRthLZjtAw/ikPJH90H1r2+x0u3061gtLW3SG2t1WOKKNQqoqjCgD0Aryv8AZn0ee3+Hf/CSamF/t3xZdNrV6x9JT+5XP+zGEGO3NezAe3NZ2dwCloorQApKWigBh+ameSNwJVfyqWloAToKRv8AVn6UtNk/1bfQ0Acx4y8X2HgnwzqmuarP5dhp8LTMe544QepJ4x71518C/Cd9dz3nxD8TW+3xP4jCtDA/P2Gz6xwqD0OOW9c1D8Zof+E6+IfgXwFIm7T5ZG1nUwOjQxfcU/V+v0r2m3gSMptj2qBhfoOBWaWoE0cKKRhQAOg9KlpMc06tACiiigBDVe+kWGBnc7Y1GWIOOB1qwelYfjbT7vVvCOs2di6x3txaSRQu3QOykAn8aT2A8c+FOn/8LQ+Imo/EbVAJLK2aSw8P2zdIolOHuPdnOcHqAK95hiCqAFwF6VyHwr8KnwZ4G0DRJlV7nT7VYZpEGFMmMsR9STXa96UdgClooqgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARvumuL+Kei3PiL4a+KtO0/JvbrTJoIkzglyhx+tdrUKxjdnvnmgDjvhfZz6f8AD/wvY3Vt9kvrfTbeOa3bqjrGoIz9Qa7eqnkr5gIHPXn2q3QAUUUUAFFFFABRRRQAUybPltgZ49cU+kb7poA8mvPC+qR/tDWGvramXSDoj2xuA3yxSb8hce4r1dM7Rzmo/JDY4Ax7VIqbcc0APooooAKKKKACmvGsikEAinUh6UARrAinKoFPU4qT0pB1p1GwBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=" /></p><p dir="RTL"><strong>مدة العلاج بليناليدوميد اس بي سي</strong></p><p dir="RTL">يُؤخذ ليناليدوميد اس بي سي وفقًا لدورات علاج، وتستمر كل دورة لمدة 21 او 28 يومًا (انظر أعلاه &quot;الدورة العلاجية&quot;). يجب أن تستمر في اتباع دورات العلاج حتى يخبرك الطبيب المعالج لك بأن تتوقف عن تناول العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من ليناليدوميد اس بي سي</strong></p><p dir="RTL">إذا تناولت كمية من ليناليدوميد اس بي سي أكثر مما وصفه الطبيب المعالج لك، فأخبر الطبيب المعالج لك على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول ليناليدوميد اس بي سي</strong></p><p dir="RTL"><strong>إذا نسيت تناول ليناليدوميد اس بي سي في الوقت المخصص له</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انقضى أقل من 12 ساعة، فتناول الكبسولة المنسية على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انقضى أكثر من 12 ساعة، فلا تتناول الكبسولة المنسية.</p><p dir="RTL">تناول فقط الكبسولة التالية الموصوفة لك في موعدها المعتاد في اليوم التالي. إذا كانت لديك أية أسئلة إضافية متعلقة باستخدام هذا الدواء، فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب ليناليدوميد اس بي سي ، مثله مثل كافة الأدوية، آثارًا جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توقف عن تناول ليناليدوميد اس بي سي وراجع الطبيب فوراً إذا لاحظت أي من الآثار الجانبية الخطيرة &ndash; تتطلب رعاية طبية عاجلة:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة ، طفح جلدي ، انتفاخ في العين ، الفم أو الوجه ، صعوبة في التنفس أو حكة ، والتي قد تكون أعراض رد فعل تحسسي خطير يسمى وذمة وعائية وتفاعل تأقي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي خطير قد يبدأ كطفح جلدي في منطقة واحدة ولكنه ينتشر مع فقدان شديد للجلد في جميع أنحاء الجسم (متلازمة ستيفنز جونسون و / أو تقشُّر الأنسجة المُتموّتة البَشرَوِية التسممي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي منتشر، ارتفاع درجة حرارة الجسم ، ارتفاع إنزيمات الكبد ، تغيرات في الدم (فرط الحمضات) ، تضخم الغدد الليمفاوية وبعض أعضاء الجسم الأخرى (تفاعل العلاج مع فرط الحمضات والأعراض الجهازية التي تعرف أيضًا باسم DRESS أو متلازمة فرط الحساسية للأدوية) انظر أيضاً القسم رقم 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ الطبيب المعالج لك فورًا، إذا شعرت بأي من الآثار الجانبية الخطيرة التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، قشعريرة، التهاب الحلق، سعال، تقرحات الفم أو أي أعراض أخرى من أعراض العدوى، بما في ذلك العدوى داخل مجرى الدم (تعفن الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف أو تكدُّم في حالة عدم وجود إصابة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر أو ألم بالساق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العظام، ضعف العضلات، ارتباك أو تعب الذي قد يكون بسبب ارتفاع مستوى الكالسيوم في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقلل ليناليدوميد اس بي سي من عدد خلايا الدم البيضاء التي تحارب العدوى وكذلك خلايا الدم التي تساعد على تجلط الدم (الصفائح الدموية) مما قد يؤدي إلى اضطرابات متعلقة بالنزيف مثل نزيف الأنف والتكدّم.</p><p dir="RTL">&nbsp;قد يسبب ليناليدوميد اس بي سي حدوث جلطات فى الاوردة (تجلط الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى</strong></p><p dir="RTL">من المهم ملاحظة أن عددًا صغيرًا من المرضى قد يصاب بأمراض سرطان أخرى، وأنه من الممكن أن يزداد هذا الخطر مع العلاج بليناليدوميد اس بي سي، لذلك يجب على الطبيب تقييم فوائد الدواء المتوقعة ومخاطره المحتملة قبل وصف ليناليدوميد اس بي سي لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًّا (قد تُؤثر على أكثر من مريض من بين كل 10 مرضى) </strong><strong>:</strong></p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء مما قد يسبب فقر الدم مما يؤدي إلى التعب والضعف.</p><p dir="RTL">&bull; طفح جلدي، حكة.</p><p dir="RTL">&bull; تشنجات في العضلات ، ضعف في العضلات ، آلام في العضلات ، آلام في العظام ، آلام في المفاصل ، آلام في الظهر ، ألم في الأطراف.</p><p dir="RTL">&bull; التورم العام بما في ذلك تورم الذراعين والساقين.</p><p dir="RTL">&bull; ضعف، تعب.</p><p dir="RTL">&bull; أعراض الحمى والأنفلونزا مثل الحمى، آلام العضلات، صداع، آلام الأذن، سعال وقشعريرة.</p><p dir="RTL">&bull; خدر، وخز أو حرقان في الجلد ، آلام في اليدين أو القدمين ، دوخة ، رعاش</p><p dir="RTL">&bull; انخفاض الشهية ، تغيرفي طريقة تذوق الأشياء</p><p dir="RTL">&bull; زيادة في الألم، حجم الورم أو الاحمرار حول الورم</p><p dir="RTL">&bull; فقدان الوزن.</p><p dir="RTL">&bull; إمساك، إسهال، غثيان، قيء، آلام في المعدة، حرقة في المعدة.</p><p dir="RTL">&bull; انخفاض مستويات البوتاسيوم أو الكالسيوم و / أو الصوديوم في الدم.</p><p dir="RTL">&bull; انخفاض فى عمل الغدة الدرقية.</p><p dir="RTL">&bull; آلام في الساق (والتي يمكن أن تكون من أعراض التخثر) ، ألم في الصدر أو ضيق في التنفس (والتي قد تكون من أعراض جلطات الدم في الرئتين ، تسمى الانسداد الرئوي).</p><p dir="RTL">&bull; الالتهابات بجميع أنواعها ، بما في ذلك التهاب الجيوب الأنفية المحيطة بالأنف وعدوى الرئة والجهاز التنفسي العلوي</p><p dir="RTL">&bull; ضيق في التنفس.</p><p dir="RTL">&bull; عدم وضوح الرؤية.</p><p dir="RTL">&bull; ضبابية العين (إعتام عدسة العين).</p><p dir="RTL">&bull; مشاكل الكلى التي تشمل عدم عمل الكلى بشكل صحيح أو عدم القدرة على الحفاظ على وظيفتها الطبيعية.</p><p dir="RTL">&bull; تغيرات فى نتائج اختبارات وظائف الكبد.</p><p dir="RTL">&bull; زيادة في نتائج فحص وظائف الكبد.</p><p dir="RTL">&bull; تغيرات في البروتين في الدم قد تؤدى الى تورم الشرايين (التهاب الأوعية الدموية).</p><p dir="RTL">&bull; زيادة في مستوى السكر في الدم (السكري).</p><p dir="RTL">&bull; انخفاض في مستويات السكر في الدم.</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&bull; نزيف في الأنف</p><p dir="RTL">&bull; جفاف الجلد.</p><p dir="RTL">&bull; اكتئاب، تغير في المزاج، صعوبة النوم</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; انخفاض في ضغط الدم.</p><p dir="RTL">&bull; شعور غامض بعدم الراحة الجسدية، الشعور بالتوعك.</p><p dir="RTL">&bull; التهاب الفم، جفاف الفم</p><p dir="RTL">&bull; جفاف.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تُؤثر على ما يصل إلى مريض من بين كل 10 مرضى</strong><strong> (</strong><strong>:</strong></p><p dir="RTL">&bull; تدمير خلايا الدم الحمراء (فقر الدم الانحلالي).</p><p dir="RTL">&bull; أنواع معينة من أورام الجلد.</p><p dir="RTL">&bull; نزيف اللثة، &nbsp;المعدة أو الأمعاء.</p><p dir="RTL">&bull; زيادة ضغط الدم، بطء ضربات القلب أوسرعتها أو عدم انتظام ضربات القلب.</p><p dir="RTL">&bull; زيادة كمية المادة الناتجة عن التكسير الطبيعي وغير الطبيعي لخلايا الدم الحمراء.</p><p dir="RTL">&bull; زيادة في نوع البروتين الذي يشير إلى التهاب في الجسم.</p><p dir="RTL">&bull; تحول البشرة الى اللون الداكن، تغير لون البشرة الناتج عن النزيف تحتها، والذي يحدث عادة بسبب كدمات وتورم في الجلد مملوء بالدم، تكدّم</p><p dir="RTL">&bull; زيادة حمض اليوريك في الدم.</p><p dir="RTL">&bull; طفح جلدي ، احمرار في الجلد ، تشقق او تقشر الجلد ، قشعريرة.</p><p dir="RTL">&bull; زيادة في التعرق، تعرق ليلي.</p><p dir="RTL">&bull; صعوبة في البلع ،التهاب الحلق ، اضطرابات فى جودة الصوت أو تغيرات في الصوت.</p><p dir="RTL">&bull; سيلان الأنف</p><p dir="RTL">&bull; تبول أكثر أو أقل بكثير من المعتاد أو عدم القدرة على التحكم في وقت التبول.</p><p dir="RTL">&bull; خروج دم في البول.</p><p dir="RTL">&bull; ضيق في التنفس خاصة عند الاستلقاء (والذي قد يكون أحد أعراض فشل القلب).</p><p dir="RTL">&bull; صعوبة في الانتصاب.</p><p dir="RTL">&bull; سكتة دماغية، إغماء، دوار (مشكلة في الأذن الداخلية تؤدي إلى الشعور بأن كل شيء يدور) ، فقدان مؤقت للوعي، صعوبة في التحدث.</p><p dir="RTL">&bull; ألم في الصدر ينتشر إلى الذراعين، الرقبة والفك، الظهر أو المعدة ، شعور بالعرق و صعوبة التنفس ، شعور بالغثيان أو القيء ، والتي قد تكون أعراض نوبة قلبية (احتشاء عضلة القلب).</p><p dir="RTL">&bull; ضعف في العضلات، نقص في الطاقة.</p><p dir="RTL">&bull; آلام في الرقبة، ألم في الصدر.</p><p dir="RTL">&bull; قشعريرة.</p><p dir="RTL">&bull; تورم في المفاصل.</p><p dir="RTL">&bull; تباطؤ أو انسداد تدفق الصفراء من الكبد.</p><p dir="RTL">&bull; انخفاض مستويات الفوسفات أو المغنيسيوم في الدم.</p><p dir="RTL">&bull; صعوبة في الكلام.</p><p dir="RTL">&bull; اصابة الكبد.</p><p dir="RTL">&bull; ضعف في التوازن، صعوبة الحركة.</p><p dir="RTL">&bull; صمم، رنين في الأذنين (طنين).</p><p dir="RTL">&bull; آلام في الأعصاب، إحساس غير طبيعي مزعج خاصة عند اللمس</p><p dir="RTL">&bull; زيادة في كمية الحديد في الجسم.</p><p dir="RTL">&bull; عطش</p><p dir="RTL">&bull; ارتباك</p><p dir="RTL">&bull; ألم في الأسنان</p><p dir="RTL">&bull; السقوط مما قد يؤدي إلى الإصابة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تُؤثر على ما يصل إلى مريض من بين كل 100 مريض</strong><strong>(:</strong></p><p dir="RTL">&bull; نزيف داخل الجمجمة.</p><p dir="RTL">&bull; مشاكل في الدورة الدموية.</p><p dir="RTL">&bull; فقدان البصر.</p><p dir="RTL">&bull; فقدان الدافع الجنسي (الرغبة الجنسية).</p><p dir="RTL">&bull; التبول بكميات كبيرة مع ألم في العظام وضعف، والتي قد تكون من أعراض اضطراب في الكلى (متلازمة فانكوني).</p><p dir="RTL">&bull; انصباغ الجلد أو الغشاء المخاطي أو العين باللون الاصفر(اليرقان) ، براز ملون شاحب ، بول داكن اللون ، حكة في الجلد ، طفح جلدي ، ألم أو تورم في المعدة - قد تكون هذه أعراض إصابة الكبد (فشل كبدي).</p><p dir="RTL">&bull; آلام في المعدة، انتفاخ أو إسهال، والتي قد تكون أعراض التهاب في الأمعاء الغليظة (تسمى التهاب القولون).</p><p dir="RTL">&bull; تلف خلايا الكلى (يسمى النخر الأنبوبي الكلوي).</p><p dir="RTL">&bull; تغير لون البشرة ، حساسية لأشعة الشمس.</p><p dir="RTL">&bull; متلازمة تحلل الورم - مضاعفات التمثيل الغذائي التي يمكن أن تحدث أثناء علاج السرطان وأحيانًا حتى بدون علاج. تحدث هذه المضاعفات بسبب تحلل منتجات الخلايا السرطانية المحتضرة وقد تشمل ما يلي: تغيرات في كيمياء الدم .ارتفاع نسبة البوتاسيوم ، الفوسفور ، حمض اليوريك ، وانخفاض الكالسيوم مما يؤدي إلى تغيرات في وظائف الكلى ، ضربات القلب ، حدوث تشنجات ، وأحيانًا الموت.</p><p dir="RTL">&bull; ارتفاع ضغط الدم داخل الأوعية الدموية التي تغذي الرئتين (ارتفاع ضغط الدم الرئوي).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية ذات النسب غير المعروفة (لا يمكن تقدير نسبة حدوثها من البيانات المتاحة):</strong></p><p dir="RTL">&bull; ألم مفاجئ أو خفيف ولكن متفاقم في الجزء العلوي من المعدة و / أو الظهر، والذي يبقى لبضعة أيام، ربما مصحوبًا بالغثيان، القيء، الحمى والنبض السريع - قد تكون هذه الأعراض بسبب التهاب البنكرياس.</p><p dir="RTL">&bull; تنفس بصفير،&nbsp; ضيق في التنفس أو سعال جاف، والتي قد تكون أعراض ناجمة عن التهاب الأنسجة في الرئتين.</p><p dir="RTL">&bull; لوحظت حالات نادرة لتكسير العضلات (آلام في العضلات، ضعف أو تورم) والتي يمكن أن تؤدي إلى مشاكل في الكلى (انحلال الربيدات)، بعضها عندما يتم إعطاء ليناليدوميد إس بي سي مع الستاتين (نوع من أدوية خفض الكوليسترول).</p><p dir="RTL">&bull; حالة تصيب الجلد بسبب التهاب الأوعية الدموية الصغيرة ، إلى جانب ألم في المفاصل والحمى (التهاب الأوعية الدموية و اعتلال كريات الدم البيضاء).</p><p dir="RTL">&bull; تكسير فى جدار المعدة أو الأمعاء. قد يؤدي هذا إلى عدوى خطيرة للغاية. أخبر طبيبك إذا كان لديك ألم شديد في المعدة، حمى، غثيان، قيء، دم في البراز أو تغيرات في عادات الاخراج.</p><p dir="RTL">&bull; التهابات فيروسية، بما في ذلك الهربس النطاقي (المعروف أيضًا باسم &quot;القوباء المنطقية&quot;، وهو مرض فيروسي يسبب طفح جلدي مؤلم مع بثور) وتكرار الإصابة بالتهاب الكبد B (الذي يمكن أن يسبب اصفرار الجلد والعينين، تغير لون البول &nbsp;الى البني الداكن ، ألم فى المعدة من الجانب الأيمن، حمى وشعور بالغثيان أو المرض).</p><p dir="RTL">&bull; عدم استقرار الأعضاء الصلبة (مثل الكلى والقلب).</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ &lt;طبيبك، أو مقدم الرعاية الصحية&gt; &lt;أو&gt; &lt;الصيدلي&gt;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا يتم تخزينه في درجة حرارة اعلى من 30 درجة مئوية</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن متناول ورؤية الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة والشريط بعد كلمة &quot; EXP &quot;. يُشير تاريخ انتهاء الصلاحية</p><p dir="RTL">إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يتطلب هذا المنتج أي ظروف تخزين خاصة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء إذا لاحظت أي تلف أو علامات تدل على العبث بالعبوة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. يُرجى إعادة الأدوية غير المستخدمة إلى الصيدلي. تساعد تلك الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ليناليدوميد 5 ملغم اس بي سي كبسولات صلبة: تحتوي كل كبسولة على 5 ملغم من ليناليدوميد.</p><p dir="RTL">ليناليدوميد 10 ملغم اس بي سي كبسولات صلبة: تحتوي كل كبسولة على 10 ملغم من ليناليدوميد.</p><p dir="RTL">ليناليدوميد 15 ملغم اس بي سي كبسولات صلبة: تحتوي كل كبسولة على 15 ملغم من ليناليدوميد.</p><p dir="RTL">ليناليدوميد 20 ملغم اس بي سي كبسولات صلبة: تحتوي كل كبسولة على 20 ملغم من ليناليدوميد.</p><p dir="RTL">ليناليدوميد 25 ملغم اس بي سي كبسولات صلبة: تحتوي كل كبسولة على 25 ملغم من ليناليدوميد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>ليناليدوميد 5 ملغم اس بي سي كبسولات صلبة</u></strong><strong><u>:</u></strong></p><p dir="RTL">مسحوق أبيض يميل إلى الأبيض المصفر معبأ في كبسولات جيلاتينية صلبة بحجم 4 ، ذات غطاء أبيض معتم مطبوع عليه &quot; SPC &quot; بالحبر الأسود، وذات جسم أبيض معتم مطبوع عليه &quot; 5 ملغم&quot; بالحبر الأسود.</p><p dir="RTL"><strong><u>ليناليدوميد 10 ملغم اس بي سي كبسولات صلبة</u></strong><strong><u>:</u></strong></p><p dir="RTL">مسحوق أبيض يميل إلى الأبيض المصفر معبأ في كبسولات جيلاتينية صلبة بحجم 2 ، ذات غطاء أخضر باهت مطبوع عليه &quot; SPC &quot; بالحبر الأسود، وذات جسم أصفر باهت مطبوع عليه &quot; 10 ملغم&quot; بالحبر الأسود.</p><p dir="RTL"><strong><u>ليناليدوميد 15 ملغم اس بي سي كبسولات صلبة</u></strong><strong><u>:</u></strong></p><p dir="RTL">مسحوق أبيض يميل الى الأبيض المصفر معبأ في كبسولات جيلاتينية صلبة بحجم 1 ، ذات غطاء ازرق مطبوع عليه &quot; SPC &quot; بالحبر الأسود، وذات جسم أبيض معتم مطبوع عليه &quot; 15 ملغم&quot; بالحبر الأسود</p><p dir="RTL"><strong><u>ليناليدوميد 20 ملغم اس بي سي كبسولات صلبة</u></strong><strong><u>:</u></strong></p><p dir="RTL">مسحوق أبيض يميل الى الأبيض المصفر معبأ في كبسولات جيلاتينية صلبة بحجم 0 ، ذات غطاء اخضر مطبوع عليه &quot; SPC &quot; بالحبر الأسود، وذات جسم أبيض معتم مطبوع عليه &quot; 20 ملغم&quot; بالحبر الأسود</p><p dir="RTL"><strong><u>ليناليدوميد 25 ملغم اس بي سي كبسولات صلبة</u></strong><strong><u>:</u></strong></p><p dir="RTL">مسحوق أبيض يميل إلى الأبيض المصفر معبأ في كبسولات جيلاتينية صلبة بحجم 0 ، ذات غطاء أبيض معتم مطبوع عليه &quot; SPC &quot; بالحبر الأسود، وذات جسم أبيض معتم مطبوع عليه &quot; 25 ملغم&quot; بالحبر الأسود.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شريط مصنوع من الألومنيوم عبوات بأحجام 7 كبسولات أو 21 كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>التصنيع وحامل ترخيص التسويق</strong><strong>:</strong></p><p dir="RTL">شركة سدير للأدوية (SPC)</p><p dir="RTL">طريق الملك فهد، الرياض جاليري، مبنى A1، الرياض، المملكة العربية السعودية</p><p dir="RTL">هاتف: &lrm;۹٦٦١١۹٢٠٠٠١٤٣٢+</p><p dir="RTL">فاكس: &lrm;۹٦٦١١٤٦٦٨١۹٥+</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p dir="RTL">المراسلة بالبريد: صندوق بريد 12363، الرياض، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lenalidomide 5 mg capsules, hard 
Lenalidomide 10 mg capsules, hard 
Lenalidomide 15 mg capsules, hard 
Lenalidomide 20 mg capsules, hard 
Lenalidomide 25mg capsules, hard
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lenalidomide 5 mg SPC capsules, hard: Each capsule contains 5 mg of Lenalidomide. 
Lenalidomide 10 mg SPC capsules, hard: Each capsule contains 10 mg of Lenalidomide. 
Lenalidomide 15 mg capsules, hard: Each capsule contains 15 mg of Lenalidomide.
Lenalidomide 20 mg capsules, hard: Each capsule contains 20 mg of Lenalidomide.
Lenalidomide 25mg SPC capsules, hard: Each capsule contains 25 mg of Lenalidomide

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
Lenalidomide 5 mg capsules, hard:
White to off-white colored powder filled in size ‘4’ hard gelatin capsules with opaque white colored cap imprinted ‘SPC’ with black ink and opaque white colored body imprinted ‘5mg’ with black ink.
Lenalidomide 10 mg capsules, hard:
White to off-white colored powder filled in size ‘2’ hard gelatin capsules with pale green colored cap imprinted ‘SPC’ with black ink and pale-yellow colored body imprinted ‘10mg’ with black ink.


Lenalidomide 15 mg capsules, hard:

White to off-white colored powder filled in size ‘1’ hard gelatin capsules with blue colored cap imprinted ‘SPC’ with black ink and white colored body imprinted ’15 mg’ with black ink.
Lenalidomide 20mg capsules, hard:

White to off-white colored powder filled in size ‘0’ hard gelatin capsules pale green colored cap imprinted ‘SPC’ with black ink and pale blue colored body imprinted ’20 mg’ with black
Lenalidomide 25mg SPC capsules, hard:

White to off-white colored powder filled in size ‘0’ hard gelatin capsules with opaque white colored cap imprinted ‘SPC’ with black ink and opaque white colored body imprinted ‘25mg’ with black ink.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Multiple myeloma</u></strong><br />Lenalidomide as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.</p><p>Lenalidomide as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.<br />Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.</p><p><u><strong>Myelodysplastic syndromes</strong></u><br />Lenalidomide is indicated for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.</p><p><u><strong>Mantle cell lymphoma</strong></u><br />Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1).</p><p><u><strong>Follicular lymphoma</strong></u><br />Lenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 &ndash; 3a).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lenalidomide treatment should be supervised by a physician experienced in the use of anti-cancer therapies.</p><p>For all indications described below:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose is modified based upon clinical and laboratory findings (see section 4.4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustments, during treatment and restart of treatment, are recommended to manage Grade 3 or 4 thrombocytopenia, neutropenia, or other Grade 3 or 4 toxicity judged to be related to lenalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In case of neutropenia, the use of growth factors in patient management should be considered.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If less than 12 hours has elapsed since missing a dose, the patient can take the dose. If more than 12 hours has elapsed since missing a dose at the normal time, the patient should not take the dose, but take the next dose at the normal time on the following day.</p><p>&nbsp;</p><p><strong><u>Posology</u></strong></p><p>Newly diagnosed multiple myeloma (NDMM)</p><p>&bull; <strong><em><u>&nbsp;Lenalidomide in combination with dexamethasone until disease progression in patients who are </u>&nbsp;<u>not eligible for transplant</u></em></strong></p><p>Lenalidomide treatment must not be started if the ANC is &lt; 1.0 x 10⁹/L, and/or platelet counts are &lt; 50 x 10⁹/L.</p><p>&nbsp;</p><p><em>Recommended dose</em></p><p>The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.</p><p>The recommended dose of dexamethasone is 40 mg orally once daily on days 1, 8, 15 and 22 of repeated 28-day cycles. Patients may continue lenalidomide and dexamethasone therapy until disease progression or intolerance.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <em>Dose reduction steps</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Lenalidomide ͣ</p></td><td><p>Dexamethasone ͣ</p></td></tr><tr><td><p>Starting dose</p></td><td><p>25 mg</p></td><td><p>40 mg</p></td></tr><tr><td><p>Dose level -1</p></td><td><p>20 mg</p></td><td><p>20 mg</p></td></tr><tr><td><p>Dose level -2</p></td><td><p>15 mg</p></td><td><p>12 mg</p></td></tr><tr><td><p>Dose level -3</p></td><td><p>10 mg</p></td><td><p>8 mg</p></td></tr><tr><td><p>Dose level- 4</p></td><td><p>5 mg</p></td><td><p>4 mg</p></td></tr><tr><td><p>Dose level -5</p></td><td><p>2.5 mg</p></td><td><p>Not applicable</p></td></tr></tbody></table><p><sup>a</sup> Dose reduction for both products can be managed independently</p><p>&bull;&nbsp;&nbsp; <em>Thrombocytopenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended course</p></td></tr><tr><td><p>Falls to &lt; 25 x 10⁹/L</p></td><td><p>Stop lenalidomide dosing for remainder of cycle&ordf;</p></td></tr><tr><td><p>Returns to &ge; 50 x 10⁹/L</p></td><td><p>Decrease by one dose level when dosing resumed at next cycle</p></td></tr></tbody></table><p>&ordf; If Dose limiting toxicity (DLT) occurs on &gt; day15 of a cycle, lenalidomide dosing will be interrupted for at least the remainder of the current 28-day cycle.</p><p>&bull;&nbsp;&nbsp; <em>Absolute neutrophil count (ANC) &ndash; neutropenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended course <sup>a</sup></p></td></tr><tr><td><p>First falls to &lt; 0.5 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Returns to &ge; 1 x 10⁹/L when neutropenia is the</p><p>only observed toxicity</p></td><td><p>Resume lenalidomide at starting dose once daily</p></td></tr><tr><td><p>Returns to &ge; 0.5 x 10<sup>9</sup>/L when dose-dependent haematological toxicities other than neutropenia are observed</p></td><td><p>Resume lenalidomide at dose level -1 once daily</p></td></tr><tr><td><p>For each subsequent drop below &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Returns to &ge; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level once daily.</p></td></tr></tbody></table><p><sup>a</sup> At the physician&#39;s discretion, if neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide.</p><p>For hematologic toxicity the dose of lenalidomide may be re-introduced to the next higher dose level (up to the starting dose) upon improvement in bone marrow function (no hematologic toxicity for at least 2 consecutive cycles: ANC &ge;1,5 x 10<sup>9</sup>/L with a platelet count &ge; 100 x 10<sup>9</sup>/L at the beginning of a new cycle).</p><p>&nbsp;</p><p>&bull; <u>&nbsp;Lenalidomide in combination with bortezomib and dexamethasone followed by lenalidomide and</u> <u>dexamethasone until disease progression in patients who are not eligible for transplant</u></p><p><em>Initial treatment: Lenalidomide in combination with bortezomib and dexamethasone</em></p><p>Lenalidomide in combination with bortezomib and dexamethasone must not be started if the ANC is &lt; 1.0 x 10<sup>9</sup>/L, and/or platelet counts are &lt; 50 x 10<sup>9</sup>/L.</p><p>The recommended starting dose is lenalidomide 25 mg orally once daily days 1-14 of each 21-day cycle in combination with bortezomib and dexamethasone. Bortezomib should be administered via subcutaneous injection (1.3 mg/m<sup>2</sup> body surface area) twice weekly on days 1, 4, 8 and 11 of each 21- day. For additional information on the dose, schedule and dose adjustments of medicinal products administered with lenalidomide, see Section 5.1 and the corresponding Summary of Product Characteristics.</p><p>Up to eight 21-day treatment cycles (24 weeks of initial treatment) are recommended.</p><p><em>Continued treatment: Lenalidomide in combination with dexamethasone until progression</em></p><p>Continue lenalidomide 25 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone. Treatment should be continued until disease progression or unacceptable toxicity.</p><p>&bull;&nbsp; <em>Dose reduction steps</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Lenalidomide<sup>a</sup></p></td></tr><tr><td><p>Starting dose</p></td><td><p>25 mg</p></td></tr><tr><td><p>Dose level -1</p></td><td><p>20 mg</p></td></tr><tr><td><p>Dose level -2</p></td><td><p>15 mg</p></td></tr><tr><td><p>Dose level -3</p></td><td><p>10 mg</p></td></tr><tr><td><p>Dose level- 4</p></td><td><p>5 mg</p></td></tr><tr><td><p>Dose level -5</p></td><td><p>2.5 mg</p></td></tr></tbody></table><p>&ordf; Dose reduction for all products can be managed independently</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp; <em>Thrombocytopenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended course</p></td></tr><tr><td><p>Fall to &lt; 30 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 50 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at dose level -1 once daily</p></td></tr><tr><td><p>For each subsequent drop below 30 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 50 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level once daily</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>&bull;&nbsp; <em>Absolute neutrophil count (ANC) - neutropenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended course<sup>a</sup></p></td></tr><tr><td><p>First fall to &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 1 x 10<sup>9</sup>/L when neutropenia is the only</p><p>observed toxicity</p></td><td><p>Resume lenalidomide at starting dose once daily</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L when dose-dependent</p><p>haematological toxicities other than neutropenia are observed</p></td><td><p>Resume lenalidomide at dose level -1 once daily</p></td></tr><tr><td><p>For each subsequent drop below &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level once daily.</p></td></tr></tbody></table><p><sup>a</sup> At the physician&#39;s discretion, if neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Lenalidomide in combination with melphalan and prednisone followed by maintenance in</u> <u>patients who are not eligible for transplant</u></p><p>Lenalidomide treatment must not be started if the ANC is &lt; 1.5 x 10<sup>9</sup>/L, and/or platelet counts are &lt; 75 x 10<sup>9</sup>/L.</p><p><em><u>Recommended dose</u></em></p><p>The recommended starting dose is lenalidomide 10 mg orally once daily on days 1-21 of repeated 28- day cycles for up to 9 cycles, melphalan 0.18 mg/kg orally on days 1 to 4 of repeated 28-day cycles, prednisone 2 mg/kg orally on days 1 to 4 of repeated 28-day cycles. Patients who complete 9 cycles or who are unable to complete the combination therapy due to intolerance are treated with lenalidomide monotherapy as follows: 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles given until disease progression.</p><p>&bull;&nbsp; <em>Dose reduction steps</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Lenalidomide</p></td><td><p>Melphalan</p></td><td><p>Prednisone</p></td></tr><tr><td><p>Starting dose</p></td><td><p>10 mg&ordf;</p></td><td><p>0.18 mg/kg</p></td><td><p>2 mg/kg</p></td></tr><tr><td><p>Dose level -1</p></td><td><p>7.5 mg</p></td><td><p>0.14 mg/kg</p></td><td><p>1 mg/kg</p></td></tr><tr><td><p>Dose level -2</p></td><td><p>5 mg</p></td><td><p>0.10 mg/kg</p></td><td><p>0.5 mg/kg</p></td></tr><tr><td><p>Dose level -3</p></td><td><p>2.5 mg</p></td><td><p>Not applicable</p></td><td><p>0.25 mg/kg</p></td></tr></tbody></table><p>&ordf; <em>If neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G- CSF) and maintain the dose level of lenalidomide</em></p><p><em>&nbsp;</em></p><p>&bull;&nbsp; <em>Thrombocytopenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended course</p></td></tr><tr><td><p>First fall to &lt; 25 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 25 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide and melphalan at Dose level -1</p></td></tr><tr><td><p>For each subsequent drop below 30 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 30 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level (Dose level -2 or -3) once daily.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>&bull;&nbsp; <em>Absolute neutrophil count (ANC) - neutropenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended course &ordf;</p></td></tr><tr><td><p>First fall to &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L when neutropenia is the</p><p>only observed toxicity</p></td><td><p>Resume lenalidomide at Starting dose once daily</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L when dose-dependent</p><p>haematological toxicities other than neutropenia are observed</p></td><td><p>Resume lenalidomide at Dose level -1 once daily</p></td></tr><tr><td><p>For each subsequent drop below &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level once daily.</p></td></tr></tbody></table><p><em>&ordf; At the physician&#39;s discretion, if neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide.</em></p><p>&bull;&nbsp;&nbsp; <u>Lenalidomide maintenance in patients who have undergone autologous stem cell transplantation</u> <u>(ASCT)</u></p><p>Lenalidomide maintenance should be initiated after adequate haematologic recovery following ASCT in patients without evidence of progression. Lenalidomide must not be started if the Absolute ANCis &lt; 1.0 x 10<sup>9</sup>/L, and/or platelet counts are &lt; 75 x 10<sup>9</sup>/L.</p><p>&nbsp;</p><p><em>Recommended dose</em></p><p>The recommended starting dose is lenalidomide 10 mg orally once daily continuously (on days 1 to 28 of repeated 28-day cycles) given until disease progression or intolerance. After 3 cycles of lenalidomide maintenance, the dose can be increased to 15 mg orally once daily if tolerated.</p><p>&bull;&nbsp; <em>Dose reduction steps</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Starting dose (10 mg)</p></td><td><p>If dose increased (15 mg) ͣ</p></td></tr><tr><td><p>Dose level -1</p></td><td><p>5 mg</p></td><td><p>10 mg</p></td></tr><tr><td><p>Dose level -2</p></td><td><p>5 mg (days 1-21 every 28 days)</p></td><td><p>5 mg</p></td></tr><tr><td><p>Dose level -3</p></td><td><p>Not applicable</p></td><td><p>5 mg (days 1-21 every 28 days)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>Do not dose below 5 mg (days 1-21 every 28 days)</p></td></tr></tbody></table><p>ͣ After 3 cycles of lenalidomide maintenance, the dose can be increased to 15 mg orally once daily if tolerated.</p><p>&bull;&nbsp; <em>Thrombocytopenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended course</p></td></tr><tr><td><p>Falls to &lt; 30 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Returns to &ge; 30 x 10⁹/L</p></td><td><p>Resume lenalidomide at dose level -1 once daily</p></td></tr><tr><td><p>For each subsequent drop below 30 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Returns to &ge; 30 x 10⁹/L</p></td><td><p>Resume lenalidomide at next lower dose level once daily</p></td></tr></tbody></table><p>&bull;&nbsp; <em>Absolute neutrophil count (ANC) &ndash; neutropenia</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended course ͣ</p></td></tr><tr><td><p>Falls to &lt; 0.5 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Returns to &ge; 0.5 x 10⁹/L</p></td><td><p>Resume lenalidomide at dose level -1 once daily</p></td></tr><tr><td><p>For each subsequent drop below &lt; 0.5 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Returns to &ge; 0.5 x 10⁹/L</p></td><td><p>Resume lenalidomide at next lower dose level once daily</p></td></tr></tbody></table><p>ͣ At the physician&#39;s discretion, if neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide.</p><p>Multiple myeloma with at least one prior therapy</p><p>Lenalidomide treatment must not be started if the ANC &lt; 1.0 x 10⁹/L, and/or platelet counts &lt; 75 x 10⁹/L or, dependent on bone marrow infiltration by plasma cells, platelet counts &lt; 30 x 10⁹/L.</p><p><em><u>Recommended dose</u></em></p><p>The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 1 to 4 every 28 days.</p><p>Prescribing physicians should carefully evaluate which dose of dexamethasone to use, taking into account the condition and disease status of the patient.</p><p>&nbsp;</p><p>&bull;&nbsp; <em>Dose reduction steps</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Starting dose</p></td><td><p>25 mg</p></td></tr><tr><td><p>Dose level -1</p></td><td><p>15 mg</p></td></tr><tr><td><p>Dose level -2</p></td><td><p>10 mg</p></td></tr><tr><td><p>Dose level -3</p></td><td><p>5 mg</p></td></tr></tbody></table><p>&bull;&nbsp; <em>Thrombocytopenia</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended course</p></td></tr><tr><td><p>First fall to &lt; 30 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 30 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at Dose level -1</p></td></tr><tr><td><p>For each subsequent drop below 30 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 30 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level</p><p>(Dose level -2 or -3) once daily. Do not dose below 5 mg once daily.</p></td></tr></tbody></table><p>&bull;&nbsp; <em>Absolute neutrophil count (ANC) - neutropenia</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended course<sup>a</sup></p></td></tr><tr><td><p>First fall to &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L when neutropenia is the</p><p>only observed toxicity</p></td><td><p>Resume lenalidomide at Starting dose once daily</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L when dose-dependent haematological toxicities other than neutropenia are observed</p></td><td><p>Resume lenalidomide at Dose level -1 once daily</p></td></tr><tr><td><p>For each subsequent drop below &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level (Dose level -1, -2 or -3) once daily. Do not dose below 5 mg once daily.</p></td></tr></tbody></table><p>ͣ At the physician&#39;s discretion, if neutropenia is the only toxicity at any dose level, add granulocyte colony stimulating factor (G-CSF) and maintain the dose level of lenalidomide.</p><p>Myelodysplastic syndromes (MDS)</p><p>Lenalidomide treatment must not be started if the ANC &lt; 0.5 x 10<sup>9</sup>/L and/or platelet counts &lt; 25 x 10<sup>9</sup>/L.</p><p><em><u>Recommended dose</u></em></p><p>The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.</p><p>&nbsp;</p><p>&bull;&nbsp; <strong><em>Dose reduction steps</em></strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Starting dose</p></td><td><p>10 mg once daily on days 1 to 21 every 28 days</p></td></tr><tr><td><p>Dose level -1</p></td><td><p>5.0 mg once daily on days 1 to 28 every 28 days</p></td></tr><tr><td><p>Dose level -2</p></td><td><p>2.5 mg once daily on days 1 to 28 every 28 days</p></td></tr><tr><td><p>Dose level -3</p></td><td><p>2.5 mg every other day 1 to 28 every 28 days</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p>&bull;&nbsp; <strong><em>Thrombocytopenia</em></strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended course</p></td></tr><tr><td><p>Fall to &lt; 25 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 25 x 10<sup>9</sup>/L - &lt; 50 x 10<sup>9</sup>/L on at least 2 occasions for &ge; 7 days or when the platelet count recovers to &ge; 50 x 10<sup>9</sup>/L at any time</p></td><td><p>Resume lenalidomide at next lower dose level (Dose level -1, -2 or -3)</p></td></tr></tbody></table><p>&nbsp;</p><p>&bull;&nbsp; <strong><em>Absolute neutrophil count (ANC) - neutropenia</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended course</p></td></tr><tr><td><p>Fall to &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Return to &ge; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level (Dose level -1, -2 or -3)</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p><em><u>Discontinuation of lenalidomide</u></em></p><p>Patients without at least a minor erythroid response within 4 months of therapy initiation, demonstrated by at least a 50% reduction in transfusion requirements or, if not transfused, a 1g/dl rise in haemoglobin, should discontinue lenalidomide treatment.</p><p>&nbsp;</p><p>Mantle cell lymphoma</p><p><em><u>Recommended dose</u></em></p><p>The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.</p><p>&bull;&nbsp; Dose reduction steps</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Starting dose</p></td><td><p>25 mg once daily on days 1 to 21, every 28 days</p></td></tr><tr><td><p>Dose Level -1</p></td><td><p>20 mg once daily on days 1 to 21, every 28 days</p></td></tr><tr><td><p>Dose Level -2</p></td><td><p>15 mg once daily on days 1 to 21, every 28 days</p></td></tr><tr><td><p>Dose Level -3</p></td><td><p>10 mg once daily on days 1 to 21, every 28 days</p></td></tr><tr><td><p>Dose Level -4</p></td><td><p>5 mg once daily on days 1 to 21, every 28 days</p></td></tr><tr><td><p>Dose Level -5</p></td><td><p>2.5 mg once daily on days 1 to 21, every 28 days<sup>1</sup></p><p>5 mg every other day on days 1 to 21, every 28 days</p></td></tr></tbody></table><p><sup>1</sup> - In countries where the 2.5 mg capsule is available.</p><p>&bull;&nbsp; <strong><em>Thrombocytopenia</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended Course</p></td></tr><tr><td><p>Fall to &lt; 50 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment and conduct Complete Blood Count (CBC) at least every 7 days</p></td></tr><tr><td><p>Return to &ge; 60 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower level (Dose Level -1)</p></td></tr><tr><td><p>For each subsequent drop below 50 x 10<sup>9</sup>/L</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Return to &ge;60 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment and conduct the CBC at least every 7 days</p><p><strong><em>&nbsp;</em></strong></p><p>Resume lenalidomide at next lower level (Dose Level -2, -3, -4 or -5). Do not dose below Dose</p><p>Level -5</p></td></tr></tbody></table><p>&bull;&nbsp; <strong><em>Absolute neutrophil count (ANC) - neutropenia</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended Course</p></td></tr><tr><td><p>Fall to &lt; 1 x 10<sup>9</sup>/L for at least 7 days or</p><p>Falls to &lt; 1 x 10<sup>9</sup>/L with associated fever (body</p><p>temperature &ge; 38.5&deg;C) or</p><p>Falls to &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment and conduct the CBC at least every 7 days</p></td></tr><tr><td><p>Return to &ge; 1 x 10<sup>9</sup>/L</p></td><td><p>Resume lenalidomide at next lower dose level (Dose Level -1)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>For each subsequent drop below 1 x 10<sup>9</sup>/L for at least 7 days or drop to &lt; 1 x 10<sup>9</sup>/L with associated fever (body temperature &ge; 38.5&deg;C) or drop to &lt; 0.5 x 10<sup>9</sup>/L</p></td><td><p>Interrupt lenalidomide treatment</p></td></tr><tr><td><p>Returns to &ge;1 x 10<sup>9</sup>/L</p></td><td><p>Resume Lenalidomide at next lower dose level (Dose Level -2, -3, -4, -5). Do not dose below Dose</p><p>Level -5</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p>Follicular lymphoma (FL)</p><p>Lenalidomide treatment must not be started if the ANC is &lt; 1 x 10⁹/L, and/or platelet count &lt; 50 x 10⁹/L, unless secondary to lymphoma infiltration of bone marrow.</p><p><em>Recommended dose</em></p><p>The recommended starting dose of lenalidomide is 20 mg, orally once daily on days 1 to 21 of repeated 28-day cycles for up to 12 cycles of treatment. The recommended starting dose of rituximab is 375 mg/m&sup2; intravenously (IV) every week in Cycle 1 (days 1, 8, 15, and 22) and day 1 of every 28-day cycle for cycles 2 through 5.</p><p>&nbsp;</p><p>&bull;&nbsp; Dose reduction steps</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Starting dose</p></td><td><p>20 mg once daily on days 1-21, every 28 days</p></td></tr><tr><td><p>Dose Level -1</p></td><td><p>15 mg once daily on days 1-21, every 28 days</p></td></tr><tr><td><p>Dose Level -2</p></td><td><p>10 mg once daily on days 1-21, every 28 days</p></td></tr><tr><td><p>Dose Level -3</p></td><td><p>5 mg once daily on days 1-21, every 28 days</p></td></tr></tbody></table><p>For dose adjustments due to toxicity with rituximab, refer to the corresponding summary of product characteristics.</p><p>&nbsp;</p><p>&bull;&nbsp; Thrombocytopenia</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When platelets</p></td><td><p>Recommended course</p></td></tr><tr><td><p>Falls to &lt; 50 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment and conduct CBC at least every 7 days</p></td></tr><tr><td><p>Returns to &ge; 50 x 10⁹/L</p></td><td><p>Resume at next lower dose level (dose level -1)</p></td></tr><tr><td><p>For each subsequent drop below 50 x 10⁹/L</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Returns to &ge; 50 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment and conduct CBC at least every 7 days</p><p>Resume lenalidomide at next lower dose level (dose level -2, -3). Do not dose below dose level</p><p>-3.</p></td></tr></tbody></table><p>&bull;&nbsp; Absolute neutrophil count (ANC) &ndash; neutropenia</p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>When ANC</p></td><td><p>Recommended course &ordf;</p></td></tr><tr><td><p>Falls &lt; 1.0 x 10⁹/L for at least 7 days or</p><p>Falls to &lt; 1.0 x 10⁹/L with associated fever (body temperature &ge; 38.5&deg;C) or</p><p>Falls to &lt; 0.5 x 10⁹/L</p></td><td><p>Interrupt lenalidomide treatment and conduct CBC at least every 7 days</p></td></tr><tr><td><p>Returns to &ge; 1.0 x 10⁹/L</p></td><td><p>Resume lenalidomide at next lower dose level (dose level -1)</p></td></tr><tr><td><p>For each subsequent drop below 1.0 x 10⁹/L for at least 7 days or drop to &lt; 1.0 x 10⁹/L with</p></td><td><p>Interrupt lenalidomide treatment and conduct CBC at least every 7 days</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>associated fever (body temperature &ge; 38.5&deg;C) or drop to &lt; 0.5 x 10⁹/L</p><p>Returns to &ge;1.0 x 10⁹/L</p></td><td><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Resume lenalidomide at next lower dose level (dose level -2, -3). Do not dose below dose level- 3</p></td></tr></tbody></table><p>&ordf; At the physician&#39;s discretion, if neutropenia is the only toxicity at any dose level, add G-CSF</p><p>&bull;&nbsp; Mantle cell lymphoma (MCL) or follicular lymphoma (FL)</p><p><strong><em>&nbsp;</em></strong></p><p><em>Tumour lysis syndrome (TLS)</em></p><p><em>&nbsp;</em></p><p>All patients should receive TLS prophylaxis (allopurinol, rasburicase or equivalent as per institutional guidelines) and be well hydrated (orally) during the first week of the first cycle or for a longer period if clinically indicated. To monitor for TLS, patients should have a chemistry panel drawn weekly during the first cycle and as clinically indicated.</p><p>Lenalidomide may be continued (maintain dose) in patients with laboratory TLS or Grade 1 clinical TLS, or at the physician&#39;s discretion, reduce dose by one level and continue lenalidomide. Vigorous intravenous hydration should be provided and appropriate medical management according to the local standard of care, until correction of electrolyte abnormalities. Rasburicase therapy may be needed to reduce hyperuricaemia. Hospitalisation of the patient will be at physician&#39;s discretion.</p><p>In patients with Grade 2 to 4 clinical TLS, interrupt lenalidomide and obtain a chemistry panel weekly or as clinically indicated. Vigorous intravenous hydration should be provided and appropriate medical management according to the local standard of care, until correction of electrolyte abnormalities. Rasburicase therapy and hospitalisation will be at physician&#39;s discretion. When the TLS resolves to Grade 0, restart lenalidomide at next lower dose per physician&#39;s discretion (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Tumour flare reaction</em></p><p>At the physician&#39;s discretion, lenalidomide may be continued in patients with Grade 1 or 2 tumour flare reaction (TFR) without interruption or modification. At the physician&#39;s discretion, therapy with non- steroidal anti-inflammatory drugs (NSAIDs), limited duration corticosteroids, and/or narcotic analgesics may be administered. In patients with Grade 3 or 4 TFR, withhold treatment with lenalidomide and initiate therapy with NSAIDs, corticosteroids and/or narcotic analgesics. When TFR resolves to &le; Grade 1, restart lenalidomide treatment at the same dose level for the rest of the cycle. Patients may be treated for management of symptoms per the guidance for treatment of Grade 1 and 2 TFR (see section 4.4).</p><p><em><u>All indications</u></em></p><p>For other grade 3 or 4 toxicities judged to be related to lenalidomide, treatment should be stopped and only restarted at next lower dose level when toxicity has resolved to &le; Grade 2 depending on the physician&#39;s discretion.</p><p>Lenalidomide interruption or discontinuation should be considered for grade 2 or 3 skin rash. Lenalidomide must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is suspected, is suspected, and should not be resumed following discontinuation from these reactions.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Paediatric population</u></p><p>Lenalidomide SPC should not be used in children and adolescents from birth to less than 18 years because of safety concerns (see section 5.1).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Elderly</u></p><p>Currently available pharmacokinetic data are described in section 5.2. Lenalidomide has been used in clinical trials in multiple myeloma patients up to 91 years of age and in myelodysplastic syndromes patients up to 95 years of age and in mantle cell lymphoma patients up to 88 years of age (see section 5.1).</p><p>Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it would be prudent to monitor renal function.</p><p><em>Newly diagnosed multiple myeloma: patients who are not eligible for transplant</em></p><p>Patients with newly diagnosed multiple myeloma aged 75 years and older should be carefully assessed before treatment is considered (see section 4.4).</p><p>For patients older than 75 years of age treated with lenalidomide in combination with dexamethasone, the starting dose of dexamethasone is 20 mg once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle.</p><p>No dose adjustment is proposed for patients older than 75 years who are treated with lenalidomide in combination with melphalan and prednisone.</p><p>In patients with newly diagnosed multiple myeloma aged 75 years and older who received lenalidomide, there was a higher incidence of serious adverse reactions and adverse reactions that led to treatment discontinuation.</p><p>Lenalidomide combined therapy was less tolerated in newly diagnosed multiple myeloma patients older than 75 years of age compared to the younger population. These patients discontinued at a higher rate due to intolerance (Grade 3 or 4 adverse events and serious adverse events), when compared to patients &lt; 75 years.</p><p><em>Multiple myeloma: Patients with at least one prior </em>therapy</p><p>The percentage of multiple myeloma patients aged 65 or over was not significantly different between the lenalidomide/dexamethasone and placebo/dexamethasone groups. No overall difference in safety or efficacy was observed between these patients and younger patients, but greater pre-disposition of older individuals cannot be ruled out.</p><p><em>Myelodysplastic syndromes</em></p><p>For myelodysplastic syndromes patients treated with lenalidomide, no overall difference in safety and efficacy was observed between patients aged over 65 and younger patients.</p><p>&nbsp;</p><p><em>Mantle cell lymphoma</em></p><p>For mantle cell lymphoma patients treated with lenalidomide, no overall difference in safety and efficacy was observed between patients aged 65 years or over compared with patients aged under 65 years of age.</p><p>&nbsp;</p><p><em>Follicular lymphoma</em></p><p>For follicular lymphoma patients treated with lenalidomide in combination with rituximab, the overall rate of adverse events is similar for patients aged 65 years or over compared with patients under 65 years of age. No overall difference in efficacy was observed between the two age groups.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Patients with renal impairment</u></p><p>Lenalidomide is primarily excreted by the kidney; patients with greater degrees of renal impairment can have impaired treatment tolerance (see section 4.4). Care should be taken in dose selection and monitoring of renal function is advised.</p><p>No dose adjustments are required for patients with mild renal impairment and multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, or follicular lymphoma.</p><p>The following dose adjustments are recommended at the start of therapy and throughout treatment for patients with moderate or severe impaired renal function or end stage renal disease.</p><p>There are no Phase 3 trial experiences with End Stage Renal Disease (ESRD) (CLcr &lt; 30 mL/min, requiring dialysis).</p><p>&nbsp;</p><p><em>Multiple myeloma</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Renal function (CLcr)</strong></p></td><td><p><strong>Dose adjustment</strong></p></td></tr><tr><td><p>Moderate renal impairment</p><p>(30 &le; CLcr &lt; 50 mL/min)</p></td><td><p>10 mg once daily<sup>1</sup></p></td></tr><tr><td><p>Severe renal impairment</p><p>(CLcr &lt; 30 mL/min, not requiring dialysis)</p></td><td><p>7.5 mg once daily<sup>2</sup></p><p>15 mg every other day</p></td></tr><tr><td><p>End Stage Renal Disease (ESRD)</p><p>(CLcr &lt; 30 mL/min, requiring dialysis)</p></td><td><p>5 mg once daily. On dialysis days, the dose should be administered following dialysis.</p></td></tr></tbody></table><p><sup>1</sup> The dose may be escalated to 15 mg once daily after 2 cycles if patient is not responding to treatment and is tolerating the treatment.</p><p><sup>2</sup> In countries where the 7.5 mg capsule is available.</p><p>&nbsp;</p><p><em>Myelodysplastic syndromes</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Renal function (CLcr)</strong></p></td><td colspan="2"><p><strong>Dose adjustment</strong></p></td></tr><tr><td rowspan="3"><p>Moderate renal impairment</p><p>(30 &le; CLcr &lt; 50 mL/min)</p></td><td><p>Starting dose</p></td><td><p>5 mg once daily</p><p>(days 1 to 21 of repeated 28-day cycles)</p></td></tr><tr><td><p>Dose level -1*</p></td><td><p>2.5 mg once daily</p><p>(days 1-28 of repeated 28-day cycles)</p></td></tr><tr><td><p>Dose level -2*</p></td><td><p>2.5 mg once every other day</p><p>(days 1 to 28 of repeated 28-day cycles)</p></td></tr><tr><td rowspan="3"><p>Severe renal impairment (CLcr &lt; 30 mL/min, not requiring dialysis)</p></td><td><p>Starting dose</p></td><td><p>2.5 mg once daily</p><p>(days 1 to 21 of repeated 28-day cycles)</p></td></tr><tr><td><p>Dose level -1*</p></td><td><p>2.5 mg every other day</p><p>(days 1 to 28 of repeated 28-day cycles)</p></td></tr><tr><td><p>Dose level -2*</p></td><td><p>2.5 mg twice a week</p><p>(days 1 to 28 of repeated 28-day cycles)</p></td></tr><tr><td rowspan="3"><p>End Stage Renal Disease (ESRD)</p><p>(CLcr &lt; 30 mL/min,</p><p>requiring dialysis)</p><p>On dialysis days, the dose</p><p>should be administered following dialysis.</p></td><td><p>Starting dose</p></td><td><p>2.5 mg once daily</p><p>(days 1 to 21 of repeated 28-day cycles)</p></td></tr><tr><td><p>Dose level -1*</p></td><td><p>2.5 mg every other day</p><p>(days 1 to 28 of repeated 28-day cycles)</p></td></tr><tr><td><p>Dose level -2*</p></td><td><p>2.5 mg twice a week</p><p>(days 1 to 28 of repeated 28-day cycles)</p></td></tr></tbody></table><p>&nbsp;</p><p>* Recommended dose reduction steps during treatment and restart of treatment to manage Grade 3 or 4 neutropenia or thrombocytopenia, or other Grade 3 or 4 toxicity judged to be related to lenalidomide, as described above.</p><p>&nbsp;</p><p><em>Mantle cell lymphoma</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Renal function (CLcr)</strong></p></td><td><p><strong>Dose adjustment</strong></p><p>(Days 1 to 21 of repeated 28- day cycles)</p></td></tr><tr><td><p>Moderate renal impairment</p><p>(30 &le; CLcr &lt; 50 mL/min)</p></td><td><p>10 mg once daily<sup>1</sup></p></td></tr><tr><td><p>Severe renal impairment</p><p>(CLcr &lt; 30 mL/min, not requiring dialysis)</p></td><td><p>7.5 mg once daily<sup>2</sup></p><p>15 mg every other day</p></td></tr><tr><td><p>End Stage Renal Disease (ESRD)</p><p>(CLcr &lt; 30 mL/min, requiring dialysis)</p></td><td><p>5 mg once daily. On dialysis days, the dose should be administered following dialysis.</p></td></tr></tbody></table><p><sup>1</sup> The dose may be escalated to 15 mg once daily after 2 cycles if patient is not responding to treatment and is tolerating the treatment.</p><p><sup>2</sup> In countries where the 7.5 mg capsule is available.</p><p>&nbsp;</p><p><em>Follicular lymphoma</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Renal function (CLcr)</strong></p></td><td><p><strong>Dose adjustment</strong></p><p>(days 1 to 21 of repeated 28-day cycles)</p></td></tr><tr><td><p>Moderate renal impairment (30 &le; CLcr &lt; 60 mL/min)</p></td><td><p>10 mg once daily&sup1;ˑ&sup2;</p></td></tr><tr><td><p>Severe renal impairment</p><p>(CLcr &lt; 30 mL/min, not requiring dialysis)</p></td><td><p>No data available&sup3;</p></td></tr><tr><td><p>End Stage Renal Disease (ESRD) (CLcr &lt; 30 mL/min, requiring dialysis)</p></td><td><p>No data available&sup3;</p></td></tr></tbody></table><p><strong>&sup1; </strong>The dose may be escalated to 15 mg once daily after 2 cycles if the patient has tolerated therapy.</p><p>&sup2; For patients on a starting dose of 10 mg, in case of dose reduction to manage Grade 3 or 4 neutropenia or thrombocytopenia, or other Grade 3 or 4. Toxicity judged to be related to lenalidomide do not dose below 5 mg every other day or 2.5 mg once daily.</p><p>&sup3; Patients with severe renal impairment or ESRD were excluded from study.</p><p>After initiation of lenalidomide therapy, subsequent lenalidomide dose modification in renally impaired patients should be based on individual patient treatment tolerance, as described above.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><u>Patients with hepatic impairment</u></em></p><p>Lenalidomide has not formally been studied in patients with impaired hepatic function and there are no specific dose recommendations.</p><p><u>Method of administration</u> Oral use.</p><p>Lenalidomide capsules should be taken orally at about the same time on the scheduled days. The capsules should not be opened, broken or chewed. The capsules should be swallowed whole, preferably with water, either with or without food.</p><p>It is recommended to press only on one end of the capsule to remove it from the blister thereby reducing the risk of capsule deformation or breakage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
	Women who are pregnant.
	Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met (see sections 4.4 and 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>When lenalidomide is given in combination with other medicinal products, the corresponding Summary of Product Characteristics must be consulted prior to initiation of treatment.</strong></p><p><strong>&nbsp;</strong></p><p><u>Pregnancy warning</u></p><p>Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Lenalidomide induced in monkeys malformations similar to those described with thalidomide (see sections 4.6 and 5.3). If lenalidomide is taken during pregnancy, a teratogenic effect of lenalidomide in humans is expected.</p><p>The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.</p><p><u>Criteria for women of non-childbearing potential</u></p><p>A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:</p><p>&bull;&nbsp; Age &ge; 50 years and naturally amenorrhoeic for &ge; 1 year (Amenorrhoea following cancer therapy or during breast-feeding does not rule out childbearing potential).</p><p>&bull;&nbsp; Premature ovarian failure confirmed by a specialist gynaecologist</p><p>&bull;&nbsp; Previous bilateral salpingo-oophorectomy, or hysterectomy</p><p>&bull;&nbsp; XY genotype, Turner syndrome, uterine agenesis.</p><p><u>Counselling</u></p><p>For women of childbearing potential, lenalidomide is contraindicated unless all of the following are met:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the expected teratogenic risk to the unborn child</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need for effective contraception, without interruption, at least 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Even if a woman of childbearing potential has amenorrhea she must follow all the advice on effective contraception</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She should be capable of complying with effective contraceptive measures</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need to commence the treatment as soon as lenalidomide is dispensed following a negative pregnancy test</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need and accepts to undergo pregnancy testing at least every 4 weeks except in case of confirmed tubal sterilisation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She acknowledges that she understands the hazards and necessary precautions associated with the use of lenalidomide.</p><p>&nbsp;</p><p>For male patients taking lenalidomide, pharmacokinetic data has demonstrated that lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2). As a precaution and taking into account special populations with prolonged elimination time such as renal impairment, all male patients taking lenalidomide must meet the following conditions:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Understand the expected teratogenic risk if engaged in sexual activity with a pregnant woman or a woman of childbearing potential</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Understand the need for the use of a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception (even if the man has had a vasectomy), during treatment and for at least 7 days after dose interruptions and/or cessation of treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Understand that if his female partner becomes pregnant whilst he is taking lenalidomide or shortly after he has stopped taking lenalidomide, he should inform his treating physician immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice.</p><p>The prescriber must ensure that for women of childbearing potential:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient complies with the conditions of the Pregnancy Prevention Programme, including confirmation that she has an adequate level of understanding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient has acknowledged the aforementioned conditions.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and until 4 weeks after lenalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis. If not established on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.</p><p>The following can be considered to be examples of suitable methods of contraception:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Implant</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Levonorgestrel-releasing intrauterine system (IUS)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medroxyprogesterone acetate depot</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tubal sterilisation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ovulation inhibitory progesterone-only pills (i.e. desogestrel)</p><p>Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide in combination therapy, and to a lesser extent in patients with multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma taking lenalidomide monotherapy, combined oral contraceptive pills are not recommended (see also section 4.5). If a patient is currently using combined oral contraception the patient should switch to one of the effective methods listed above. The risk of venous thromboembolism continues for 4&minus;6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during co-treatment with dexamethasone (see section 4.5).</p><p>Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia.</p><p>Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.</p><p>&nbsp;</p><p><u>Pregnancy testing</u></p><p>According to local practice, medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL must be performed for women of childbearing potential as outlined below. This requirement includes women of childbearing potential who practice absolute and continuous abstinence. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription.</p><p><em>Prior to starting treatment</em></p><p>A medically supervised pregnancy test should be performed during the consultation, when lenalidomide is prescribed, or in the 3 days prior to the visit to the prescriber once the patient had been using effective contraception for at least 4 weeks. The test should ensure the patient is not pregnant when she starts treatment with lenalidomide.</p><p><em>Follow-up and end of treatment</em></p><p>A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation. These pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.</p><p>&nbsp;</p><p><u>Additional precautions</u></p><p>Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment for safe disposal.</p><p>Patients should not donate blood during therapy or for at least 7 days following discontinuation of lenalidomide.</p><p>Healthcare professionals and caregivers should wear disposable gloves when handling the blister or capsule.</p><p>Women who are pregnant or suspect they may be pregnant should not handle the blister or capsule (see section 6.6).</p><p><u>Educational materials, prescribing and dispensing restrictions</u></p><p>In order to assist patients in avoiding foetal exposure to lenalidomide, the marketing authorisation holder will provide educational material to health care professionals to reinforce the warnings about the expected teratogenicity of lenalidomide, to provide advice on contraception before therapy is started, and to provide guidance on the need for pregnancy testing. The prescriber must inform male and female patients about the expected teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme and provide patients with appropriate patient educational brochure, patient card and/or equivalent tool in accordance to the national implemented patient card system. A national controlled distribution system has been implemented in collaboration with each National Competent Authority. The controlled distribution system includes the use of a patient card and/or equivalent tool for prescribing and/or dispensing controls, and the collecting of detailed data relating to the indication in order to monitor closely the off-label use within the national territory. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription and following a medically supervised negative pregnancy test result. Prescriptions for women of childbearing potential can be for a maximum duration of treatment of 4 weeks according to the approved indications dosing regimens (see section 4.2), and prescriptions for all other patients can be for a maximum duration of treatment of 12 weeks.</p><p>&nbsp;</p><p><u>Other special warnings and precautions for use</u></p><p><em><u>Myocardial infarction</u></em></p><p>Myocardial infarction has been reported in patients receiving lenalidomide, particularly in those with known risk factors and within the first 12 months when used in combination with dexamethasone. Patients with known risk factors &ndash;including prior thrombosis &ndash; should be closely monitored, and action should be taken to try to minimize all modifiable risk factors (eg. smoking, hypertension, and hyperlipidaemia).</p><p><em><u>Venous and arterial thromboembolic events</u></em></p><p>In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism). The risk of venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone.</p><p>In patients with multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, treatment with lenalidomide monotherapy was associated with a lower risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) than in patients with multiple myeloma treated with lenalidomide in combination therapy (see sections 4.5 and 4.8).</p><p>In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) and was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone. The risk of arterial thromboembolism is lower in patients with multiple myeloma treated with lenalidomide monotherapy than in patients with multiple myeloma treated with lenalidomide in combination therapy.</p><p>Consequently, patients with known risk factors for thromboembolism &ndash; including prior thrombosis &ndash; should be closely monitored. Action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia). Concomitant administration of erythropoietic agents or previous history of thromboembolic events may also increase thrombotic risk in these patients. Therefore, erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. A haemoglobin concentration above 12 g/dl should lead to discontinuation of erythropoietic agents.</p><p>Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling. Prophylactic antithrombotic medicines should be recommended, especially in patients with additional thrombotic risk factors. The decision to take antithrombotic prophylactic measures should be made after careful assessment of an individual patient&#39;s underlying risk factors.</p><p>If the patient experiences any thromboembolic events, treatment must be discontinued and standard anticoagulation therapy started. Once the patient has been stabilised on the anticoagulation treatment and any complications of the thromboembolic event have been managed, the lenalidomide treatment may be restarted at the original dose dependent upon a benefit risk assessment. The patient should continue anticoagulation therapy during the course of lenalidomide treatment.</p><p><em>Pulmonary hypertension</em></p><p>Cases of pulmonary hypertension, some fatal, have been reported in patients treated with lenalidomide. Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease prior to initiating and during lenalidomide therapy.</p><p><em>Neutropenia and thrombocytopenia</em></p><p>The major dose limiting toxicities of lenalidomide include neutropenia and thrombocytopenia. A complete blood cell count, including white blood cell count with differential count, platelet count, haemoglobin, and haematocrit should be performed at baseline, every week for the first 8 weeks of lenalidomide treatment and monthly thereafter to monitor for cytopenias. In mantle cell lymphoma patients, the monitoring scheme should be every 2 weeks in cycles 3 and 4, and then at the start of each cycle. In follicular lymphoma, the monitoring scheme should be weekly for the first 3 weeks of cycle 1 (28 days), every 2 weeks during cycles 2 through 4, and then at the start of each cycle thereafter. A dose interruption and/or a dose reduction may be required (see section 4.2).</p><p>&nbsp;</p><p>In case of neutropenia, the physician should consider the use of growth factors in patient management. Patients should be advised to promptly report febrile episodes.</p><p>Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxis, especially in patients receiving concomitant medicinal products susceptible to induce bleeding (see section 4.8, Haemorrhagic disorders).</p><p>Co-administration of lenalidomide with other myelosuppressive agents should be undertaken with caution.</p><p>&nbsp;</p><p>&bull; <u>&nbsp;Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide</u> <u>maintenance</u></p><p>The adverse reactions from CALGB 100104 included events reported post-high dose melphalan and ASCT(HDM/ASCT) as well as events from the maintenance treatment period. A second analysis identified events that occurred after the start of maintenance treatment. In IFM 2005-02, the adverse reactions were from the maintenance treatment period only.</p><p>Overall, Grade 4 neutropenia was observed at a higher frequency in the lenalidomide maintenance arms compared to the placebo maintenance arms in the 2 studies evaluating lenalidomide maintenance in NDMM patients who have undergone ASCT (32.1% vs 26.7% [16.1% vs 1.8% after the start of maintenance treatment] in CALGB 100104 and 16.4% vs 0.7% in IFM 2005-02, respectively). Treatment-emergent AEs of neutropenia leading to lenalidomide discontinuation were reported in 2.2% of patients in CALGB 100104 and 2.4% of patients in IFM 2005-02, respectively. Grade 4 febrile neutropenia was reported at similar frequencies in the lenalidomide maintenance arms compared to placebo maintenance arms in both studies (0.4% vs 0.5% [0.4% vs 0.5% after the start of maintenance treatment] in CALGB 100104 and 0.3% vs 0% in IFM 2005-02, respectively). Patients should be advised to promptly report febrile episodes, a treatment interruption and/or dose reduction may be required (see section 4.2).</p><p>Grade 3 or 4 thrombocytopenia was observed at a higher frequency in the lenalidomide maintenance arms compared to the placebo maintenance arms in studies evaluating lenalidomide maintenance in NDMM patients who have undergone ASCT (37.5% vs 30.3% [17.9% vs 4.1% after the start of maintenance treatment] in CALGB 100104 and 13.0% vs 2.9%in IFM 2005-02, respectively). Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products susceptible to induce bleeding (see section 4.8, Haemorrhagic disorders).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape id="Graphic_x0020_1" o:spid="_x0000_s1028"
 style='position:absolute;left:0;text-align:left;margin-left:90pt;margin-top:10.55pt;
 width:3.85pt;height:1.6pt;z-index:-18384384;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' coordsize="48895,20320" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m48768,l,,,19812r48768,l48768,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="2" src="file:///C:/Users/O9B2F~1.ALH/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with</u> <u>lenalidomide in combination with bortezomib and dexamethasone</u></p><p>Grade 4 neutropenia was observed at a lower frequency in the lenalidomide in combination with bortezomib and dexamethasone (RVd) arm compared to the Rd comparator arm (2.7% vs 5.9%) inthe SWOG S0777 study. Grade 4 febrile neutropenia was reported at similar frequencies in the RVd arm and Rd arm (0.0% vs 0.4%). Patients should be advised to promptly report febrile episodes; a treatment interruption and/or dose reduction may be required (see section 4.2).</p><p>Grade 3 or 4 thrombocytopenia was observed at a higher frequency in the RVd arm compared to the Rd comparator arm (17.2 % vs 9.4%).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape id="Graphic_x0020_2" o:spid="_x0000_s1027"
 style='position:absolute;left:0;text-align:left;margin-left:90pt;margin-top:16.25pt;
 width:3.85pt;height:1.6pt;z-index:-18383872;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' coordsize="48895,20320" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m48768,l,,,19812r48768,l48768,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="2" src="file:///C:/Users/O9B2F~1.ALH/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><u>Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with</u> <u>lenalidomide in combination with low dose dexamethasone</u></p><p>Grade 4 neutropenia was observed in the lenalidomide arms in combination with dexamethasone to a lesser extent than in the comparator arm (8.5% in the Rd [continuous treatment] and Rd18 [treatment for 18 four-week cycles] compared with 15% in the melphalan/prednisone/thalidomide arm, see section 4.8). Grade 4 febrile neutropenia episodes were consistent with the comparator arm (0.6 % in the Rd and Rd18 lenalidomide/dexamethasone-treated patients compared with 0.7% in the melphalan/prednisone/thalidomide arm, see section 4.8).</p><p>Grade 3 or 4 thrombocytopenia was observed to a lesser extent in the Rd and Rd18 arms than in the comparator arm (8.1% vs 11.1%, respectively).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape id="Graphic_x0020_3" o:spid="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:90pt;margin-top:10.55pt;
 width:3.85pt;height:1.6pt;z-index:-18383360;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' coordsize="48895,20320" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m48768,l,,,19811r48768,l48768,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="2" src="file:///C:/Users/O9B2F~1.ALH/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with</u> <u>lenalidomide in combination with melphalan and prednisone</u></p><p>The combination of lenalidomide with melphalan and prednisone in clinical trials of newly diagnosed multiple myeloma patients is associated with a higher incidence of Grade 4 neutropenia (34.1% in melphalan, prednisone and lenalidomide arm followed by lenalidomide [MPR+R] and melphalan, prednisone and lenalidomide followed by placebo [MPR+p] treated patients compared with 7.8% in MPp+p-treated patients; see section 4.8). Grade 4 febrile neutropenia episodes were observed infrequently (1.7% in MPR+R/MPR+p treated patients compared to 0.0% in MPp+p treated patients; see section 4.8).</p><p>The combination of lenalidomide with melphalan and prednisone in multiple myeloma patients is associated with a higher incidence of Grade 3 and Grade 4 thrombocytopenia (40.4% in MPR+R/MPR+p treated patients, compared with 13.7%in MPp+p-treated patients; see section 4.8).</p><p>&nbsp;</p><p>&bull; <u>&nbsp;Multiple myeloma: patients with at least one prior therapy</u></p><p>The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of Grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8). Grade 4 febrile neutropenia episodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in placebo/dexamethasone treated patients; see section 4.8).</p><p>The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of Grade 3 and Grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone- treated patients; see section 4.8).</p><p>&nbsp;</p><p>&bull; <u>&nbsp;Myelodysplastic syndromes</u></p><p>Lenalidomide treatment in myelodysplastic syndromes patients is associated with a higher incidence of Grade 3 and 4 neutropenia and thrombocytopenia compared to patients on placebo (see section 4.8).</p><p>&nbsp;</p><p>&bull; <u>&nbsp;Mantle cell lymphoma</u></p><p>Lenalidomide treatment in mantle cell lymphoma patients is associated with a higher incidence of Grade 3 and 4 neutropenia compared with patients on the control arm (see section 4.8).</p><p>&nbsp;</p><p>&bull; <u>&nbsp;Follicular lymphoma</u></p><p>The combination of lenalidomide with rituximab in follicular lymphoma patients is associated with a higher incidence of Grade 3 or 4 neutropenia compared with patients on the placebo/rituximab arm. Febrile neutropenia and Grade 3 or 4 thrombocytopenia were more commonly observed in the lenalidomide/ rituximab arm (see section 4.8).</p><p>&nbsp;</p><p><em>Thyroid disorders</em></p><p>Cases of hypothyroidism and cases of hyperthyroidism have been reported. Optimal control of co- morbid conditions influencing thyroid function is recommended before start of treatment. Baseline and ongoing monitoring of thyroid function is recommended.</p><p>&nbsp;</p><p><em>Peripheral neuropathy</em></p><p>Lenalidomide is structurally related to thalidomide, which is known to induce severe peripheral neuropathy.</p><p>There was no increase in peripheral neuropathy observed with lenalidomide in combination with dexamethasone or melphalan and prednisone or lenalidomide monotherapy or with long term use of lenalidomide for the treatment of newly diagnosed multiple myeloma.</p><p>The combination of lenalidomide with intravenous bortezomib and dexamethasone in multiple myeloma patients is associated with a higher frequency of peripheral neuropathy. The frequency was lower when bortezomib was administered subcutaneously. For additional information, see Section 4.8 and the SmPC for bortezomib.</p><p>&nbsp;</p><p><em><u>Tumour flare reaction and tumour lysis syndrome</u></em></p><p>Because lenalidomide has anti-neoplastic activity, the complications of tumour lysis syndrome (TLS) may occur. Cases of TLS and tumour flare reaction (TFR), including fatal cases, have been reported (see section 4.8). The patients at risk of TLS and TFR are those with high tumour burden prior to treatment. Caution should be practiced when introducing these patients to lenalidomide. These patients should be monitored closely, especially during the first cycle or dose-escalation, and appropriate precautions taken.</p><p><u>Mantle cell lymphoma</u></p><p>Careful monitoring and evaluation for TFR is recommended. Patients with high mantle cell lymphoma International Prognostic Index (MIPI) at diagnosis or bulky disease (at least one lesion that is &ge; 7 cm in the longest diameter) at baseline may be at risk of TFR. Tumour flare reaction may mimic progression of disease (PD). Patients in studies MCL-002 and MCL-001 that experienced Grade 1 and 2 TFR were treated with corticosteroids, NSAIDs and/or narcotic analgesics for management of TFR symptoms. The decision to take therapeutic measures for TFR should be made after careful clinical assessment of the individual patient (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><u>Follicular lymphoma</u></p><p>Careful monitoring and evaluation for TFR is recommended. Tumour flare may mimic PD. Patients who experienced Grade 1 and 2 TFR were treated with corticosteroids, NSAIDs and/or narcotic analgesics for management of TFR symptoms. The decision to take therapeutic measures for TFR should be made after careful clinical assessment of the individual patient (see sections 4.2 and 4.8).</p><p>Careful monitoring and evaluation for TLS is recommended. Patients should be well hydrated and receive TLS prophylaxis, in addition to weekly chemistry panels during the first cycle or longer, as clinically indicated (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><em><u>Tumour burden</u></em></p><p>&bull;&nbsp; Mantle cell lymphoma</p><p>Lenalidomide is not recommended for the treatment of patients with high tumour burden if alternative treatment options are available.</p><p>&nbsp;</p><p><em>Early death</em></p><p>In study MCL-002 there was overall an apparent increase in early (within 20 weeks) deaths. Patients with high tumour burden at baseline are at increased risk of early death, there were 16/81 (20%) early deaths in the lenalidomide arm and 2/28 (7%) early deaths in the control arm. Within 52 weeks corresponding figures were 32/81 (40%) and 6/28 (21%) (See section 5.1).</p><p><em>Adverse events</em></p><p>In study MCL-002, during treatment cycle 1, 11/81 (14%) patients with high tumour burden were withdrawn from therapy in the lenalidomide arm vs. 1/28 (4%) in the control group. The main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%).</p><p>Patients with high tumour burden should therefore be closely monitored for adverse reactions (see Section 4.8) including signs of tumour flare reaction (TFR). Please refer to section 4.2 for dose adjustments for TFR.</p><p>High tumour burden was defined as at least one lesion &ge;5 cm in diameter or 3 lesions &ge;3 cm.</p><p>&nbsp;</p><p><em><u>Allergic reactions Severe skin reactions</u></em></p><p><em>&nbsp;</em></p><p>Cases of allergic reaction including angioedema, anaphylactic reaction and severe cutaneous reactions including SJS, TEN and DRESS have been reported in patients treated with lenalidomide (see section 4.8). Patients should be advised of the signs and symptoms of these reactions by their prescribers and should be told to seek medical attention immediately if they develop these symptoms. Lenalidomide must be discontinued for angioedema, anaphylactic reaction, exfoliative or bullous rash, or if SJS, TEN or DRESS is suspected, and should not be resumed following discontinuation for these reactions. Interruption or discontinuation of lenalidomide should be considered for other forms of skin reaction depending on severity. Patients who had previous allergic reactions while treated with thalidomide should be monitored closely, as a possible cross-reaction between lenalidomide and thalidomide has been reported in the literature. Patients with a history of severe rash associated with thalidomide treatment should not receive lenalidomide</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Second primary malignancies</u></em></p><p>An increase of second primary malignancies (SPM) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years). Non-invasive SPM comprise basal cell or squamous cell skin cancers. Most of the invasive SPMs were solid tumour malignancies.</p><p>&nbsp;</p><p>In clinical trials of newly diagnosed multiple myeloma patients not eligible for transplant, a 4.9-fold increase in incidence rate of hematologic SPM (cases of AML, MDS) has been observed in patients receiving lenalidomide in combination with melphalan and prednisone until progression (1.75 per 100 person-years) compared with melphalan in combination with prednisone (0.36 per 100 person-years).</p><p>A 2.12-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide (9 cycles) in combination with melphalan and prednisone (1.57 per 100 person-years) compared with melphalan in combination with prednisone (0.74 per 100 person-years).</p><p>In patients receiving lenalidomide in combination with dexamethasone until progression or for 18 months, the hematologic SPM incidence rate (0.16 per 100 person-years) was not increased as compared to thalidomide in combination with melphalan and prednisone (0.79 per 100 person-years).</p><p>A 1.3-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide in combination with dexamethasone until progression or for 18 months (1.58 per 100 person-years) compared to thalidomide in combination with melphalan and prednisone (1.19 per 100 person-years).</p><p>In newly diagnosed multiple myeloma patients receiving lenalidomide in combination with bortezomib and dexamethasone, the hematologic SPM incidence rate was 0.00 &ndash; 0.16 per 100 person- years and the incidence rate of solid tumour SPM 0.21 &ndash; 1.04 per 100 person-years.</p><p>The increased risk of secondary primary malignancies associated with lenalidomide is relevant also in the context of NDMM after stem cell transplantation. Though this risk is not yet fully characterized, it should be kept in mind when considering and using Lenalidomide in this setting.</p><p>The incidence rate of hematologic malignancies, most notably AML, MDS and B-cell malignancies (including Hodgkin&#39;s lymphoma), was 1.31 per 100 person-years for the lenalidomide arms and 0.58 per 100 person-years for the placebo arms (1.02 per 100 person-years for patients exposed to lenalidomide after ASCT and 0.60 per 100 person-years for patients not-exposed to lenalidomide after ASCT). The incidence rate of solid tumour SPMs was 1.36 per 100 person-years for the lenalidomide arms and 1.05 per 100 person-years for the placebo arms (1.26 per 100 person-years for patients exposed to lenalidomide after ASCT and 0.60 per 100 person-years for patients not-exposed to lenalidomide after ASCT).</p><p>The risk of occurrence of hematologic SPM must be taken into account before initiating treatment with lenalidomide either in combination with melphalan or immediately following high-dose melphalan and ASCT. Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of SPM and institute treatment as indicated.</p><p><em><u>Progression to acute myeloid leukaemia in low- and intermediate-1-risk MDS</u></em></p><p>&bull;&nbsp; Karyotype</p><p>Baseline variables including complex cytogenetics are associated with progression to AML in subjects who are transfusion dependent and have a Del (5q) abnormality. In a combined analysis of two clinical trials of lenalidomide in low- or intermediate-1-risk myelodysplastic syndromes, subjects who had a complex cytogenetics had the highest estimated 2-year cumulative risk of progression to AML (38.6%). The estimated 2-year rate of progression to AML in patients with an isolated Del (5q) abnormality was 13.8%, compared to 17.3% for patients with Del (5q) and one additional cytogenetic abnormality.</p><p>As a consequence, the benefit/risk ratio of lenalidomide when MDS is associated with Del (5q) and complex cytogenetics is unknown.</p><p>&nbsp;</p><p>&bull;&nbsp; TP53 status</p><p>A TP53 mutation is present in 20 to 25% of lower-risk MDS Del 5q patients and is associated with a higher risk of progression to acute myeloid leukaemia (AML). In a post-hoc analysis of a clinical trial of lenalidomide in low- or intermediate-1-risk myelodysplastic syndromes (MDS-004), the estimated 2-year rate of progression to AML was 27.5 %in patients with IHC-p53 positivity (1% cut-off level of strong nuclear staining, using immunohistochemical assessment of p53 protein as a surrogate for TP53 mutation status) and 3.6% in patients with IHC-p53 negativity (p=0.0038) (see section 4.8)</p><p><em><u>Progression to other malignancies in mantle cell lymphoma</u></em></p><p>In mantle cell lymphoma, AML, B-cell malignancies and non-melanoma skin cancer (NMSC) are identified risks.</p><p><em><u>Second primary malignancies in follicular lymphoma</u></em></p><p>In a relapsed/refractory iNHL study which included follicular lymphoma patients, no increased risk of SPMs in the lenalidomide/rituximab arm, compared to the placebo/rituximab arm, was observed. Hematologic SPM of AML occurred in 0.29 per 100 person-years in the lenalidomide/rituximab arm compared with 0.29 per 100 person-years in patients receiving placebo/rituximab. The incidence rate of hematologic plus solid tumour SPMs (excluding non-melanoma skin cancers) was 0.87 per 100 person-years in the lenalidomide/rituximab arm, compared to 1.17 per 100 person-years in patients receiving placebo/rituximab with a median follow-up of 30.59 months (range 0.6 to 50.9 months).</p><p>Non-melanoma skin cancers are identified risks and comprise squamous cell carcinomas of skin or basal cell carcinomas.</p><p>Physicians should monitor patients for the development of SPMs. Both the potential benefit of lenalidomide and the risk of SPMs should be considered when considering treatment with lenalidomide.</p><p>&nbsp;</p><p><em><u>Hepatic disorders</u></em></p><p>Hepatic failure, including fatal cases, has been reported in patients treated with lenalidomide in combination therapy: acute hepatic failure, toxic hepatitis, cytolytic hepatitis, cholestatic hepatitis, and mixed cytolytic/cholestatic hepatitis have been reported. The mechanisms of severe drug-induced hepatotoxicity remain unknown although, in some cases, pre-existing viral liver disease, elevated baseline liver enzymes, and possibly treatment with antibiotics might be risk factors.</p><p>Abnormal liver function tests were commonly reported and were generally asymptomatic and reversible upon dosing interruption. Once parameters have returned to baseline, treatment at a lower dose may be considered.</p><p>Lenalidomide is excreted by the kidneys. It is important to dose adjust patients with renal impairment in order to avoid plasma levels which may increase the risk for higher haematological adverse reactions or hepatotoxicity. Monitoring of liver function is recommended, particularly when there is a history of or concurrent viral liver infection or when lenalidomide is combined with medicinal products known to be associated with liver dysfunction.</p><p>&nbsp;</p><p><em><u>Infection with or without neutropenia</u></em></p><p>Patients with multiple myeloma are prone to develop infections including pneumonia. Ahigher rate of infections was observed with lenalidomide in combination with dexamethasone than with MPT in patients with NDMM who are not eligible for transplant, and with lenalidomide maintenance compared to placebo in patients with NDMM who had undergone ASCT. Grade &ge; 3 infections occurred within the context of neutropenia in less than one-third of the patients. Patients with known risk factors for infections should be closely monitored. All patients should be advised to seek medical attention promptly at the first sign of infection (eg, cough, fever, etc) thereby allowing for early management to reduce severity.</p><p><em><u>Viral reactivation</u></em></p><p>Cases of viral reactivation have been reported in patients receiving lenalidomide, including serious cases of herpes zoster or hepatitis B virus (HBV) reactivation.</p><p>Some of the cases of viral reactivation had a fatal outcome.</p><p>&nbsp;</p><p>Some of the cases of herpes zoster reactivation resulted in disseminated herpes zoster, meningitis herpes zoster or ophthalmic herpes zoster requiring a temporary hold or permanent discontinuation of the treatment with lenalidomide and adequate antiviral treatment.</p><p>Reactivation of hepatitis B has been reported rarely in patients receiving lenalidomide who have previously been infected with the hepatitis B virus (HBV). Some of these cases have progressed to acute hepatic failure resulting in discontinuation of lenalidomide and adequate antiviral treatment. Hepatitis B virus status should be established before initiating treatment with lenalidomide. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Caution should be exercised when lenalidomide is used in patients previously infected with HBV, including patients who are anti-HBc positive but HBsAg negative. These patients should be closely monitored for signs and symptoms of active HBV infection throughout therapy.</p><p>&nbsp;</p><p><em><u>Progressive multifocal leukoencephalopathy</u></em></p><p>Cases of progressive multifocal leukoencephalopathy (PML), including fatal cases, have been reported with lenalidomide. PML was reported several months to several years after starting the treatment with lenalidomide. Cases have generally been reported in patients taking concomitant dexamethasone or prior treatment with other immunosuppressive chemotherapy. Physicians should monitor patients at regular intervals and should consider PML in the differential diagnosis in patients with new or worsening neurological symptoms, cognitive or behavioural signs or symptoms. Patients should also be advised to inform their partner or caregivers about their treatment, since they may notice symptoms that the patient is not aware of.</p><p>The evaluation for PML should be based on neurological examination, magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for JC virus (JCV) DNA by polymerase chain reaction (PCR) or a brain biopsy with testing for JCV. A negative JCV PCR does not exclude PML. Additional follow- up and evaluation may be warranted if no alternative diagnosis can be established.</p><p>If PML is suspected, further dosing must be suspended until PML has been excluded. If PML is confirmed, lenalidomide must be permanently discontinued.</p><p><em><u>Newly diagnosed multiple myeloma patients</u></em></p><p>There was a higher rate of intolerance (Grade 3 or 4 adverse events, serious adverse events, discontinuation) in patients with age &gt; 75 years, ISS stage III, ECOG PS&ge;2 or CLcr&lt;60 mL/minwhen lenalidomide is given in combination. Patients should be carefully assessed for their ability to tolerate lenalidomide in combination, with consideration to age, ISS stage III, ECOG PS&ge;2 or CLcr&lt;60 mL/min (see sections 4.2 and 4.8).</p><p><em><u>Cataract</u></em></p><p>Cataract has been reported with a higher frequency in patients receiving lenalidomide in combination with dexamethasone particularly when used for a prolonged time. Regular monitoring of visual ability is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone (see sections 4.4 and 4.8).</p><p><u>Oral contraceptives</u></p><p>No interaction study has been performed with oral contraceptives. Lenalidomide is not an enzyme inducer. In an <em>in vitro </em>study with human hepatocytes, lenalidomide, at various concentrations tested did not induce CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4/5. Therefore, induction leading to reduced efficacy of medicinal products, including hormonal contraceptives, is not expected if lenalidomide is administered alone. However, dexamethasone is known to be a weak to moderate inducer of CYP3A4 and is likely to also affect other enzymes as well as transporters. It may not be excluded that the efficacy of oral contraceptives may be reduced during treatment. Effective measures to avoid pregnancy must be taken (see sections 4.4 and 4.6).</p><p><u>Warfarin</u></p><p>Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin. Co-administration of a single 25 mg dose of warfarin had no effect on the pharmacokinetics of lenalidomide. However, it is not known whether there is an interaction during clinical use (concomitant treatment with dexamethasone). Dexamethasone is a weak to moderate enzyme inducer and its effect on warfarin is unknown. Close monitoring of warfarin concentration is advised during the treatment.</p><p>&nbsp;</p><p><u>Digoxin</u></p><p>Concomitant administration with lenalidomide 10 mg/day increased the plasma exposure of digoxin (0.5 mg, single dose) by 14% with a 90% CI (confidence interval) [0.52%-28.2%]. It is not known whether the effect will be different in the clinical use (higher lenalidomide doses and concomitant treatment with dexamethasone). Therefore, monitoring of the digoxin concentration is advised during lenalidomide treatment.</p><p>&nbsp;</p><p><u>Statins</u></p><p>There is an increased risk of rhabdomyolysis when statins are administered with lenalidomide, which may be simply additive. Enhanced clinical and laboratory monitoring is warranted notably during the first weeks of treatment.</p><p>&nbsp;</p><p><u>Dexamethasone</u></p><p>Co-administration of single or multiple doses of dexamethasone (40 mg/ day) has no clinically relevant effect on the multiple dose pharmacokinetics of lenalidomide (25 mg/ day).</p><p>&nbsp;</p><p><u>Interactions with P-glycoprotein (P-gp) inhibitors</u></p><p><em>In vitro</em>, lenalidomide is a substrate of P-gp, but is not a P-gp inhibitor. Co-administration of multiple doses of the strong P-gp inhibitor quinidine (600 mg, twice daily) or the moderate P-gp inhibitor/substrate temsirolimus (25 mg) has no clinically relevant effect on the pharmacokinetics of lenalidomide (25 mg). Co-administration of lenalidomide does not alter the pharmacokinetics of temsirolimus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Due to the teratogenic potential, lenalidomide must be prescribed under a Pregnancy Prevention Programme (see section 4.4) unless there is reliable evidence that the patient does not have childbearing potential.</strong></p><p><u>Women of childbearing potential / Contraception in males and females</u></p><p>Women of childbearing potential should use effective method of contraception. If pregnancy occurs in a woman treated with lenalidomide, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice. If pregnancy occurs in a partner of a male patient taking lenalidomide, it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice.</p><p>&nbsp;</p><p>Lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2). As a precaution, and taking into account special populations with prolonged elimination time such as renal impairment, all male patients taking lenalidomide should use condoms throughout treatment duration, during dose interruption and for 1 week after cessation of treatment if their partner is pregnant or of childbearing potential and has no contraception.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects.</p><p>Lenalidomide induced in monkeys malformations similar to those described with thalidomide (see section 5.3). Therefore, a teratogenic effect of lenalidomide is expected and lenalidomide is contraindicated during pregnancy (see section 4.3).</p><p><u>Breast-feeding</u></p><p>It is not known whether lenalidomide is excreted in human milk. Therefore breast-feeding should be discontinued during therapy with lenalidomide.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>A fertility study in rats with lenalidomide doses up to 500 mg/kg (approximately 200 to 500 times the human doses of 25 mg and 10 mg, respectively, based on body surface area) produced no adverse effects on fertility and no parental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lenalidomide has minor or moderate influence on the ability to drive and use machines. Fatigue, dizziness, somnolence, vertigo and blurred vision have been reported with the use of lenalidomide. Therefore, caution is recommended when driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p><u>Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide</u> <u>maintenance</u></p><p>A conservative approach was applied to determine the adverse reactions from CALGB 100104. The adverse reactions described in Table 1 included events reported post-HDM/ASCT as well as events from the maintenance treatment period. A second analysis that identified events that occurred after the start of maintenance treatment suggests that the frequencies described in Table 1 may be higher than actually observed during the maintenance treatment period. In IFM 2005-02, the adverse reactions were from the maintenance treatment period only.</p><p>The serious adverse reactions observed more frequently (&ge;5%) with lenalidomide maintenance than</p><p>placebo were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonias (10.6%; combined term) from IFM 2005-02</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung infection (9.4% [9.4% after the start of maintenance treatment]) from CALGB 100104</p><p>In the IFM 2005-02 study, the adverse reactions observed more frequently with lenalidomide maintenance than placebo were neutropenia (60.8%), bronchitis (47.4%), diarrhoea (38.9%), nasopharyngitis (34.8%), muscle spasms (33.4%), leucopenia (31.7%), asthenia (29.7%), cough (27.3%), thrombocytopenia (23.5%), gastroenteritis (22.5%) and pyrexia (20.5%).</p><p>In the CALGB 100104 study, the adverse reactions observed more frequently with lenalidomide maintenance than placebo were neutropenia (79.0% [71.9% after the start of maintenance treatment]), thrombocytopenia (72.3% [61.6%]), diarrhoea (54.5% [46.4%]), rash (31.7% [25.0%]),&nbsp; upper respiratory tract infection (26.8% [26.8%]), fatigue (22.8% [17.9%]), leucopenia (22.8% [18.8%]) and anaemia (21.0% [13.8%]).</p><p>&nbsp;</p><p><u>Newly diagnosed multiple myeloma patients who are not eligible for transplant receiving</u> <u>lenalidomide in combination with bortezomib and dexamethasone</u></p><p>In the SWOG S0777 study, the serious adverse reactions observed more frequently (&ge; 5%) with lenalidomide in combination with intravenous bortezomib and dexamethasone than with lenalidomide in combination with dexamethasone were:</p><p>&bull;&nbsp; Hypotension (6.5%), lung infection (5.7%), dehydration (5.0%)</p><p>The adverse reactions observed more frequently with lenalidomide in combination with bortezomib and dexamethasone than with lenalidomide in combination with dexamethasone were: Fatigue (73.7%), peripheral neuropathy (71.8%), thrombocytopenia (57.6%), constipation (56.1%), hypocalcaemia (50.0%).</p><p>&nbsp;</p><p><u>Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with</u> <u>lenalidomide in combination with low dose dexamethasone</u></p><p>The serious adverse reactions observed more frequently (&ge;5%) with lenalidomide in combination with low dose dexamethasone (Rd and Rd18) than with melphalan, prednisone and thalidomide (MPT) were:</p><p>&bull;&nbsp; Pneumonia (9.8%)</p><p>&bull;&nbsp; Renal failure (including acute) (6.3%)</p><p>The adverse reactions observed more frequently with Rd or Rd18 than MPT were: diarrhoea (45.5%), fatigue (32.8%), back pain (32.0%), asthenia (28.2%), insomnia (27.6%), rash (24.3%), decreased appetite (23.1%), cough (22.7%), pyrexia (21.4%), and muscle spasms (20.5%).</p><p>&nbsp;</p><p><u>Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with</u> <u>lenalidomide in combination with melphalan and prednisone</u></p><p>The serious adverse reactions observed more frequently (&ge;5%) with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance (MPR+R) or melphalan, prednisone and lenalidomide followed by placebo (MPR+p) than melphalan, prednisone and placebo followed by placebo (MPp+p) were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Febrile neutropenia (6.0%)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (5.3%)</p><p>The adverse reactions observed more frequently with MPR+R or MPR+p than MPp+p were:</p><p>neutropenia (83.3%), anaemia (70.7%), thrombocytopenia (70.0%), leucopenia (38.8%), constipation (34.0%), diarrhoea (33.3%), rash (28.9%), pyrexia (27.0%), peripheral oedema (25.0%), cough (24.0%), decreased appetite (23.7%), and asthenia (22.0%).</p><p>&nbsp;</p><p>Multiple myeloma: patients with at least one prior therapy</p><p>In two phase 3 placebo-controlled studies, 353 patients with multiple myeloma were exposed to the lenalidomide/dexamethasone combination and 351 to the placebo/dexamethasone combination.</p><p>&nbsp;</p><p>The most serious adverse reactions observed more frequently in lenalidomide/dexamethasone than placebo/dexamethasone combination were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous thromboembolism (deep vein thrombosis, pulmonary embolism) (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 4 neutropenia (see section 4.4).</p><p>The observed adverse reactions which occurred more frequently with lenalidomide and dexamethasone than placebo and dexamethasone in pooled multiple myeloma clinical trials (MM-009 and MM-010) were fatigue (43.9%), neutropenia (42.2%), constipation (40.5%), diarrhoea (38.5%), muscle cramp (33.4%), anaemia (31.4%), thrombocytopenia (21.5%), and rash (21.2%).</p><p>&nbsp;</p><p><u>Myelodysplastic syndromes</u></p><p>The overall safety profile of lenalidomide in patients with myelodysplastic syndromes is based on data from a total of 286 patients from one phase 2 study and one phase 3 study (see section 5.1). In the phase 2, all 148 patients were on lenalidomide treatment. In the phase 3 study, 69 patients were on lenalidomide 5 mg, 69 patients on lenalidomide 10 mg and 67 patients were on placebo during the double-blind phase of the study.</p><p>Most adverse reactions tended to occur during the first 16 weeks of therapy with lenalidomide. Serious adverse reactions include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous thromboembolism (deep vein thrombosis, pulmonary embolism) (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or 4 neutropenia, febrile neutropenia and Grade 3 or 4 thrombocytopenia (see section 4.4).</p><p>The most commonly observed adverse reactions which occurred more frequently in the lenalidomide groups compared to the control arm in the phase 3 study were neutropenia (76.8%), thrombocytopenia (46.4%), diarrhoea (34.8%), constipation (19.6%), nausea (19.6%), pruritus (25.4%), rash (18.1%), fatigue (18.1%) and muscle spasms (16.7%).</p><p>&nbsp;</p><p>Mantle cell lymphoma</p><p>The overall safety profile of lenalidomide in patients with mantle cell lymphoma is based on data from 254 patients from a phase 2 randomised, controlled study MCL-002 (see section 5.1).</p><p>Additionally, adverse drug reactions from supportive study MCL-001 have been included in table 3.</p><p>The serious adverse reactions observed more frequently in study MCL-002 (with a difference of at least 2 percentage points) in the lenalidomide arm compared with the control arm were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia (3.6%)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary embolism (3.6%)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea (3.6%)</p><p>The most frequently observed adverse reactions which occurred more frequently in the lenalidomide arm compared with the control arm in study MCL-002 were neutropenia (50.9%), anaemia (28.7%), diarrhoea (22.8%), fatigue (21.0%), constipation (17.4%), pyrexia (16.8%), and rash (including dermatitis allergic) (16.2%).</p><p>In study MCL-002 there was overall an apparent increase in early (within 20 weeks) deaths. Patients with high tumour burden at baseline are at increased risk of early death, 16/81 (20%) early deaths in the lenalidomide arm and 2/28 (7%) early deaths in the control arm. Within 52 weeks corresponding figures were 32/81 (39.5%) and 6/28 (21%) (see section 5.1).</p><p>During treatment cycle 1, 11/81 (14%) patients with high tumour burden were withdrawn from therapy in the lenalidomide arm vs. 1/28 (4%) in the control group. The main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%). High tumour burden was defined as at least one lesion &ge;5 cm in diameter or 3 lesions &ge;3 cm.</p><p>&nbsp;</p><p>Follicular lymphoma</p><p>The overall safety profile of lenalidomide in combination with rituximab in patients with previously treated follicular lymphoma is based on data from 294 patients from a Phase 3 randomised, controlled study NHL-007. Additionally, adverse drug reactions from supportive study NHL-008 have been included in Table 5.</p><p>The serious adverse reactions observed most frequently (with a difference of at least 1 percentage point) in study NHL-007 in the lenalidomide/rituximab arm compared with the placebo/rituximab arm were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Febrile neutropenia (2.7%)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary embolism (2.7%)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia (2.7%)</p><p>In the NHL-007 study the adverse reactions observed more frequently in the lenalidomide/rituximab arm compared with the placebo/rituximab arm (with at least 2% higher frequency between arms) were neutropenia (58.2%), diarrhea (30.8%), leucopenia (28.8%), constipation (21.9%), cough (21.9%) and fatigue (21.9%).</p><p>&nbsp;</p><p><strong><u>Tabulated list of adverse reactions</u></strong></p><p>The adverse reactions observed in patients treated with lenalidomide are listed below by system organ class and frequency. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>Adverse reactions have been included under the appropriate category in the table below according to the highest frequency observed in any of the main clinical trials.</p><p>&nbsp;</p><p><u>Tabulated summary for monotherapy in MM</u></p><p>The following table is derived from data gathered during NDMM studies in patients who have undergone ASCT treated with lenalidomide maintenance. The data were not adjusted according to the longer duration of treatment in the lenalidomide-containing arms continued until disease progression versus the placebo arms in the pivotal multiple myeloma studies (see section 5.1).</p><p>Table 1: ADRs reported in clinical trials in patients with multiple myeloma treated with lenalidomide maintenance therapy</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class/ Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Infections and Infestations</strong></p></td><td><p><u>Very Common</u></p><p>Pneumonias<sup>&loz;,</sup> <sup>a</sup>, Upper respiratory tract infection, Neutropenic infection, Bronchitis<sup>&loz;</sup>, Influenza<sup>&loz;</sup>, Gastroenteritis<sup>&loz;</sup>, Sinusitis, Nasopharyngitis, Rhinitis <u>Common</u></p><p>Infection<sup>&loz;</sup>, Urinary tract</p><p>infection<sup>&loz;</sup>*, Lower respiratory tract infection, Lung infection<sup>&loz;</sup></p></td><td><p><u>Very Common</u> Pneumonias<sup>&loz;,</sup> <sup>a</sup>, Neutropenic infection</p><p><u>Common</u></p><p>Sepsis<sup>&loz;,</sup> <sup>b</sup>, Bacteraemia, Lung infection<sup>&loz;</sup>, Lower respiratory tract infection bacterial, Bronchitis<sup>&loz;</sup>, Influenza<sup>&loz;</sup>, Gastroenteritis<sup>&loz;</sup>, Herpes zoster<sup>&loz;</sup>,</p><p>Infection<sup>&loz;</sup></p></td></tr><tr><td><p><strong>Neoplasms Benign, Malignant and</strong></p></td><td><p><u>Common</u></p><p>Myelodysplastic syndrome<sup>&loz;,</sup>*</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Unspecified (incl cysts and polyps)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td><p><u>Very Common</u> Neutropenia^<sup>,&loz;</sup>, Febrile neutropenia^<sup>,&loz;</sup>,</p><p>Thrombocytopenia^<sup>,&loz;,</sup>, Anemia, Leucopenia<sup>&loz;</sup>, Lymphopenia</p></td><td><p><u>Very Common</u> Neutropenia^<sup>,&loz;</sup>, Febrile neutropenia^<sup>,&loz;</sup>,</p><p>Thrombocytopenia^<sup>,&loz;</sup>, Anemia, Leucopenia<sup>&loz;</sup>, Lymphopenia <u>Common</u></p><p>Pancytopenia<sup>&loz;</sup></p></td></tr><tr><td><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td><p><u>Very Common</u> Hypokalaemia</p></td><td><p><u>Common</u></p><p>Hypokalaemia, Dehydration</p></td></tr><tr><td><p><strong>Nervous System Disorders</strong></p></td><td><p><u>Very Common</u> Paraesthesia <u>Common</u></p><p>Peripheral neuropathy<sup>c</sup></p></td><td><p><u>Common</u> Headache</p></td></tr><tr><td><p><strong>Vascular Disorders</strong></p></td><td><p><u>Common</u></p><p>Pulmonary embolism<sup>&loz;</sup>*</p></td><td><p><u>Common</u></p><p>Deep vein thrombosis^<sup>,&loz;,d</sup></p></td></tr><tr><td><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td><p><u>Very Common</u> Cough <u>Common</u></p><p>Dyspnoea<sup>&loz;</sup>, Rhinorrhoea</p></td><td><p><u>Common</u> Dyspnoea<sup>&loz;</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal Disorders</strong></p></td><td><p><u>Very Common</u> Diarrhoea, Constipation, Abdominal pain, Nausea <u>Common</u></p><p>Vomiting, Abdominal pain upper</p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Diarrhoea, Vomiting, Nausea</p></td></tr><tr><td><p><strong>Hepatobiliary Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Abnormal liver function tests</p></td><td><p><u>Common</u></p><p>Abnormal liver function tests</p></td></tr><tr><td><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td><p><u>Very Common</u> Rash, Dry skin</p></td><td><p><u>Common</u> Rash, Pruritus</p></td></tr><tr><td><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td><p><u>Very Common</u> Muscle spasms <u>Common</u></p><p>Myalgia, Musculoskeletal pain</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>General Disorders and</strong></p><p><strong>Administration Site Conditions</strong></p></td><td><p><u>Very Common</u></p><p>Fatigue, Asthenia, Pyrexia</p></td><td><p><u>Common</u> Fatigue, Asthenia</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>◇&nbsp;&nbsp; Adverse reactions reported as serious in clinical trials in patients with NDMM who had undergone ASCT</p><p>* Applies to serious adverse drug reactions only</p><p>^See 4.8 undesirable effects description of selected adverse reactions</p><p><sup>a</sup> &ldquo;Pneumonias&rdquo; combined AE term includes the following PTs: Bronchopneumonia, Lobar pneumonia, Pneumocystis jiroveci pneumonia, Pneumonia, Pneumonia klebsiella, Pneumonia legionella, Pneumonia mycoplasmal, Pneumonia pneumococcal, Pneumonia streptococcal, Pneumonia viral, Lung disorder, Pneumonitis</p><p><sup>b</sup> &ldquo;Sepsis&rdquo; combined AE term includes the following PTs: Bacterial sepsis, Pneumococcal sepsis, Septic shock, Staphylococcal sepsis</p><p><sup>c</sup> &ldquo;Peripheral neuropathy&rdquo; combined AE term includes the following preferred terms (PTs): Neuropathy peripheral, Peripheral sensory neuropathy, Polyneuropathy</p><p><sup>d</sup> &ldquo;Deep vein thrombosis&rdquo; combined AE term includes the following PTs: Deep vein thrombosis, Thrombosis, Venous thrombosis</p><p>&nbsp;</p><p><em><u>Tabulated summary for combination therapy in MM</u></em></p><p>The following table is derived from data gathered during the multiple myeloma studies with combination therapy. The data were not adjusted according to the longer duration of treatment in the lenalidomide-containing arms continued until disease progression versus the comparator arms in the pivotal multiple myeloma studies (see section 5.1).</p><p>Table 2. ADRs reported in clinical studies in patients with multiple myeloma treated with lenalidomide in combination with bortezomib and dexamethasone, dexamethasone, or melphalan and prednisone</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ</strong></p><p><strong>Class / Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Infections and Infestations</strong></p></td><td><p><u>Very Common</u></p><p>Pneumonia&loz;,&loz;&loz;, Upper respiratory tract infection&loz;, Bacterial, viral and fungal infections (including opportunistic infections)&loz;, Nasopharyngitis, Pharyngitis, Bronchitis&loz;, Rhinitis</p><p><u>Common</u></p><p>Sepsis&loz;,&loz;&loz;, Lung infection&loz;&loz;, Urinary tract infection&loz;&loz;, Sinusitis&loz;</p></td><td><p><u>Common</u></p><p>Pneumonia&loz;,&loz;&loz;, Bacterial, viral and fungal infections (including opportunistic infections)&loz;, Cellulitis&loz;, Sepsis&loz;,&loz;&loz;, Lung infection&loz;&loz;, Bronchitis&loz;, Respiratory tract infection&loz;&loz;, Urinary tract infection&loz;&loz;, Enterocolitis infectious</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Uncommon</u></p><p>Basal cell carcinoma^,&loz;, Squamous skin cancer^,&loz;,*</p></td><td><p><u>Common</u></p><p>Acute myeloid leukaemia&loz;, Myelodysplastic syndrome&loz;, Squamous cell carcinoma of skin^,&loz;,**</p><p><u>Uncommon</u></p><p>T-cell type acute leukaemia&loz;,</p><p>Basal cell carcinoma^,&loz;,</p><p>Tumour lysis syndrome</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p><u>Very Common</u></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><u>Very Common</u></p></td><td><p>Neutropenia^,&loz;,&loz;&loz;,</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Neutropenia^,&loz;,&loz;&loz;,</p></td><td><p>Thrombocytopenia^,&loz;,&loz;&loz;,</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Thrombocytopenia^,&loz;,&loz;&loz;, Anaemia&loz;,</p></td><td><p>Anaemia&loz;, Leucopenia,</p></td></tr><tr><td><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td><p>Haemorrhagic disorder^, Leucopenia, Lymphopenia</p><p><u>Common</u></p><p>Febrile neutropenia^,&loz;, Pancytopenia&loz;</p></td><td><p>Lymphopenia <u>Common</u></p><p>Febrile neutropenia^,&loz;, Pancytopenia&loz;, Haemolytic</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><u>Uncommon</u></p></td><td><p>anaemia</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Haemolysis, Autoimmune haemolytic</p></td><td><p><u>Uncommon</u></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>anemia, Haemolytic anemia</p></td><td><p>Hypercoagulation,</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Coagulopathy</p></td></tr><tr><td><p><strong>Immune System Disorders</strong></p></td><td><p><u>Uncommon</u> Hypersensitivity^</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Endocrine Disorders</strong></p></td><td><p><u>Common</u> Hypothyroidism</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><u>Very Common</u></p></td><td rowspan="5"><p><u>Common</u> Hypokalaemia&loz;,&loz;&loz;, Hyperglycaemia,</p><p>Hypocalcaemia&loz;, Diabetes mellitus&loz;, Hypophosphataemia, Hyponatraemia&loz;, Hyperuricaemia, Gout,</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypokalaemia&loz;,&loz;&loz;, Hyperglycaemia,</p></td></tr><tr><td><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td><p>Hypoglycaemia, Hypocalcaemia&loz;, Hyponatraemia&loz;, Dehydration&loz;&loz;, Decreased appetite&loz;&loz;, Weight decreased</p><p><u>Common</u></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypomagnesaemia, Hyperuricaemia,</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypercalcaemia+</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Dehydration&loz;&loz;, Decreased appetite&loz;&loz;, Weight decreased</p></td></tr><tr><td><p><strong>Psychiatric Disorders</strong></p></td><td><p><u>Very Common</u> Depression, Insomnia <u>Uncommon</u></p><p>Loss of libido</p></td><td><p><u>Common</u> Depression, Insomnia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Nervous System Disorders</strong></p></td><td><p><strong>&nbsp;</strong></p><p><u>Very Common</u></p><p>Peripheral neuropathies&loz;&loz;, Paraesthesia, Dizziness&loz;&loz;, Tremor, Dysgeusia, Headache</p><p><u>Common</u></p><p>Ataxia, Balance impaired, Syncope&loz;&loz;,</p><p>Neuralgia, Dysaesthesia</p></td><td><p><u>Very Common</u></p><p>Peripheral neuropathies&loz;&loz;</p><p><u>Common</u></p><p>Cerebrovascular accident&loz;, Dizziness&loz;&loz;, Syncope&loz;&loz;, Neuralgia</p><p><u>Uncommon</u></p><p>Intracranial haemorrhage^, Transient ischaemic attack, Cerebral ischemia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Eye Disorders</strong></p></td><td><p><u>Very Common</u> Cataracts, Blurred vision <u>Common</u></p><p>Reduced visual acuity</p></td><td><p><u>Common</u> Cataract</p><p><u>Uncommon</u> Blindness</p></td></tr><tr><td><p><strong>Ear and</strong></p><p><strong>Labyrinth Disorders</strong></p></td><td><p><u>Common</u></p><p>Deafness (Including Hypoacusis), Tinnitus</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Cardiac Disorders</strong></p></td><td><p><u>Common</u></p><p>Atrial fibrillation&loz;,&loz;&loz;, Bradycardia</p><p><u>Uncommon</u></p><p>Arrhythmia, QT prolongation, Atrial</p><p>flutter, Ventricular extrasystoles</p></td><td><p><u>Common</u></p><p>Myocardial infarction (including acute)^,&loz;, Atrial fibrillation&loz;,&loz;&loz;, Congestive cardiac failure&loz;, Tachycardia, Cardiac failure&loz;,&loz;&loz;, Myocardial ischemia&loz;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Vascular Disorders</strong></p></td><td><p><strong>&nbsp;</strong></p><p><u>Very Common</u></p><p>Venous thromboembolic events^, predominantly deep vein thrombosis and pulmonary embolism^,&loz;,&loz;&loz;, Hypotension&loz;&loz;</p><p><u>Common</u></p><p>Hypertension, Ecchymosis^</p></td><td><p><u>Very Common</u></p><p>Venous thromboembolic events^, predominantly deep vein thrombosis and pulmonary embolism^,&loz;,&loz;&loz;</p><p><u>Common</u></p><p>Vasculitis, Hypotension&loz;&loz;,</p><p>Hypertension <u>Uncommon</u></p><p>Ischemia, Peripheral ischemia, Intracranial venous sinus thrombosis</p></td></tr><tr><td><p><strong>Respiratory, Thoracic and</strong></p><p><strong>Mediastinal Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Dyspnoea&loz;,&loz;&loz;, Epistaxis^, Cough</p><p><u>Common</u> Dysphonia</p></td><td><p><u>Common</u></p><p>Respiratory distress&loz;, Dyspnoea&loz;,&loz;&loz;, Pleuritic pain&loz;&loz;, Hypoxia&loz;&loz;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Diarrhoea&loz;,&loz;&loz;, Constipation&loz;, Abdominal pain&loz;&loz;, Nausea, Vomiting,&loz;&loz;, Dyspepsia, Dry mouth, Stomatitis</p><p><u>Common</u></p><p>Gastrointestinal haemorrhage (including rectal haemorrhage, haemorrhoidal</p></td><td><p><u>Common</u> Gastrointestinal</p><p>haemorrhage^,&loz;,&loz;&loz;, Small intestinal obstruction&loz;&loz;, Diarrhoea&loz;&loz;, Constipation&loz;,</p><p>Abdominal pain&loz;&loz;, Nausea, Vomiting&loz;&loz;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>haemorrhage, peptic ulcer haemorrhage and gingival bleeding)^ ,&loz;&loz;, Dysphagia <u>Uncommon</u></p><p>Colitis, Caecitis</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Hepatobiliary Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Alanine aminotransferase increased, Aspartate aminotransferase increased <u>Common</u></p><p>Hepatocellular injury&loz;&loz;, Abnormal liver function tests&loz;, Hyperbilirubinaemia <u>Uncommon</u></p><p>Hepatic failure^</p></td><td><p><u>Common</u></p><p>Cholestasis&loz;, Hepatotoxicity, Hepatocellular injury&loz;&loz;, Alanine aminotransferase increased, Abnormal liver function tests&loz;</p><p><u>Uncommon</u> Hepatic failure^</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td><p><u>Very Common</u> Rashes&loz;&loz;, Pruritus <u>Common</u></p><p>Urticaria, Hyperhidrosis, Dry skin, Skin hyperpigmentation, Eczema, Erythema <u>Uncommon</u></p><p>Drug rash with eosinophilia and systemic</p><p>symptoms&loz;&loz;, Skin discolouration,</p><p>Photosensitivity reaction</p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u> Rashes&loz;&loz; <u>Uncommon</u></p><p>Drug rash with eosinophilia and</p><p>systemic symptoms&loz;&loz;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td><p>Very Common</p><p>Muscular weakness&loz;&loz;, Muscle spasms, Bone pain&loz;, Musculoskeletal and connective tissue pain and discomfort (including back pain&loz;,&loz;&loz;), Pain in extremity, Myalgia, Arthralgia&loz; Common</p><p>Joint swelling</p></td><td><p><u>Common</u></p><p>Muscular weakness&loz;&loz;, Bone pain&loz;, Musculoskeletal and connective tissue pain and discomfort (including back pain&loz;,&loz;&loz;)</p><p><u>Uncommon</u> Joint swelling</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Renal and Urinary Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Renal failure (including acute)&loz; ,&loz;&loz;</p><p><u>Common</u></p><p>Haematuria^, Urinary retention, Urinary incontinence</p><p><u>Uncommon</u></p><p>Acquired Fanconi syndrome</p></td><td><p><strong>&nbsp;</strong></p><p><u>Uncommon</u></p><p>Renal tubular necrosis</p></td></tr><tr><td><p><strong>Reproductive</strong></p><p><strong>System and Breast Disorders</strong></p></td><td><p><u>Common</u></p><p>Erectile dysfunction</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td><p><u>Very Common</u></p><p>Fatigue&loz;,&loz;&loz;, Oedema (including peripheral oedema), Pyrexia&loz;,&loz;&loz;, Asthenia, Influenza like illness syndrome (including pyrexia, cough, myalgia, musculoskeletal pain, headache and rigors)</p><p><u>Common</u></p><p>Chest pain&loz;,&loz;&loz;, Lethargy</p></td><td><p><strong>&nbsp;</strong></p><p><u>Very common</u> Fatigue&loz;,&loz;&loz; <u>Common</u></p><p>Oedema peripheral,</p><p>Pyrexia&loz;,&loz;&loz;, Asthenia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Investigations</strong></p></td><td><p><u>Very common</u></p><p>Blood alkaline phosphatase increased <u>Common</u></p><p>C-reactive protein increased</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Injury, Poisoning</strong></p><p><strong>and Procedural Complications</strong></p></td><td><p><u>Common</u></p><p>Fall, Contusion^</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&loz;&loz; Adverse reactions reported as serious in clinical trials in patients with NDMM who had received lenalidomide in combination with bortezomib and dexamethasone</p><p>^See section 4.8 description of selected adverse reactions</p><p>◇&nbsp;&nbsp; Adverse reactions reported as serious in clinical trials in patients with multiple myeloma treated with lenalidomide in combination with dexamethasone, or with melphalan and prednisone</p><p>+ Applies to serious adverse drug reactions only</p><p>* Squamous skin cancer was reported in clinical trials in previously treated myeloma patients with lenalidomide/dexamethasone compared to controls</p><p>** Squamous cell carcinoma of skin was reported in a clinical trial in newly diagnosed myeloma patients with lenalidomide/dexamethasone compared to controls</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tabulated summary from monotherapy</u></p><p><strong><em>&nbsp;</em></strong></p><p>The following table are derived from data gathered during the main studies in monotherapy for myelodysplastic syndromes and mantle cell lymphoma.</p><p>Table 3. ADRs reported in clinical trials in patients with myelodysplastic syndromes treated with lenalidomide#</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class / Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Infections and Infestations</strong></p></td><td><p><u>Very Common</u></p><p>Bacterial, viral and fungal infections (including opportunistic infections)&loz;</p></td><td><p><u>Very Common</u> Pneumonia<sup>&loz;</sup> <u>Common</u></p><p>Bacterial, viral and fungal infections (including opportunistic infections) <sup>&loz;</sup>, Bronchitis</p></td></tr><tr><td><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td><p><u>Very Common</u> Thrombocytopenia^,&loz;, Neutropenia^,&loz;, Leucopenia</p></td><td><p><u>Very Common</u> Thrombocytopenia^,&loz;, Neutropenia^,&loz;, Leucopenia <u>Common</u></p><p>Febrile neutropenia^<sup>&loz;</sup></p></td></tr><tr><td><p><strong>Endocrine Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Hypothyroidism</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td><p><u>Very Common</u> Decreased appetite <u>Common</u></p><p>Iron overload, Weight decreased</p></td><td><p><u>Common</u></p><p>Hyperglycaemia<sup>&loz;</sup>, Decreased appetite</p></td></tr><tr><td><p><strong>Psychiatric Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p><u>Common</u> Altered mood<sup>&loz;~</sup></p></td></tr><tr><td><p><strong>Nervous System Disorders</strong></p></td><td><p><u>Very Common</u> Dizziness, Headache <u>Common</u></p><p>Paraesthesia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Cardiac Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p><u>Common</u></p><p>Acute myocardial infarction^<sup>&loz;</sup>, Atrial fibrillation<sup>&loz;</sup>, Cardiac failure<sup>&loz;</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Vascular Disorders</strong></p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Hypertension, Haematoma</p></td><td><p><u>Common</u></p><p>Venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^<sup>&loz;</sup></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Respiratory, Thoracic and</strong></p><p><strong>Mediastinal Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Epistaxis^</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Diarrhoea&loz;, Abdominal pain (including upper), Nausea, Vomiting, Constipation <u>Common</u></p><p>Dry mouth, Dyspepsia</p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Diarrhoea<sup>&loz;</sup>, Nausea, Toothache</p></td></tr><tr><td><p><strong>Hepatobiliary Disorders</strong></p></td><td><p><u>Common</u></p><p>Abnormal liver function tests</p></td><td><p><u>Common</u></p><p>Abnormal liver function tests</p></td></tr><tr><td><p><strong>Skin and</strong></p><p><strong>Subcutaneous Tissue Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Rashes, Dry Skin, Pruritus</p></td><td><p><u>Common</u> Rashes, Pruritus</p></td></tr><tr><td><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Muscle spasms, Musculoskeletal pain (including back pain&loz; and pain in extremity), Arthralgia, Myalgia</p></td><td><p><u>Common</u> Back pain<sup>&loz;</sup></p></td></tr><tr><td><p><strong>Renal and Urinary Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p><u>Common</u> Renal failure<sup>&loz;</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td><p><u>Very Common</u></p><p>Fatigue, Peripheral oedema, Influenza like illness syndrome (including pyrexia, cough,</p><p>pharyngitis, myalgia, musculoskeletal pain, headache)</p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u> Pyrexia</p></td></tr><tr><td><p><strong>Injury, Poisoning</strong></p><p><strong>and Procedural Complications</strong></p></td><td><p>&nbsp;</p></td><td><p><u>Common</u> Fall</p></td></tr></tbody></table><p>^see section 4.8 description of selected adverse reactions</p><p>&loz; Adverse events reported as serious in myelodysplastic syndromes clinical trials</p><p>~Altered mood was reported as a common serious adverse event in the myelodysplastic syndromes phase III study; it was not reported as a grade 3 or 4 adverse event</p><p>&nbsp;</p><p>Algorithm applied for inclusion in the SmPC: All ADRs captured by the phase 3 study algorithm are included in the EU SmPC. For these ADRs, an additional check of the frequency of the ADRs captured by the phase 2 study algorithm was undertaken and, if the frequency of the ADRs in the phase 2 study was higher than in the phase 3 study, the event was included in the EU SmPC at the frequency it occurred in the phase 2 study.</p><p>&nbsp;</p><p># Algorithm applied for myelodysplastic syndromes:</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp; Myelodysplastic syndromes phase 3 study (double-blind safety population, difference between lenalidomide 5/10mg and placebo by initial dosing regimen occurring in at least 2 subjects)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent adverse events with &ge; 5% of subjects in lenalidomide and at least 2% difference in proportion between lenalidomide and placebo</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent Grade 3 or 4 adverse events in 1% of subjects in lenalidomide and at least 1% difference in proportion between lenalidomide and placebo</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent serious adverse events in 1% of subjects in lenalidomide and at least 1% difference in proportion between lenalidomide and placebo</p><p>&nbsp;</p><p>&bull;&nbsp; Myelodysplastic syndromes Phase 2 study</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent adverse events with &ge; 5% of lenalidomide treated subjects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent grade 3 or 4 adverse\events in 1% of lenalidomide treated subjects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent serious adverse events in 1% of lenalidomide treated subjects</p><p>&nbsp;</p><p>Table 4: ADRs reported in clinical trials in patients with mantle cell lymphoma treated with lenalidomide</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class / Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Infections and Infestations</strong></p></td><td><p><u>Very Common</u></p><p>Bacterial, viral and fungal infections (including opportunistic infections)</p><p>&loz;, Nasopharyngitis, Pneumonia&loz;</p><p><u>Common</u> Sinusitis</p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Bacterial, viral and fungal infections (including opportunistic infections) <sup>&loz;</sup>, Pneumonia<sup>&loz;</sup></p></td></tr><tr><td><p><strong>Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)</strong></p></td><td><p><u>Common</u></p><p>Tumour flare reaction</p></td><td><p><u>Common</u></p><p>Tumour flare reaction, Squamous skin cancer&circ;<sup>&loz;,</sup> Basal cell Carcinoma<sup>^,&loz;</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Thrombocytopenia^, Neutropenia^,&loz;, Leucopenia&loz;, Anaemia&loz;</p><p><u>Common</u></p><p>Febrile neutropenia^,&loz;</p></td><td><p><u>Very Common</u></p><p>Thrombocytopenia^, Neutropenia^<sup>&loz;</sup>, Anaemia<sup>&loz;</sup></p><p><u>Common</u></p><p>Febrile neutropenia^<sup>&loz;</sup>, Leucopenias<sup>&loz;</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Decreased appetite, Weight decreased, Hypokalaemia</p><p><u>Common</u></p><p>Dehydration&loz;</p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Dehydration<sup>&loz;</sup>, Hyponatraemia, Hypocalcaemia</p></td></tr><tr><td><p><strong>Psychiatric Disorders</strong></p></td><td><p><u>Common</u> Insomnia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Nervous System Disorders</strong></p></td><td><p><u>Common</u></p><p>Dysgeuesia, Headache, neuropathy peripheral</p></td><td><p><u>Common</u></p><p>Peripheral sensory neuropathy, Lethargy</p></td></tr><tr><td><p><strong>Ear and Labyrinth Disorders</strong></p></td><td><p><u>Common</u></p><p>Vertigo</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Cardiac Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p><u>Common</u></p><p>myocardial infarction (including acute)^ <sup>&loz;</sup>, Cardiac failure</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Vascular Disorders</strong></p></td><td><p><u>Common</u> Hypotension</p><p>&loz;</p></td><td><p><u>Common</u></p><p>Deep vein thrombosis<sup>&loz;</sup>, pulmonary embolism^<sup>&loz;</sup>, Hypotension<sup>&loz;</sup></p></td></tr><tr><td><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td><p><u>Very Common</u> Dyspnoea&loz;</p></td><td><p><u>Common</u> Dyspnoeia<sup>&loz;</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Diarrhoea&loz;, Nausea&loz;, Vomiting&loz;,</p><p>Constipation</p></td><td><p><u>Common</u></p><p>Diarrhoea<sup>&loz;</sup>, Abdominal pain<sup>&loz;</sup>, Constipation</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><u>Common</u></p><p>Abdominal pain&loz;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Rashes (including dermatitis allergic), Pruritus</p><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Night sweats, Dry skin</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Common</u> Rashes</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td><p><u>Very Common</u></p><p>Muscle spasms, Back pain</p><p><u>Common</u></p><p>Arthralgia, Pain in extremity, Muscular</p><p>weakness &loz;</p></td><td><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Back pain, Muscular weakness<sup>&loz;</sup>, Arthralgia, Pain in extremity</p></td></tr><tr><td><p><strong>Renal and Urinary Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p><u>Common</u> Renal failure<sup>&loz;</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td><p><u>Very Common</u></p><p>Fatigue, Asthenia &loz;, Peripheral oedema, Influenza like illness syndrome (including pyrexia &loz;, cough)</p><p><u>Common</u> Chills</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Common</u></p><p>Pyrexia<sup>&loz;</sup>, Asthenia<sup>&loz;</sup>, Fatigue</p></td></tr></tbody></table><p>^see section 4.8 description of selected adverse reactions</p><p>◇&nbsp;&nbsp; Adverse events reported as serious in mantle cell lymphoma clinical trials Algorithm applied for mantle cell lymphoma:</p><p>Mantle cell lymphoma controlled phase 2 study</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent adverse events with &ge; 5% of subjects in lenalidomide arm and at least 2% difference in proportion between lenalidomide and control arm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent Grade 3 or 4 adverse events in &ge;1% of subjects in lenalidomide arm and at least 1.0% difference in proportion between lenalidomide and control arm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All Serious treatment-emergent adverse events in &ge;1% of subjects in lenalidomide arm and at least 1.0% difference in proportion between lenalidomide and control arm</p><p>Mantle cell lymphoma single arm phase 2 study</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All treatment-emergent adverse events with &ge; 5% of subjects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All grade 3 or 4 treatment-emergent adverse events reported in 2 or more subjects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All Serious treatment-emergent adverse events reported in 2 or more subjects</p><p>&nbsp;</p><p><u>Tabulated summary for combination therapy in FL</u></p><p>The following table is derived from data gathered during the main studies (NHL-007 and NHL-008) using lenalidomide in combination with rituximab for patients with follicular lymphoma.</p><p>Table 5: ADRs reported in clinical trials in patients with follicular lymphoma treated with lenalidomide in combination with rituximab</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p><p><strong>/Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p>Infections and Infestations</p></td><td><p><u>Very Common</u></p></td><td><p><u>Common</u></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Upper respiratory tract infection</p><p><u>Common</u></p><p>Pneumonia&loz;, Influenza, Bronchitis, Sinusitis, Urinary tract infection</p></td><td><p>Pneumonia&loz;, Sepsis&loz;, Lung infection, Bronchitis, Gastroenteritis, Sinusitis, Urinary tract infection, Cellulitis&loz;</p></td></tr><tr><td><p>Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)</p></td><td><p><u>Very Common</u> Tumour flare^ <u>Common</u></p><p>Squamous Cell Carcinoma of</p><p>Skin&loz;,^,+</p></td><td><p><u>Common</u></p><p>Basal cell carcinoma^,&loz;</p></td></tr><tr><td><p>Blood and Lymphatic System Disorders</p></td><td><p><u>Very Common</u></p><p>Neutropenia^,&loz;, Anaemia&loz;, Thrombocytopenia^, Leucopenia** Lymphopenia***</p></td><td><p><u>Very Common</u> Neutropenia^,&loz; <u>Common</u></p><p>Anaemia&loz;, Thrombocytopenia^, Febrile neutropenia&loz;, Pancytopenia, Leucopenia**, Lymphopenia***</p></td></tr><tr><td><p>Metabolism and Nutrition Disorders</p></td><td><p><u>Very Common</u></p><p>Decreased ppetite, Hypokalaemia</p><p><u>Common</u></p><p>Hypophosphataemia, Dehydration</p></td><td><p><u>Common</u></p><p>Dehydration, Hypercalcaemia&loz;, Hypokalaemia, Hypophosphataemia, Hyperuricaemia</p></td></tr><tr><td><p>Psychiatric Disorders</p></td><td><p><u>Common</u></p><p>Depression, Insomnia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nervous System Disorders</p></td><td><p><u>Very Common</u> Headache, Dizziness <u>Common</u></p><p>Peripheral sensory neuropathy, Dysgeusia</p></td><td><p><u>Common</u> Syncope</p></td></tr><tr><td><p>Cardiac Disorders</p></td><td><p><u>Uncommon</u></p><p>Arrhythmia&loz;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Vascular Disorders</p></td><td><p><u>Common</u> Hypotension</p></td><td><p><u>Common</u></p><p>Pulmonary embolism^,&loz;,</p><p>Hypotension</p></td></tr><tr><td><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td><p><u>Very Common</u> Dyspnoea&loz;, Cough,</p></td><td><p><u>Common</u></p><p>Dyspnoea&loz;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><u>Common</u></p><p>Oropharyngeal pain, Dysphonia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal Disorders</p></td><td><p><u>Very Common</u></p><p>Abdominal pain&loz;, Diarrhoea, Constipation, Nausea, Vomiting, Dyspepsia</p><p><u>Common</u></p><p>Upper abdominal pain, Stomatitis, Dry mouth</p></td><td><p><u>Common</u></p><p>Abdominal pain&loz;, Diarrhoea,</p><p>Constipation, Stomatitis</p></td></tr><tr><td><p>Skin and Subcutaneous Tissue Disorders</p></td><td><p><u>Very Common</u> Rash*, Pruritus <u>Common</u></p><p>Dry skin, Night sweats, Erythema</p></td><td><p><u>Common</u> Rash*, Pruritus</p></td></tr><tr><td><p>Musculoskeletal and Connective Tissue Disorders</p></td><td><p><u>Very Common</u></p><p>Muscle spasms, Back pain, Arthralgia</p><p><u>Common</u></p><p>Pain in extremity, Muscular weakness, Musculoskeletal pain, Myalgia, Neck pain</p></td><td><p><u>Common</u></p><p>Muscular weakness, Neck pain</p></td></tr><tr><td><p>Renal and Urinary Disorders</p></td><td><p>&nbsp;</p></td><td><p><u>Common</u></p><p>Acute kidney injury&loz;</p></td></tr><tr><td><p>General Disorders and Administration Site Conditions</p></td><td><p><u>Very Common</u></p><p>Pyrexia, Fatigue, Asthenia, Peripheral oedema</p><p><u>Common</u> Malaise, Chills</p></td><td><p><u>Common</u> Fatigue, Asthenia</p></td></tr><tr><td><p>Investigations</p></td><td><p><u>Very Common</u></p><p>Alanine aminotransferase increased</p><p><u>Common</u></p><p>Weight decreased, Blood Bilirubin increased</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>^see section 4.8 description of selected adverse reactions Algorithm applied for follicular lymphoma:</p><p>Controlled&ndash; Phase 3 trial:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NHL-007 ADRs- All treatment-emergent AEs with &ge; 5.0% of subjects in lenalidomide/rituximab arm and at least 2.0%higher frequency (%) in Len arm compared to control arm - (Safety population)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NHL-007 Gr 3/4 ADRs- All Grades 3 or Grade 4 treatment-emergent AEs with at least 1.0% subjects in lenalidomide/rituximab arm and at least 1.0% higher frequency in lenalidomide arm compared to control arm - (safety population)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NHL-007 Serious ADRs- All serious treatment-emergent AEs with at least 1.0% subjects in lenalidomide/rituximab arm and at least 1.0% higher frequency in lenalidomide/rituximab arm compared to control arm - (safety population)</p><p>FL single arm - phase 3 trial:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NHL-008 ADRs- All treatment-emergent adverse events with &ge; 5.0% of subjects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NHL-008 Gr 3/4 ADRs- All Grade 3/4 treatment-emergent adverse events reported in &ge; 1.0% of subjects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NHL-008 Serious ADRs- All serious treatment-emergent adverse events reported in &ge; 1.0% of subjects</p><p>&loz; Adverse events reported as serious in follicular lymphoma clinical trials</p><p>+ Applies to serious adverse drug reactions only</p><p>* Rash includes PT of rash and rash maculo-papular</p><p>**Leucopenia includes PT leucopenia and white blood cell count decreased</p><p>***Lymphopenia includes PT lymphopenia and lymphocyte count decreased</p><p>&nbsp;</p><p><em><u>Tabulated summary of post-marketing adverse reactions</u></em></p><p>In addition to the above adverse reactions identified from the pivotal clinical trials, the following table is derived from data gathered from post-marketing data.</p><p>Table 6: ADRs reported in post-marketing use in patients treated with lenalidomide</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class / Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Infections and Infestations</p></td><td><p><u>Not known</u></p><p>Viral infections, including herpes zoster and hepatitis B virus reactivation</p></td><td><p><u>Not known</u></p><p>Viral infections, including herpes zoster and hepatitis B virus reactivation</p></td></tr><tr><td><p>Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)</p></td><td><p>&nbsp;</p></td><td><p><u>Rare</u></p><p>Tumour lysis syndrome</p></td></tr><tr><td><p>Blood and Lymphatic System Disorders</p></td><td><p><u>Not known</u></p><p>Acquired haemophilia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p>Immune System disorders</p></td><td><p><u>Rare</u></p><p>Anaphylactic reaction^ <u>Not known</u></p><p>Solid organ transplant rejection</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Endocrine Disorders</p></td><td><p><u>Common</u></p><p>Hyperthyroidism</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td><p><u>Uncommon</u></p><p>Pulmonary hypertension</p></td><td><p><u>Rare</u></p><p>Pulmonary hypertension <u>Not Known</u></p><p>Interstitial pneumonitis</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Gastrointestinal Disorders</p></td><td><p>&nbsp;</p></td><td><p><u>Not Known</u></p><p>Pancreatitis, Gastrointestinal perforation (including diverticular, intestinal and large</p><p>intestine perforations) ^</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Hepatobiliary Disorders</p></td><td><p><u>Not Known</u></p><p>Acute hepatic failure^, Hepatitis toxic^, Cytolytic hepatitis^, Cholestatic hepatitis^, Mixed cytolytic/cholestatic</p><p>hepatitis^</p></td><td><p><strong>&nbsp;</strong></p><p><u>Not Known</u></p><p><u>Acute hepatic failure^,</u> <u>Hepatitis toxic^</u></p></td></tr><tr><td><p>Skin and Subcutaneous Tissue</p></td><td rowspan="10"><p>&nbsp;</p></td><td><p><u>Uncommon</u></p></td></tr><tr><td><p>Disorders</p></td><td><p>Angioedema</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><u>Rare</u></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Stevens-Johnson Syndrome^,</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Toxic epidermal necrolysis^</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><u>Not Known</u></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Leukocytoclastic vasculitis,</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Drug Reaction with</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Eosinophilia and Systemic</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Symptoms^</p></td></tr></tbody></table><p>^see section 4.8 description of selected adverse reactions</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Teratogenicity</u></em></p><p>Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. In monkeys, lenalidomide induced malformations similar to those described with thalidomide (see sections 4.6 and 5.3). If lenalidomide is taken during pregnancy, a teratogenic effect of lenalidomide in humans is expected.</p><p>&nbsp;</p><p><em><u>Neutropenia and thrombocytopenia</u></em></p><p>&bull; <u>&nbsp;Newly diagnosed multiple myeloma: patients who have undergone ASCT treated with lenalidomide</u> <u>maintenance</u></p><p><em>Lenalidomide maintenance after ASCT is associated with a higher frequency of Grade 4 neutropenia compared to placebo maintenance (32.1% vs 26.7% [16.1% vs 1.8% after the start of maintenance treatment] in CALGB 100104 and 16.4% vs 0.7% in IFM 2005-02, respectively). Treatment-emergent AEs of neutropenia leading to lenalidomide discontinuation were reported in 2.2% of patients in CALGB 100104 and 2.4% of patients in IFM 2005-02, respectively. Grade 4 febrile neutropenia was reported at similar frequencies in the lenalidomide maintenance arms compared to placebo maintenance arms in both studies (0.4% vs 0.5% [0.4% vs 0.5% after the start of maintenance treatment] in CALGB 100104 and 0.3% vs 0% in IFM 2005-02, respectively).</em></p><p><em>Lenalidomide maintenance after ASCT is associated with a higher frequency of Grade 3 or 4 thrombocytopenia compared to placebo maintenance (37.5% vs 30.3% [17.9% vs 4.1% after the start of maintenance treatment] in CALGB 100104 and 13.0% vs 2.9% in IFM 2005-02, respectively).</em></p><p><em>&nbsp;</em></p><p>&bull; <u>&nbsp;Newly diagnosed multiple myeloma patients who are not eligible for transplant receiving</u> <u>lenalidomide in combination with bortezomib and dexamethasone</u></p><p><em>Grade 4 neutropenia was observed in the RVd arm to a lesser extent than in the Rd comparator arm (2.7% vs 5.9%) in the SWOG S0777 study. Grade 4 febrile neutropenia was reported at similar frequencies in the RVd arm compared to the Rd arm (0.0% vs 0.4%).</em></p><p><em>Grade 3 or 4 thrombocytopenia was observed in the RVd arm to a greater extent than in the Rd comparator arm (17.2 %vs 9.4%).</em></p><p>&bull; <strong><u>&nbsp;Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with</u> <u>lenalidomide in combination with dexamethasone</u></strong></p><p>The combination of lenalidomide with dexamethasone in newly diagnosed multiple myeloma patients is associated with a lower frequency of Grade 4 neutropenia (8.5% in Rd and Rd18, compared with MPT (15%). Grade 4 febrile neutropenia was observed infrequently (0.6% in Rd and Rd18 compared with 0.7% in MPT).</p><p>The combination of lenalidomide with dexamethasone in newly diagnosed multiple myeloma patients is associated with a lower frequency of Grade 3 and 4 thrombocytopenia (8.1% in Rd and Rd18) compared with MPT (11.1%).</p><p><strong><u>Newly diagnosed multiple myeloma: patients who are not eligible for transplant treated with</u> <u>lenalidomide in combination with melphalan and prednisone</u></strong></p><p>The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher frequency of Grade 4 neutropenia (34.1% in MPR+R/MPR+p) compared with MPp+p (7.8%). There was a higher frequency of Grade 4 febrile neutropenia observed (1.7% in MPR+R/MPR+p compared to 0.0% in MPp+p).</p><p>The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher frequency of Grade 3 and Grade 4 thrombocytopenia (40.4% in MPR+R/MPR+p) compared with MPp+p (13.7%).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape id="Graphic_x0020_4" o:spid="_x0000_s1030"
 style='position:absolute;left:0;text-align:left;margin-left:90pt;margin-top:14.45pt;
 width:3.85pt;height:1.6pt;z-index:-18382848;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' coordsize="48895,20320" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m48768,l,,,19811r48768,l48768,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="2" src="file:///C:/Users/O9B2F~1.ALH/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Multiple myeloma patients with at least one prior therapy</p><p>The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of Grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients). Grade 4 febrile neutropenia episodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in placebo/dexamethasone treated patients).</p><p>The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of Grade 3 and Grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone- treated patients).</p><p>&bull;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
 id="Graphic_x0020_5" o:spid="_x0000_s1029" style='position:absolute;left:0;
 text-align:left;margin-left:90pt;margin-top:16.6pt;width:3.85pt;height:1.6pt;
 z-index:-18382336;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' coordsize="48895,20320"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m48768,l,,,19811r48768,l48768,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="2" src="file:///C:/Users/O9B2F~1.ALH/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Myelodysplastic syndromes patients</p><p>In myelodysplastic syndromes patients, lenalidomide is associated with a higher incidence of Grade 3 or 4 neutropenia (74.6% in lenalidomide-treated patients compared with 14.9% in patients on placebo in the phase 3 study). Grade 3 or 4 febrile neutropenia episodes were observed in 2.2% of lenalidomide- treated patients compared with 0.0% in patients on placebo). Lenalidomide is associated with a higher incidence of Grade 3 or 4 thrombocytopenia (37% in lenalidomide-treated patients compared with 1.5% in patients on placebo in the phase 3 study).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mantle cell lymphoma patients</p><p>In mantle cell lymphoma patients, lenalidomide is associated with a higher incidence of Grade 3 or 4 neutropenia (43.7%in lenalidomide-treated patients compared with 33.7% in patients in the control arm in the phase 2 study). Grade 3 or 4 febrile neutropenia episodes were observed in 6.0% of lenalidomide- treated patients compared with 2.4% in patients on control arm.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
 id="Graphic_x0020_6" o:spid="_x0000_s1028" style='position:absolute;left:0;
 text-align:left;margin-left:90pt;margin-top:10.55pt;width:3.85pt;height:1.6pt;
 z-index:-18381824;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' coordsize="48895,20320"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m48768,l,,,19812r48768,l48768,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="2" src="file:///C:/Users/O9B2F~1.ALH/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Follicular lymphoma patients</p><p>The combination of lenalidomide with rituximab in follicular lymphoma is associated with a higher rate of grade 3 or grade 4 neutropenia (50.7% in lenalidomide/rituximab treated patients compared with 12.2% in placebo/rituximab treated patients). All grade 3 or 4 neutropenia were reversible through dose interruption, reduction and/or supportive care with growth factors. Additionally, febrile neutropenia was observed infrequently (2.7% in lenalidomide/rituximab treated patients compared with 0.7% in placebo/rituximab treated patients).</p><p>Lenalidomide in combination with rituximab is also associated with a higher incidence of grade 3 or 4 thrombocytopenia (1.4% in lenalidomide/rituximab treated patients compared to 0% in placebo/rituximab patients).</p><p>&nbsp;</p><p><em><u>Venous thromboembolism</u></em></p><p>An increased risk of DVT and PE is associated with the use of the combination of lenalidomide with dexamethasone in patients with multiple myeloma, and to a lesser extent in patients treated with lenalidomide in combination with melphalan and prednisone or in patients with multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma treated with lenalidomide monotherapy (see section 4.5).</p><p>Concomitant administration of erythropoietic agents or previous history of DVT may also increase thrombotic risk in these patients.</p><p>&nbsp;</p><p><em><u>Myocardial infarction</u></em></p><p>Myocardial infarction has been reported in patients receiving lenalidomide, particularly in those with known risk factors.</p><p>&nbsp;</p><p><em><u>Haemorrhagic disorders</u></em></p><p>Haemorrhagic disorders are listed under several system organ classes: Blood and lymphatic system disorders; nervous system disorders (intracranial haemorrhage); respiratory, thoracic and mediastinal disorders (epistaxis); gastrointestinal disorders (gingival bleeding, haemorrhoidal haemorrhage, rectal haemorrhage); renal and urinary disorders (haematuria); injury, poisoning and procedural complications (contusion) and vascular disorders (ecchymosis).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Allergic reactions and severe skin reactions</u></em></p><p><em>&nbsp;</em></p><p>Cases of allergic reactions including angioedema, anaphylactic reaction and severe cutaneous reactions including SJS, TEN and DRESS have been reported with the use of lenalidomide. A possible cross- reaction between lenalidomide and thalidomide has been reported in the literature. Patients with a history of severe rash associated with thalidomide treatment should not receive lenalidomide (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Second primary malignancies</u></em></p><p>In clinical trials in previously treated myeloma patients with lenalidomide/dexamethasone compared to controls, mainly comprising of basal cell or squamous cell skin cancers.</p><p>&nbsp;</p><p><em><u>Acute myeloid leukaemia</u></em></p><p>&bull;&nbsp;&nbsp; <em>Multiple myeloma</em></p><p>Cases of AML have been observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide treatment in combination with melphalan or immediately following HDM/ASCT (see section 4.4). This increase was not observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide in combination with dexamethasone compared to thalidomide in combination with melphalan and prednisone.</p><p>&bull;&nbsp;&nbsp; <em>Myelodysplastic syndromes</em></p><p>Baseline variables including complex cytogenetics and TP53 mutation are associated with progression to AML in subjects who are transfusion dependent and have a Del (5q) abnormality (see section 4.4). The estimated 2-year cumulative risk of progression to AML were 13.8% in patients with an isolated Del (5q) abnormality compared to 17.3%for patients with Del (5q) and one additional cytogenetic abnormality and 38.6% in patients with a complex karyotype.</p><p>In a post-hoc analysis of a clinical trial of lenalidomide in myelodysplastic syndromes, the estimated 2- year rate of progression to AML was 27.5 % in patients with IHC-p53 positivity and 3.6% in patients with IHC-p53 negativity (p=0.0038). In the patients with IHC-p53 positivity, a lower rate of progression to AML was observed amongst patients who achieved a transfusion independence (TI) response (11.1%) compared to a non-responder (34.8%).</p><p>&nbsp;</p><p><em><u>Hepatic disorders</u></em></p><p>The following post-marketing adverse reactions have been reported (frequency unknown): acute hepatic failure and cholestasis (both potentially fatal), toxic hepatitis, cytolytic hepatitis, mixed cytolytic/cholestatic hepatitis.</p><p>&nbsp;</p><p><em><u>Rhabdomyolysis</u></em></p><p>Rare cases of rhabdomyolysis have been observed, some of them when lenalidomide is administered with a statin.</p><p>&nbsp;</p><p><em><u>Thyroid disorders</u></em></p><p>Cases of hypothyroidism and cases of hyperthyroidism have been reported (see section 4.4 Thyroid disorders).</p><p>&nbsp;</p><p><em><u>Tumour flare reaction and tumour lysis syndrome</u></em></p><p>In study MCL-002, approximately 10% of lenalidomide-treated patients experienced TFR compared to 0% in the control arm. The majority of the events occurred in cycle 1, all were assessed as treatment- related, and the majority of the reports were grade 1 or 2. Patients with high MIPI at diagnosis or bulky disease (at least one lesion that is &ge; 7 cm in the longest diameter) at baseline may be at risk of TFR. In study MCL-002, TLS was reported for one patient in each of the two treatment arms. In the supportive study MCL-001, approximately 10% of subjects experienced TFR; all report were grade 1 or 2 in severity and all were assessed as treatment-related. The majority of the events occurred in cycle 1. There were no reports of TLS in study MCL-001 (see section 4.4).</p><p>In study NHL-007, TFR was reported in 19/146 (13.0%) of patients in the lenalidomide/rituximab arm versus 1/148 (0.7%) patients in the placebo/rituximab arm. Most TFRs (18 out of 19) reported in the lenalidomide/rituximab arm occurred during first two cycles of treatment. One FL patient in the lenalidomide/rituximab arm experienced a Grade 3 TFR event versus no patients in the placebo/rituximab arm. In study NHL-008, 7/177 (4.0%) of FL patients experienced TFR; (3 reports</p><p>were Grade 1 and 4 reports were Grade 2 severity); while 1 report was considered serious. In study NHL-007, TLS occurred in 2 FL patients (1.4%) in the lenalidomide/rituximab arm and no FL patients in the placebo/rituximab arm; neither patient had a Grade 3 or 4 event. TLS occurred in 1 FL patient (0.6%) in study NHL-008. This single event was identified as a serious, Grade 3 adverse reaction. For study NHL-007 no patients had to discontinue lenalidomide/rituximab therapy due to TFR or TLS.</p><p>&nbsp;</p><p><em><u>Gastrointestinal disorders</u></em></p><p>Gastrointestinal perforations have been reported during treatment with lenalidomide. Gastrointestinal perforations may lead to septic complications and may be associated with fatal outcome.</p><p>&nbsp;</p><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><u>To reports any side effect(s):</u></p><p><u><img alt="" width="975" height="292" src="data:image/jpeg;base64,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" /></u></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific experience in the management of lenalidomide overdose in patients, although in dose-ranging studies some patients were exposed to up to 150 mg, and in single-dose studies, some patients were exposed to up to 400 mg. The dose limiting toxicity in these studies was essentially haematological. In the event of overdose, supportive care is advised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other immunosuppressants. ATC code: L04AX04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Lenalidomide binds directly to cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex that includes deoxyribonucleic acid (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4), and regulator of cullins 1 (Roc1). In haematopoietic cells, lenalidomide binding to cereblon recruits substrate proteins Aiolos and Ikaros, lymphoid transcriptional factors, leading to their ubiquitination and subsequent degradation resulting in direct cytotoxic and immunomodulatory effects.</p><p>Specifically, lenalidomide inhibits proliferation and enhances apoptosis of certain haematopoietic tumour cells (including MM plasma tumour cells, follicular lymphoma tumour cells and those with deletions of chromosome 5), enhances T cell-and Natural Killer (NK) cell-mediated immunity and increases the number of NK, T and NK T cells. In MDS Del (5q), lenalidomide selectively inhibits the abnormal clone by increasing the apoptosis of Del (5q) cells.</p><p>The combination of lenalidomide and rituximab increases ADCC and direct tumor apoptosis in follicular lymphoma cells.</p><p>The lenalidomide mechanism of action also includes additional activities such as anti-angiogenic and pro-erythropoietic properties. Lenalidomide inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-&alpha; and IL-6) by monocytes.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Lenalidomide efficacy and safety have been evaluated in six phase 3 studies in newly diagnosed multiple myeloma, two phase 3 studies in relapsed refractory multiple myeloma, one phase 3 study and one phase 2 study in myelodysplastic syndromes and one phase 2 study in mantle cell lymphoma and one phase 3 and one phase 3b study in iNHL as described below.</p><p><em><u>Newly diagnosed multiple myeloma</u></em></p><p>&bull;&nbsp; <u>Lenalidomide maintenance in patients who have undergone ASCT</u></p><p>The efficacy and safety of lenalidomide maintenance was assessed in two phase 3 multicenter, randomised, double-blind 2-arm, parallel group, placebo-controlled studies: CALGB 100104 and IFM 2005-02</p><p><em>CALGB 100104</em></p><p>Patients between 18 and 70 years of age with active MM requiring treatment and without prior progression after initial treatment were eligible.</p><p>Patients were randomised 1:1 within 90-100 days after ASCT to receive either lenalidomide or placebo maintenance. The maintenance dose was 10 mg once daily on days 1-28 of repeated 28-day cycles (increased up to 15 mg once daily after 3 months in the absence of dose-limiting toxicity), and treatment was continued until disease progression</p><p>The primary efficacy endpoint in the study was progression free survival (PFS) from randomisation to the date of progression or death, whichever occurred first; the study was not powered for the overall survival endpoint. In total 460 patients were randomised: 231 patients to Lenalidomide and 229 patients to placebo. The demographic and disease-related characteristics were balanced across both arms.</p><p>The study was unblinded upon the recommendations of the data monitoring committee after surpassing the threshold for a preplanned interim analysis of PFS. After unblinding, patients in the placebo arm were allowed to cross over to receive lenalidomide before disease progression.</p><p>The results of PFS at unblinding, following a preplanned interim analysis, using a cut-off of 17 December 2009 (15.5 months follow up) showed a 62% reduction in risk of disease progression or death favouring lenalidomide (HR = 0.38; 95% CI 0.27, 0.54; p &lt;0.001). The median overall PFS was 33.9 months (95% CI NE, NE) in the lenalidomide arm versus 19.0 months (95% CI 16.2, 25.6) in the placebo arm.</p><p>The PFS benefit was observed both in the subgroup of patients with CR and in the subgroup of patients who had not achieved a CR.</p><p>The results for the study, using a cut-off of 1 February 2016, are presented in Table 7</p><p>&nbsp;</p><p>Table 7: Summary of overall efficacy data</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Lenalidomide</p><p>(N = 231)</p></td><td><p>Placebo</p><p>(N = 229)</p></td></tr><tr><td><p><strong>Investigator-assessed PFS</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> PFS time, months (95% CI)<sup>b</sup></p></td><td><p><strong>56.9 </strong>(41.9, 71.7)</p></td><td><p><strong>29,4 </strong>(20.7, 35.5)</p></td></tr><tr><td><p>HR [95% CI]<sup>c</sup>; p-value<sup>d</sup></p></td><td colspan="2"><p><strong>0.61 </strong>(0.48, 0.76); &lt;0.001</p></td></tr><tr><td><p><strong>PFS2<sup>e</sup></strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> PFS2 time, months (95% CI)b</p></td><td><p><strong>80.2 </strong>(63.3,</p><p>101.8)</p></td><td><p><strong>52.8 </strong>(41.3, 64.0)</p></td></tr><tr><td><p>HR [95% CI]c ; p-value<sup>d</sup></p></td><td colspan="2"><p><strong>0.61 </strong>(0.48, 0.78); &lt;0.001</p></td></tr><tr><td><p><strong>Overall survival</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> OS time, months (95% CI)<sup>b</sup></p></td><td><p><strong>111.0 </strong>(101.8, NE)</p></td><td><p><strong>84.2 </strong>(71.0,</p><p>102.7)</p></td></tr><tr><td><p>8-year survival rate, % (SE)</p></td><td><p>60.9 (3.78)</p></td><td><p>44.6 (3.98)</p></td></tr><tr><td><p>HR [95% CI]<sup>c</sup> ; p-value<sup>d</sup></p></td><td colspan="2"><p><strong>0.61 </strong>(0.46, 0.81); &lt;0.001</p></td></tr><tr><td><p><strong>Follow-up</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>f</sup> (min, max), months: all surviving patients</p></td><td><p><strong>81.9 </strong>(0.0, 119.8)</p></td><td><p><strong>81.0 </strong>(4.1, 119.5)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>CI = confidence interval; HR = hazard ratio; max = maximum; min = minimum; NE = not estimable; OS = overall survival; PFS = progression-free survival;</p><p><sup>a</sup> The median is based on the Kaplan-Meier estimate.</p><p><sup>b</sup> The 95% CI about the median.</p><p><sup>c</sup> Based on Cox proportional hazards model comparing the hazard functions associated with the indicated treatment arms.</p><p><sup>d</sup> The p-value is based on the unstratified log-rank test of Kaplan-Meier curve differences between the indicated treatment arms.</p><p><sup>e</sup> Exploratory endpoint (PFS2). Lenalidomide received by subjects in the placebo arm who crossed over prior to PD upon study unblinding was not considered as a second-line therapy.</p><p><sup>f</sup> Median follow-up post-ASCT for all surviving subjects.</p><p><strong>Data cuts: </strong>17 Dec 2009 and 01 Feb 2016</p><p>&nbsp;</p><p><em>IFM 2005-02</em></p><p>Patients aged &lt; 65 years at diagnosis who had undergone ASCT and had achieved at least a stable disease response at the time of hematologic recovery were eligible. Patients were randomised 1:1 to receive either lenalidomide or placebo maintenance (10 mg once daily on days 1-28 of repeated 28-day cycles increased up to 15 mg once daily after 3 months in the absence of dose-limiting toxicity) following 2 courses of lenalidomide consolidation (25 mg/day, days 1-21 of a 28-day cycle). Treatment was to be continued until disease progression.</p><p>The primary endpoint was PFS defined from randomisation to the date of progression or death, whichever occurred first; the study was not powered for the overall survival endpoint. In total 614 patients were randomised: 307 patients to lenalidomide and 307 patients to placebo.</p><p>The study was unblinded upon the recommendations of the data monitoring committee after surpassing the threshold for a preplanned interim analysis of PFS. After unblinding, patients receiving placebo were not crossed over to lenalidomide therapy prior to progressive disease. The lenalidomide arm was discontinued, as a proactive safety measure, after observing an imbalance of SPMs (see Section 4.4).</p><p>The results of PFS at unblinding, following a preplanned interim analysis, using a cut-off of 7 July 2010 (31.4 months follow up) showed a 48% reduction in risk of disease progression or death favoring lenalidomide (HR = 0.52; 95% CI 0.41, 0.66; p &lt;0.001). The median overall PFS was 40.1 months (95% CI 35.7, 42.4) in the lenalidomide arm versus 22.8 months (95% CI 20.7, 27.4) in the placebo arm.</p><p>&nbsp;</p><p>The PFS benefit was less in the subgroup of patients with CR than in the subgroup of patients who had not achieved a CR.</p><p>&nbsp;</p><p>The updated PFS, using a cut-off of 1 February 2016 (96.7 months follow up) continues to show a PFS advantage: HR = 0.57 (95% CI 0.47, 0.68; p &lt; 0.001). The median overall PFS was 44.4 months (39.6, 52.0) in the lenalidomide arm versus 23.8 months (95% CI 21.2, 27.3) in the placebo arm. For PFS2, the observed HR was 0.80 (95% CI 0.66, 0.98; p = 0.026) for lenalidomide versus placebo. The median overall PFS2 was 69.9 months (95% CI 58.1, 80.0) in the lenalidomide arm versus 58.4 months (95% CI 51.1, 65.0) in the placebo arm. For OS, the observed HR was 0.90: (95% CI 0.72, 1.13; p = 0.355) for lenalidomide versus placebo. The median overall survival time was 105.9 months (95% CI 88.8, NE) in the lenalidomide arm versus 88.1 months (95% CI 80.7, 108.4) in the placebo arm.</p><p>&nbsp;</p><p>&bull;&nbsp; <u>Lenalidomide in combination with bortezomib and dexamethasone in patients who are not eligible</u> <u>for stem cell transplantation</u></p><p>The SWOG S0777 study evaluated the addition of bortezomib to a foundation of lenalidomide and dexamethasone, as initial treatment, followed by continued Rd until disease progression, in patients with previously untreated multiple myeloma who are either ineligible for transplant or eligible for transplant with no plan to undertake immediate transplant.</p><p>Patients in the lenalidomide, bortezomib and dexamethasone (RVd) arm received lenalidomide 25 mg/day orally on days 1-14, intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11, and dexamethasone 20 mg/day orally on days 1, 2, 4, 5, 8, 9, 11, and 12 of repeated 21-day cycles for up to eight 21-day cycles (24 weeks). Patients in the lenalidomide and dexamethasone (Rd) arm received lenalidomide 25 mg/day orally on days 1-21, and dexamethasone 40 mg/day orally on days 1, 8, 15, and 22 of repeated 28-day cycles for up to six 28-day cycles (24 weeks). Patients in both arms took continued Rd: lenalidomide 25 mg/day orally on days 1-21 and dexamethasone 40 mg/day orally on days 1, 8, 15, and 22 of repeated 28-day cycles. Treatment was to be continued until disease progression.</p><p>The primary efficacy endpoint in the study was progression free survival (PFS). In total 523 patients were enrolled into the study, with 263 patients randomised to RVd and 260 patients randomised to Rd. The demographics and disease-related baseline characteristics of the patients were well balanced between arms.</p><p>The results of PFS, as assessed by IRAC, at the time of the primary analysis, using a cut-off of 05 November 2015 (50.6 months follow up) showed a 24% reduction in risk of disease progression or death favouring RVd (HR = 0.76; 95% CI 0.61, 0.94; p = 0.010). The median overall PFS was 42.5 months (95% CI 34.0, 54.8) in the RVd arm versus 29.9 months (95% CI 25.6, 38.2) in the Rd arm.</p><p>The benefit was observed regardless of eligibility for stem cell transplant.</p><p>The results for the study, using a cut-off of 01 December 2016, where the median follow-up time for all surviving subjects was 69.0 months, are presented in Table 8. The benefit favouring RVd was observed regardless of eligibility for stem cell transplant.</p><p>Table 8. Summary of overall efficacy data</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Initial treatment</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>RVd</strong></p><p><strong>(3-week cycles &times; 8)(N = 263)</strong></p></td><td><p><strong>Rd</strong></p><p><strong>(4-week cycles &times; 6)(N = 260)</strong></p></td></tr><tr><td colspan="3"><p><strong>IRAC-assessed PFS (months)</strong></p></td></tr><tr><td><p>Mediana<sup>a</sup> PFS time, months</p><p>(95% CI)ᵇ</p></td><td><p><strong>41.7 </strong>(33.1, 51.5)</p></td><td><p><strong>29.7 </strong>(24.2, 37.8)</p></td></tr><tr><td><p>HR [95% CI]<sup>c</sup>; p-valueᵈ</p></td><td colspan="2"><p>0.<strong>76 </strong>(0.62, 0.94); 0.010</p></td></tr><tr><td colspan="3"><p><strong>Overall survival (months)</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Mediana<sup>a</sup> OS time, months (95% CI)ᵇ</p></td><td><p><strong>89</strong>.1 (76.1, NE)</p></td><td><p><strong>67</strong>.2 (58.4, 90.8)</p></td></tr><tr><td><p>HR [95% CI]ᶜ ; p-valueᵉ</p></td><td colspan="2"><p>0.<strong>72 </strong>(0.56, 0.94); 0.013</p></td></tr><tr><td colspan="3"><p><strong>Responseᶠ &ndash; n (%)</strong></p></td></tr><tr><td><p>Overall response: CR, VGPR,</p><p>or PR</p></td><td><p>199 (75.7)</p></td><td><p>170 (65.4)</p></td></tr><tr><td><p>&ge; VGPR</p></td><td><p>153 (58.2)</p></td><td><p>83 (31.9)</p></td></tr><tr><td colspan="3"><p><strong>Follow-up (months)</strong></p></td></tr><tr><td><p>Median<sup>e</sup> (min, max): all patients</p></td><td><p>61.6 (0.2, 99.4)</p></td><td><p>59.4 (0.4, 99.1)</p></td></tr></tbody></table><p>CI = confidence interval; HR = hazard ratio; max = maximum; min = minimum; NE = not estimable; OS = overall survival; PFS = progression-free survival.</p><p><sup>a</sup> The median is based on Kaplan-Meier estimate.</p><p><sup>b</sup> Two-sided 95% CI about the median time.</p><p><sup>c</sup> Based on unstratified Cox proportional hazards model comparing hazard functions associated with</p><p>treatment arms (RVd:Rd).</p><p><sup>d</sup> The p-value is based on unstratified log-rank test.</p><p><sup>e</sup> Median follow-up was calculated from the date of randomization.</p><p>Data cutoff date = 01 Dec 2016.</p><p>Updated OS results, using a cut-off of 01 May 2018 (84.2 months median follow-up for surviving subjects) continue to show an OS advantage favouring RVd: HR = 0.73 (95% CI 0.57, 0.94; p=0.014). The proportion of subjects alive after 7 years was 54.7% in the RVd arm versus 44.7% in the Rd arm.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp; <u>Lenalidomide in combination with dexamethasone in patients who are not eligible for stem </u>&nbsp;<u>cell transplantation</u></p><p>&nbsp;</p><p>The safety and efficacy of lenalidomide was assessed in a phase 3, multicentre, randomised, open-label, 3-arm study (MM-020) of patients who were at least 65 years of age or older or, if younger than 65 years of age, were not candidates for stem cell transplantation because they declined to undergo stem cell transplantation or stem cell transplantation is not available to the patient due to cost or other reason.The study (MM-020) compared lenalidomide and dexamethasone (Rd) given for 2 different durations of time (i.e., until progressive disease [Arm Rd] or for up to eighteen 28-day cycles [72 weeks, Arm Rd18]) to melphalan, prednisone and thalidomide (MPT) for a maximum of twelve 42-day cycles (72 weeks). Patients were randomised (1:1:1) to 1 of 3 treatment arms. Patients were stratified at randomisation by age (&le;75 versus &gt;75 years), stage (ISS Stages I and II versus Stage III), and country.</p><p>&nbsp;</p><p>Patients in the Rd and Rd18 arms took lenalidomide 25 mg once daily on days 1 to 21 of 28-day cycles according to protocol arm. Dexamethasone 40 mg was dosed once daily on days 1, 8, 15, and 22 of each 28-day cycle. Initial dose and regimen for Rd and Rd18 were adjusted according to age andrenal function (see section 4.2). Patients &gt;75 years received a dexamethasone dose of 20 mg once daily on days 1, 8, 15, and 22 of each 28-day cycle. All patients received prophylactic anticoagulation (low molecular weight heparin, warfarin, heparin, low-dose aspirin) during the study.</p><p>&nbsp;</p><p>The primary efficacy endpoint in the study was progression free survival (PFS). In total 1623 patients were enrolled into the study, with 535 patients randomised to Rd, 541 patients randomised to Rd18 and 547 patients randomised to MPT. The demographics and disease-related baseline characteristics of the patients were well balanced in all 3 arms. In general, study subjects had advanced-stage disease: of the total study population, 41% had ISS stage III, 9% had severe renal insufficiency (creatinine clearance [CLcr] &lt; 30 mL/min). The median age was 73 in the 3 arms.</p><p>In an updated analysis of PFS, PFS2 and OS using a cut off of 3 March 2014 where the median follow- up time for all surviving subjects was 45.5 months, the results of the study are presented in Table 9:</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 9. Summary of overall efficacy data</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Rd</strong></p><p><strong>(N = 535)</strong></p></td><td><p><strong>Rd18</strong></p><p><strong>(N = 541)</strong></p></td><td><p><strong>MPT</strong></p><p><strong>(N = 547)</strong></p></td></tr><tr><td><p><strong>Investigator-assessed PFS </strong>- <strong>(months)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> PFS time, months (95% CI)<sup>b</sup></p></td><td><p>26.0 (20.7, 29.7)</p></td><td><p>21.0 (19.7, 22.4)</p></td><td><p>21.9 (19.8,</p><p>23.9)</p></td></tr><tr><td><p>HR [95% CI]<sup>c</sup>; p-value<sup>d</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rd vs MPT</p></td><td colspan="3"><p>0.69 (0.59, 0.80); &lt;0.001</p></td></tr><tr><td><p>Rd vs Rd18</p></td><td colspan="3"><p>0.71 (0.61, 0.83); &lt;0.001</p></td></tr><tr><td><p>Rd18 vs MPT</p></td><td colspan="3"><p>0.99 (0.86, 1.14); 0.866</p></td></tr><tr><td><p><strong>PFS2<sup>e</sup> </strong>- <strong>(months)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> PFS2 time, months (95% CI)<sup>b</sup></p></td><td><p>42.9 (38.1, 47.4)</p></td><td><p>40.0 (36.2, 44.2)</p></td><td><p>35.0 (30.4,</p><p>37.8)</p></td></tr><tr><td><p>HR [95% CI]<sup>c</sup>; p-value<sup>d</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rd vs MPT</p></td><td colspan="3"><p>0.74 (0.63, 0.86); &lt;0.001</p></td></tr><tr><td><p>Rd vs Rd18</p></td><td colspan="3"><p>0.92 (0.78, 1.08); 0.316</p></td></tr><tr><td><p>Rd18 vs MPT</p></td><td colspan="3"><p>0.80 (0.69, 0.93); 0.004</p></td></tr><tr><td><p><strong>Overall survival (months)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> OS time, months (95% CI)<sup>b</sup></p></td><td><p>58.9 (56.0, NE)</p></td><td><p>56.7 (50.1, NE)</p></td><td><p>48.5 (44.2,</p><p>52.0)</p></td></tr><tr><td><p>HR [95% CI]<sup>c</sup>; p-value<sup>d</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rd vs MPT</p></td><td colspan="3"><p>0.75 (0.62, 0.90); 0.002</p></td></tr><tr><td><p>Rd vs Rd18</p></td><td colspan="3"><p>0.91 (0.75, 1.09); 0.305</p></td></tr><tr><td><p>Rd18 vs MPT</p></td><td colspan="3"><p>0.83 (0.69, 0.99); 0.034</p></td></tr><tr><td><p>Follow-up (months)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>f</sup> (min, max): all patients</p></td><td><p>40.8 (0.0, 65.9)</p></td><td><p>40.1 (0.4, 65.7)</p></td><td><p>38.7 (0.0, 64.2)</p></td></tr><tr><td><p><strong>Myeloma response</strong><sup>g</sup> <strong>n (%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>CR</p></td><td><p>81 (15.1)</p></td><td><p>77 (14.2)</p></td><td><p>51 (9.3)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>VGPR</p></td><td><p>152 (28.4)</p></td><td><p>154 (28.5)</p></td><td><p>103 (18.8)</p></td></tr><tr><td><p>PR</p></td><td><p>169 (31.6)</p></td><td><p>166 (30.7)</p></td><td><p>187 (34.2)</p></td></tr><tr><td><p>Overall response: CR, VGPR, or PR</p></td><td><p>402 (75.1)</p></td><td><p>397 (73.4)</p></td><td><p>341 (62.3)</p></td></tr><tr><td><p><strong>Duration of response </strong>- <strong>(months)</strong><sup>h</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> (95% CI)<sup>b</sup></p></td><td><p>35.0 (27.9, 43.4)</p></td><td><p>22.1 (20.3, 24.0)</p></td><td><p>22.3 (20.2,</p><p>24.9)</p></td></tr></tbody></table><p>AMT = antimyeloma therapy; CI = confidence interval; CR = complete response; d = low-dose dexamethasone; HR = hazard ratio; IMWG = International Myeloma Working Group; IRAC = Independent Response Adjudication Committee; M = melphalan; max = maximum; min = minimum; NE = not estimable; OS = overall survival; P = prednisone; PFS = progression-free survival; PR = partial response; R = lenalidomide; Rd = Rd given until documentation of progressive disease; Rd18 = Rd given for &le;18 cycles; SE = standard error; T = thalidomide; VGPR = very good partial response; vs</p><p>= versus.</p><p><sup>a</sup> The median is based on the Kaplan-Meier estimate.</p><p><sup>b</sup> The 95% CI about the median.</p><p><sup>c</sup> Based on Cox proportional hazards model comparing the hazard functions associated with the indicated treatment arms.</p><p><sup>d</sup> The p-value is based on the unstratified log-rank test of Kaplan-Meier curve differences between the indicated treatment arms.</p><p><sup>e</sup> Exploratory endpoint (PFS2)</p><p><sup>f</sup> The median is the univariate statistic without adjusting for censoring.</p><p><sup>g</sup> Best assessment of adjudicated response during the treatment phase of the study (for definitions of each response category, Data cut-off date = 24 May 2013).</p><p><sup>h</sup> data cut 24 May 2013</p><p>&nbsp;</p><p>&bull;&nbsp; <u>Lenalidomide in combination with melphalan and prednisone followed by maintenance therapy in</u> <u>patients who are not eligible for transplant</u></p><p>The safety and efficacy of lenalidomide was assessed in a phase 3 multicentre, randomised double blind 3 arm study (MM-015) of patients who were 65 years or older and had a serum creatinine &lt; 2.5 mg/dL. The study compared lenalidomide in combination with melphalan and prednisone (MPR) with or without lenalidomide maintenance therapy until disease progression, to that of melphalan and prednisone for a maximum of 9 cycles. Patients were randomised in a 1:1:1 ratio to one of 3 treatment arms. Patients were stratified at randomisation by age (&le; 75 vs. &gt; 75 years) and stage (ISS; Stages I and II vs. stage III).</p><p>This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1 to 4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1 to 4 of repeated 28-day cycles; and lenalidomide 10 mg/day orally on days 1 to 21 of repeated 28-day cycles) for induction therapy, up to 9 cycles. Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenance therapy starting with lenalidomide 10 mg orally on days 1 to 21 of repeated 28-day cycles until disease progression.</p><p>&nbsp;</p><p>The primary efficacy endpoint in the study was progression free survival (PFS). In total 459 patients were enrolled into the study, with 152 patients randomised to MPR+R, 153 patients randomised to MPR+p and 154 patients randomised to MPp+p. The demographics and disease-related baseline characteristics of the patients were well balanced in all 3 arms; notably, approximately 50% of the patients enrolled in each arm had the following characteristics; ISS Stage III, and creatinine clearance</p><p>&lt; 60 mL/min. The median age was 71 in the MPR+R and MPR+p arms and 72 in the MPp+p arm.</p><p>In an analysis of PFS, PFS2, OS using a cut-off of April 2013 where the median follow up time for all surviving subjects was 62.4 months, the results of the study are presented in Table 10:</p><p>&nbsp;</p><p>Table 10. Summary of overall efficacy data</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>MPR+R</strong></p><p><strong>(N = 152)</strong></p></td><td><p><strong>MPR+p</strong></p><p><strong>(N = 153)</strong></p></td><td><p><strong>MPp +p</strong></p><p><strong>(N = 154)</strong></p></td></tr><tr><td><p><strong>Investigator-assessed PFS </strong>- <strong>(months)</strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> PFS time, months (95% CI)</p></td><td><p>27.4 (21.3, 35.0)</p></td><td><p>14.3 (13.2, 15.7)</p></td><td><p>13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (12.0,</p><p>14.8)</p></td></tr><tr><td><p>HR [95% CI]; p-value</p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>MPR+R vs MPp+p</p></td><td colspan="3"><p>0.37 (0.27, 0.50); &lt;0.001</p></td></tr><tr><td><p>MPR+R vs MPR+p</p></td><td colspan="3"><p>0.47 (0.35, 0.65); &lt;0.001</p></td></tr><tr><td><p>MPR+p vs MPp +p</p></td><td colspan="3"><p>0.78 (0.60, 1.01); 0.059</p></td></tr><tr><td><p><strong>PFS2 </strong>- <strong>(months) </strong><sup>&curren;</sup></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> PFS2 time, months (95% CI)</p></td><td><p>39.7 (29.2, 48.4)</p></td><td><p>27.8 (23.1, 33.1)</p></td><td><p>28.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (24.3,</p><p>33.8)</p></td></tr><tr><td><p>HR [95% CI]; p-value</p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>MPR+R vs MPp+p</p></td><td colspan="3"><p>0.70 (0.54, 0.92); 0.009</p></td></tr><tr><td><p>MPR+R vs MPR+p</p></td><td colspan="3"><p>0.77 (0.59, 1.02); 0.065</p></td></tr><tr><td><p>MPR+p vs MPp +p</p></td><td colspan="3"><p>0.92 (0.71, 1.19); 0.051</p></td></tr><tr><td><p><strong>Overall survival (months)</strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> OS time, months (95% CI)</p></td><td><p>55.9 (49.1, 67.5)</p></td><td><p>51.9 (43.1, 60.6)</p></td><td><p>53.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (47.3,</p><p>64.2)</p></td></tr><tr><td><p>HR [95% CI]; p-value</p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>MPR+R vs MPp+p</p></td><td colspan="3"><p>0.95 (0.70, 1.29); 0.736</p></td></tr><tr><td><p>MPR+R vs MPR+p</p></td><td colspan="3"><p>0.88 (0.65, 1.20); 0.43</p></td></tr><tr><td><p>MPR+p vs MPp +p</p></td><td colspan="3"><p>1.07 (0.79, 1.45); 0.67</p></td></tr><tr><td><p>Follow-up (months)</p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Median (min, max): all patients</p></td><td><p>48.4 (0.8, 73.8)</p></td><td><p>46.3 (0.5, 71.9)</p></td><td><p>50.4 (0.5, 73.3)</p></td></tr><tr><td><p><strong>Investigator-assessed Myeloma response n (%)</strong></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>CR</p></td><td><p>30 (19.7)</p></td><td><p>17 (11.1)</p></td><td><p>9 (5.8)</p></td></tr><tr><td><p>PR</p></td><td><p>90 (59.2)</p></td><td><p>99 (64.7)</p></td><td><p>75 (48.7)</p></td></tr><tr><td><p>Stable Disease (SD)</p></td><td><p>24 (15.8)</p></td><td><p>31 (20.3)</p></td><td><p>63 (40.9)</p></td></tr><tr><td><p>Response Not Evaluable (NE)</p></td><td><p>8 (5.3)</p></td><td><p>4 (2.6)</p></td><td><p>7 (4.5)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Investigator-assessed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of response (CR+PR) </strong>- <strong>(months)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>a</sup> (95% CI)</p></td><td><p>26.5 (19.4, 35.8)</p></td><td><p>12.4 (11.2, 13.9)</p></td><td><p>12.0 (9.4, 14.5)</p></td></tr></tbody></table><p>CI = confidence interval; CR = complete response; HR = Hazard Rate; M = melphalan; NE = not estimable; OS = overall survival; p = placebo; P = prednisone; PD = progressive disease; PR = partial response; R = lenalidomide; SD = stable disease; VGPR = very good partial response.</p><p><sup>a</sup> The median is based on the Kaplan-Meier estimate</p><p><sup>&curren;</sup>PFS2 (an exploratory endpoint) was defined for all patients (ITT) as time from randomisation to start of 3rd line antimyeloma therapy (AMT) or death for all randomised patients</p><p><em>Supportive newly diagnosed multiple myeloma studies</em></p><p>An open-label, randomised, multicenter, phase III study (ECOG E4A03) was conducted in 445 patients with newly diagnosed multiple myeloma; 222 patients were randomised to the lenalidomide/low dose dexamethasone arm, and 223 were randomised to the lenalidomide/standard dose dexamethasonearm. Patients randomised to the lenalidomide/standard dose dexamethasone arm received lenalidomide 25 mg/day, days 1 to 21 every 28 days plus dexamethasone 40 mg/day on days 1 to 4, 9 to 12, and 17 to 20 every 28 days for the first four cycles. Patients randomised to the lenalidomide/low dose dexamethasone arm received lenalidomide 25 mg/day, days 1 to 21 every 28 days plus low dose dexamethasone &ndash; 40 mg/day on days 1, 8, 15, and 22 every 28 days. In the lenalidomide/low dose dexamethasone group, 20 patients (9.1%) underwent at least one dose interruption compared to 65 patients (29.3%) in the lenalidomide/standard dose dexamethasone arm.</p><p>In a post-hoc analysis, lower mortality was observed in the lenalidomide/low dose dexamethasone arm 6.8% (15/220) compared to the lenalidomide/standard dose dexamethasone arm 19.3% (43/223), in the newly diagnosed multiple myeloma patient population, with a median follow up of 72.3 weeks.</p><p>However with a longer follow-up, the difference in overall survival in favour of lenalidomide/ low dose dexamethasone tends to decrease.</p><p>&nbsp;</p><p><em><u>Multiple myeloma with at least one prior therapy</u></em></p><p>The efficacy and safety of lenalidomide were evaluated in two phase 3 multicentre, randomised, double- blind, placebo-controlled, parallel-group controlled studies (MM-009 and MM-010) of lenalidomide plus dexamethasone therapy versus dexamethasone alone in previously treated patients with multiple myeloma. Out of 353 patients in the MM-009 and MM-010 studies who received lenalidomide/dexamethasone, 45.6% were aged 65 or over. Of the 704 patients evaluated in the MM- 009 and MM-010 studies, 44.6% were aged 65 or over.</p><p>In both studies, patients in the lenalidomide/dexamethasone (len/dex) group took 25 mg of lenalidomide orally once daily on days 1 to 21 and a matching placebo capsule once daily on days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone (placebo/dex) group took 1 placebo capsule on days 1 to 28 of each 28-day cycle. Patients in both treatment groups took 40 mg of dexamethasone orally once daily on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. The dose of dexamethasone was reduced to 40 mg orally once daily on days 1 to 4 of each 28- day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression. In both studies, dose adjustments were allowed based on clinical and laboratory finding.</p><p>The primary efficacy endpoint in both studies was time to progression (TTP). In total, 353 patients were evaluated in the MM-009 study; 177 in the len/dex group and 176 in the placebo/dex group and, in total, 351 patients were evaluated in the MM-010 study; 176 in the len/dex group and 175 in the placebo/dex group.</p><p>In both studies, the baseline demographic and disease-related characteristics were comparable between the len/dex and placebo/dex groups. Both patient populations presented a median age of 63 years, with a comparable male to female ratio. The ECOG performance status was comparable between both groups, as was the number and type of prior therapies.</p><p>Pre-planned interim analyses of both studies showed that len/dex was statistically significantly superior (p &lt; 0.00001) to dexamethasone alone for the primary efficacy endpoint, TTP (median follow-up duration of 98.0 weeks). Complete response and overall response rates in the len/dex arm were also significantly higher than the placebo/dex arm in both studies. Results of these analyses subsequently led to an unblinding in both studies, in order to allow patients in the placebo/dex group to receive treatment with the len/dex combination.</p><p>An extended follow-up efficacy analysis was conducted with a median follow-up of 130.7 weeks. Table 11 summarizes the results of the follow-up efficacy analyses &ndash; pooled studies MM-009 and MM-010.</p><p>In this pooled extended follow-up analysis, the median TTP was 60.1 weeks (95% CI: 44.3, 73.1) in patients treated with len/dex (N = 353) versus 20.1 weeks (95% CI: 17.7, 20.3) in patients treatedwith placebo/dex (N = 351). The median progression free survival was 48.1 weeks (95% CI: 36.4, 62.1) in patients treated with len/dex versus 20.0 weeks (95%CI: 16.1, 20.1) in patients treated with placebo/dex. The median duration of treatment was 44.0 weeks (min: 0.1, max: 254.9) for len/dex and 23.1 weeks (min: 0.3, max: 238.1) for placebo/dex. Complete response (CR), partial response (PR) and overall response (CR+PR) rates in the len/dex arm remain significantly higher than in the placebo/dex arm in both studies. The median overall survival in the extended follow-up analysis of the pooled studies is 164.3 weeks (95%CI: 145.1, 192.6) in patients treated with len/dex versus 136.4 weeks (95% CI: 113.1, 161.7) in patients treated with placebo/dex. Despite the fact that 170 out of the 351 patients randomised to placebo/dex received lenalidomide after disease progression or after the studies were unblinded, the pooled analysis of overall survival demonstrated a statistically significant survival advantage for len/dex relative to placebo/dex (HR = 0.833, 95% CI = [0.687, 1.009], p=0.045).</p><p>&nbsp;</p><p>Table 11. Summary of results of efficacy analyses as of cut-off date for extended follow-up &mdash; pooled studies MM-009 and MM-010 (cut-offs 23 July 2008 and 2 March 2008, respectively)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>len/dex (N=353)</strong></p></td><td><p><strong>placebo/dex(N=351)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Time to event</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p><strong>HR [95% CI], p-value </strong><sup>a</sup></p></td></tr><tr><td><p>Time to progression</p><p>Median [95% CI], weeks</p></td><td><p>60.1 [44.3,</p><p>73.1]</p></td><td><p>20.1 [17.7, 20.3]</p></td><td><p>0.350 [0.287, 0.426], p &lt;</p><p>0.001</p></td></tr><tr><td><p>Progression free survival</p><p>Median [95% CI], weeks</p></td><td><p>48.1 [36.4,</p><p>62.1]</p></td><td><p>20.0 [16.1, 20.1]</p></td><td><p>0.393 [0.326, 0.473], p &lt;</p><p>0.001</p></td></tr><tr><td><p>Overall survival</p><p>Median [95% CI], weeks</p><p>1-year Overall survival rate</p></td><td><p>164.3</p><p>[145.1,</p><p>192.6]</p><p>82%</p></td><td><p>136.4 [113.1, 161.7]</p><p>75%</p></td><td><p><strong>&nbsp;</strong></p><p>0.833 [0.687, 1.009], p =</p><p>0.045</p></td></tr><tr><td><p><strong>Response rate</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p><strong>Odds ratio [95% CI], p- value </strong><sup>b</sup></p></td></tr><tr><td><p>Overall response [n, %]</p><p>Complete response [n, %]</p></td><td><p>212 (60.1)</p><p>58 (16.4)</p></td><td><p>75 (21.4)</p><p>11 (3.1)</p></td><td><p>5.53 [3.97, 7.71], p &lt; 0.001</p><p>6.08 [3.13, 11.80], p &lt; 0.001</p></td></tr></tbody></table><p><sup>a</sup>: Two-tailed log rank test comparing survival curves between treatment groups.</p><p><sup>b</sup>: Two-tailed continuity-corrected chi-square test.</p><p>&nbsp;</p><p><em><u>Myelodysplastic syndromes</u></em></p><p>The efficacy and safety of lenalidomide were evaluated in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities, in two main studies: a phase 3, multicentre, randomised, double-blind, placebo-controlled, 3-arm study of two doses of oral lenalidomide (10 mg and 5 mg) versus placebo (MDS-004); and a phase 2, a multicentre, single-arm, open-label study of lenalidomide (10 mg) (MDS-003).</p><p>The results presented below represent the intent-to-treat population studied in MDS-003 and MDS-004; with the results in the isolated Del (5q) sub-population also shown separately.</p><p>In study MDS-004, in which 205 patients were equally randomised to receive lenalidomide 10 mg, 5 mg or placebo, the primary efficacy analysis consisted of a comparison of the transfusion-independence response rates of the 10 mg and 5 mg lenalidomide arms versus the placebo arm (double-blind phase 16 to 52 weeks and open-label up to a total of 156 weeks). Patients who did not have evidence of at least a minor erythroid response after 16 weeks were to be discontinued from treatment. Patients who had evidence of at least a minor erythroid response could continue therapy until erythroid relapse, disease progression or unacceptable toxicity. Patients, who initially received placebo or 5 mg lenalidomide and did not achieve at least a minor erythroid response after 16 weeks of treatment were permitted to switch from placebo to 5 mg lenalidomide or continue lenalidomide treatment at higher dose (5 mg to 10 mg).</p><p>In, study MDS-003, in which 148 patients received lenalidomide at a dose of 10 mg, the primary efficacy analysis consisted of an evaluation of the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk myelodysplastic syndromes.</p><p>&nbsp;</p><p>Table 12. Summary of efficacy results &ndash; studies MDS-004 (double-blind phase) and MDS-003, intent- to-treat population Endpoint</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>&nbsp;</p></td><td colspan="3"><p><strong>MDS-004</strong></p><p><strong>N = 205</strong></p></td><td><p><strong>MDS-003</strong></p><p><strong>N = 148</strong></p></td></tr><tr><td><p><strong>10 mg<sup>&dagger;</sup></strong></p><p><strong>N = 69</strong></p></td><td><p><strong>5 mg<sup>&dagger;&dagger;</sup></strong></p><p><strong>N = 69</strong></p></td><td><p><strong>Placebo*</strong></p><p><strong>N = 67</strong></p></td><td><p><strong>10 mg</strong></p><p><strong>N = 148</strong></p></td></tr><tr><td><p>Transfusion Independence</p><p>(&ge; 182 days) <sup>#</sup></p></td><td><p>38 (55.1%)</p></td><td><p>24 (34.8%)</p></td><td><p>4 (6.0%)</p></td><td><p>86 (58.1%)</p></td></tr><tr><td><p>Transfusion Independence</p><p>(&ge; 56 days) <sup>#</sup></p></td><td><p>42 (60.9%)</p></td><td><p>33 (47.8%)</p></td><td><p>5 (7.5%)</p></td><td><p>97 (65.5%)</p></td></tr><tr><td><p>Median Time to Transfusion Independence (weeks)</p></td><td><p>4.6</p></td><td><p>4.1</p></td><td><p>0.3</p></td><td><p>4.1</p></td></tr><tr><td><p>Median Duration of Transfusion Independence (weeks)</p></td><td><p>NR<sup>&infin;</sup></p></td><td><p>NR</p></td><td><p>NR</p></td><td><p>114.4</p></td></tr><tr><td><p>Median Increase in Hgb, g/dL</p></td><td><p>6.4</p></td><td><p>5.3</p></td><td><p>2.6</p></td><td><p>5.6</p></td></tr></tbody></table><p>&dagger; Subjects treated with lenalidomide 10 mg on 21 days of 28-day cycles</p><p>&dagger;&dagger; Subjects treated with lenalidomide 5 mg on 28 days of 28-day cycles</p><p>* The majority of patients on placebo discontinued the double-blind treatment for lack of efficacy after</p><p>16 weeks of treatment before entering the open-label phase</p><p><sup>#</sup>Associated with an increase in Hgb of &ge; 1g/dL</p><p>&infin; Not reached (i.e. the median was not reached)</p><p>&nbsp;</p><p>In MDS-004, a significant larger proportion of patients with myelodysplastic syndromes achieved the primary endpoint of transfusion independence (&gt;182 days) on lenalidomide 10 mg compared with placebo (55.1% vs. 6.0%). Amongst the 47 patients with an isolated Del (5q) cytogenetic abnormality and treated with lenalidomide 10 mg, 27 patients (57.4%) achieved red blood cell transfusion independence.</p><p>The median time to transfusion independence in the lenalidomide 10 mg arm was 4.6 weeks. The median duration of transfusion independence was not reached in any of the treatment arms but should exceed 2 years for the lenalidomide-treated subjects. The median increase in haemoglobin (Hgb) from baseline in the 10 mg arm was 6.4 g/dL.</p><p>Additional endpoints of the study included cytogenetic response (in the 10 mg arm major and minor cytogenetic responses were observed in 30.0% and 24.0% of subjects, respectively), assessment of Health Related Quality of Life (HRQoL) and progression to acute myeloid leukaemia. Results of the cytogenetic response and HRQoL were consistent with the findings of the primary endpoint and in favour of lenalidomide treatment compared to placebo.</p><p>In MDS-003, a large proportion of patients with myelodysplastic syndromes achieved transfusion independence (&gt;182 days) on lenalidomide 10 mg (58.1%). The median time to transfusion independence was 4.1 weeks. The median duration of transfusion independence was 114.4 weeks. The median increase in haemoglobin (Hgb) was 5.6 g/dL. Major and minor cytogenetic responses were observed in 40.9% and 30.7% of subjects, respectively.</p><p>A large proportion of subjects enrolled in MDS-003 (72.9%) and MDS-004 (52.7%) had received prior erythropoiesis-stimulating agents.</p><p>&nbsp;</p><p><em><u>Mantle cell lymphoma</u></em></p><p>The efficacy and safety of lenalidomide were evaluated in patients with mantle cell lymphoma in a phase II, multicenter, randomised open-label study versus single agent of investigator&#39;s choice in patients who were refractory to their last regimen or had relapsed one to three times (study MCL-002).</p><p>Patients who were at least 18 years of age with histologically-proven MCL and CT-measurable disease were enrolled. Patients were required to have received adequate previous treatment with at least one prior combination chemotherapy regimen. Also, patients had to be ineligible for intensive chemotherapy and/or transplant at time of inclusion in the study. Patients were randomised 2:1 to the lenalidomide or the control arm. The investigator&#39;s choice treatment was selected before randomisation and consisted of monotherapy with either chlorambucil, cytarabine, rituximab, fludarabine, or gemcitabine.</p><p>Lenalidomide was administered orally 25 mg once daily for the first 21 days (D1 to D21) of repeating 28-day cycles until progression or unacceptable toxicity. Patients with moderate renal insufficiency were to receive a lower starting dose of lenalidomide 10 mg daily on the same schedule.</p><p>The baseline demographic were comparable between the lenalidomide arm and control arm. Both patient populations presented a median age of 68.5 years with comparable male to female ratio. The ECOG performance status was comparable between both groups, as was the number of prior therapies.</p><p>The primary efficacy endpoint in study MCL-002 was progression-free survival (PFS).</p><p>The efficacy results for the Intent-to-Treat (ITT) population were assessed by the Independent Review Committee (IRC), and are presented in the table below.</p><p>&nbsp;</p><p>Table 13. Summary of efficacy results &ndash; study MCL-002, intent-to-treat population</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Lenalidomide Arm</strong></p><p>N = 170</p></td><td><p><strong>Control Arm</strong></p><p>N = 84</p></td></tr><tr><td><p><strong>PFS</strong></p><p><strong>PFS, median</strong><sup>a</sup> [95% CI]<sup>b</sup> (weeks)</p></td><td><p>37.6 [24.0, 52.6]</p></td><td><p>22.7 [15.9, 30.1]</p></td></tr><tr><td><p><strong>Sequential HR </strong>[95% CI]<sup>e</sup></p></td><td colspan="2"><p>0.61 [0.44, 0.84]</p></td></tr><tr><td><p>Sequential log-rank test, p-value<sup>e</sup></p></td><td colspan="2"><p>0.004</p></td></tr><tr><td><p><strong>Response</strong><sup>a</sup>, n (%)</p><p>Complete response (CR)</p></td><td><p>8 (4.7)</p></td><td><p>0 (0.0)</p></td></tr><tr><td><p>Partial response (PR)</p></td><td><p>60 (35.3)</p></td><td><p>9 (10.7)</p></td></tr><tr><td><p>Stable disease (SD)<sup>b</sup></p></td><td><p>50 (29.4)</p></td><td><p>44 (52.4)</p></td></tr><tr><td><p>Progressive disease</p></td><td><p>34 (20.0)</p></td><td><p>26 (31.0)</p></td></tr><tr><td><p>(PD)</p></td><td><p>18 (10.6)</p></td><td><p>5 (6.0)</p></td></tr><tr><td><p>Not done/Missing</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p><strong>ORR (CR, CRu, PR)</strong>, n (%) [95% CI]<sup>c</sup></p><p>p-value<sup>e</sup></p></td><td><p>68 (40.0) [32.58, 47.78]</p></td><td><p>9 (10.7)<sup>d</sup> [5.02, 19.37]</p></td></tr><tr><td colspan="2"><p>&lt; 0.001</p></td></tr><tr><td rowspan="2"><p><strong>CRR (CR, CRu)</strong>, n (%) [95% CI]<sup>c</sup></p><p>p-value<sup>e</sup></p></td><td><p>8 (4.7) [2.05, 9.06]</p></td><td><p>0 (0.0) [95.70, 100.00]</p></td></tr><tr><td colspan="2"><p>0.043</p></td></tr><tr><td><p><strong>Duration of Response, median</strong><sup>a</sup> [95% CI]</p><p>(weeks)</p></td><td><p>69.6 [41.1, 86.7]</p></td><td><p>45.1 [36.3, 80.9]</p></td></tr><tr><td><p><strong>Overall Survival</strong></p><p><strong>HR </strong>[95% CI]<sup>c</sup></p></td><td colspan="2"><p>0.89 [0.62, 1.28]</p></td></tr><tr><td><p>Log-rank test, p- value</p></td><td colspan="2"><p>0.520</p></td></tr></tbody></table><p>CI = confidence interval; CRR = complete response rate; CR = complete response; CRu = complete response unconfirmed; DMC = Data Monitoring Committee; ITT = intent-to-treat; HR = hazard ratio; KM = Kaplan-Meier; MIPI = Mantle Cell Lymphoma International Prognostic Index; NA = not applicable; ORR = overall response rate; PD = progressive disease; PFS = progression-free survival; PR= partial response; SCT = stem cell transplantation; SD = stable disease; SE = standard error.</p><p><sup>a</sup> The median was based on the KM estimate.</p><p><sup>b</sup> Range was calculated as 95% CIs about the median survival time.</p><p><sup>c</sup> The mean and median are the univariate statistics without adjusting for censoring.</p><p><sup>d</sup> The stratification variables included time from diagnosis to first dose (&lt; 3 years and &ge; 3 years), time from last prior systemic anti-lymphoma therapy to first dose (&lt; 6 months and &ge; 6 months), prior SCT (yes or no), and MIPI at baseline (low, intermediate, and high risk).</p><p><sup>e</sup> Sequential test was based on a weighted mean of a log-rank test statistic using the unstratified log- rank test for sample size increase and the unstratified log-rank test of the primary analysis. The weights are based on observed events at the time the third DMC meeting was held and based on the difference between observed and expected events at the time of the primary analysis. The associated sequential HR and the corresponding 95% CI are presented.</p><p>&nbsp;</p><p>In study MCL-002 in the ITT population, there was an overall apparent increase in deaths within 20 weeks in the lenalidomide arm 22/170 (13%) versus 6/84 (7%) in the control arm. In patients with high tumour burden, corresponding figures were 16/81 (20%) and 2/28 (7%) (see section 4.4).</p><p>&nbsp;</p><p><em><u>Follicular lymphoma</u></em></p><p>AUGMENT - CC-5013-NHL-007</p><p>The efficacy and safety of lenalidomide in combination with rituximab versus rituximab plus placebo was evaluated in patients with relapsed/refractory iNHL including FL in a phase 3, multicentre, randomised, double- blind controlled study (CC-5013-NHL-007 [AUGMENT]).</p><p>A total of 358 patients who were at least 18 years of age with histologically confirmed MZL or Grade 1, 2 or 3a FL (CD20+ by flow cytometry or histochemistry) as assessed by the investigator or local pathologist were randomised in a 1:1 ratio. Subjects had been previously treated with at least one prior systemic chemotherapy, immunotherapy or chemoimmunotherapy.</p><p>Lenalidomide was administered orally 20 mg once daily for the first 21 days of repeating 28-day cycles for 12 cycles or until unacceptable toxicity. The dose of rituximab was 375 mg/m2 every week in Cycle 1 (days 1, 8, 15, and 22) and on day 1 of every 28-day cycle from cycles 2 through 5. All dosage calculations for rituximab were based on the patient&#39;s body surface area (BSA), using actual patient weight.</p><p>The demographic and disease-related baseline characteristics were similar across the 2 treatment groups.</p><p>The primary objective of the study was to compare the efficacy of lenalidomide in combination with rituximab to rituximab plus placebo in subjects with relapsed/refractory FL Grade 1, 2 or 3a or MZL. Efficacy determination was based upon PFS as the primary endpoint, as assessed by the IRC using the 2007 International Working Group (IWG) criteria but without positron emission tomography (PET).</p><p>The secondary objectives of the study were to compare the safety of lenalidomide in combination with rituximab versus rituximab plus placebo. Further secondary objectives were to compare the efficacy of rituximab plus lenalidomide versus rituximab plus placebo using the following other parameters of efficacy:</p><p>Overall response rate (ORR), CR rate, and duration of response (DoR) by IWG 2007 without PET and OS.</p><p>Results from the overall population including FL and MZL showed that at a median follow up of 28.3&deg;months, the study met its primary endpoint of PFS with a hazard ratio (HR) (95% confidence interval [CI]) of 0.45 (0.33,0.61) p-value &lt; 0.0001. The efficacy results from the follicular lymphoma population are presented in Table 14.</p><p>Table 14: Summary of follicular lymphoma efficacy data- Study CC-5013-NHL-007</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p>FL</p><p>(N = 295)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Lenalidomide and Rituximab</p><p>(N = 147)</p></td><td><p>Placebo and Rituximab</p><p>(N = 148)</p></td></tr><tr><td colspan="3"><p><strong>Progression-free survival (PFS) (EMA Censoring Rules)</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Median PFS ͣ (95% CI) (months)</p></td><td><p>39.4</p></td><td><p>13.8</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>(25.1, NE)</p></td><td><p>(11.2, 16.0)</p></td></tr><tr><td><p>HR [95% CI]</p></td><td colspan="2"><p>0.40 (0.29, 0.55)ᵇ</p></td></tr><tr><td><p>p-value</p></td><td colspan="2"><p>&lt; 0.0001 ᶜ</p></td></tr><tr><td><p><strong>Objective response</strong><strong>ᵈ</strong><strong> </strong><strong>(CR +PR), n</strong></p></td><td><p>118 (80.3)</p></td><td><p>82 (55.4)</p></td></tr><tr><td><p><strong>(%)</strong></p></td><td><p>(72.9, 86.4)</p></td><td><p>(47.0, 63.6)</p></td></tr><tr><td><p>(IRC, 2007 IWGRC)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>95 % CIᶠ</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Complete responseᵈ, n (%)</strong></p></td><td><p>51 (34.7)</p></td><td><p>29 (19.6)</p></td></tr><tr><td><p>(IRC, 2007 IWGRC)</p></td><td><p>(27.0, 43.0)</p></td><td><p>(13.5, 26.9)</p></td></tr><tr><td><p>95 % CIᶠ</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Duration of responseᵈ (median)</strong></p></td><td><p>36.6</p></td><td><p>15.5</p></td></tr><tr><td><p><strong>(months)</strong></p></td><td><p>(24.9, NE)</p></td><td><p>(11.2, 25.0)</p></td></tr><tr><td><p>95% CI ͣ</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><strong>Overall Survivalᵈˑᵉ (OS)</strong></p></td></tr><tr><td><p>OS rate at 2 years %</p></td><td><p>139 (94.8)</p></td><td><p>127 (85.8)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>(89.5, 97.5)</p></td><td><p>(78.5, 90.7)</p></td></tr><tr><td><p>HR [95% CI]</p></td><td colspan="2"><p>0.45 (0.22, 0.92)ᵇ</p></td></tr><tr><td colspan="3"><p><strong>Follow-</strong><strong>up</strong></p></td></tr><tr><td><p>Median duration of follow-up</p></td><td><p>29.2</p></td><td><p>27.9</p></td></tr><tr><td><p>(min, max)(months)</p></td><td><p>(0.5, 50.9)</p></td><td><p>(0.6, 50.9)</p></td></tr></tbody></table><p>&ordf; Median estimate from Kaplan-Meier analysis</p><p><sup>b</sup> Hazard ratio and its confidence interval were estimated from unstratified Cox proportional hazard model.</p><p><sup>c</sup> P-value from log-rank test</p><p><sup>d</sup> Secondary and exploratory endpoints are not &alpha;-controlled</p><p><sup>e</sup> With a median follow up of 28.6 months, there were 11 deaths in the R2 arm and 24 deaths in the Control Arm.</p><p><sup>f</sup> Exact confidence interval for binomial distribution.</p><p>&nbsp;</p><p><em><u>Follicular lymphoma for patients refractory to Rituximab</u></em></p><p><em>&nbsp;</em></p><p>MAGNIFY - CC-5013-NHL-008</p><p>A total of 232 subjects who were at least 18 years of age with histologically confirmed FL (Grade 1, 2, 3a or MZL), as assessed by the investigator or local pathologist, were enrolled into the initial treatment period with 12 cycles of lenalidomide plus rituximab. Subjects who achieved CR/CRu, PR, or SD by the end of the induction treatment period were randomised to enter the maintenance treatment period. All enrolled subjects must have previously been treated with at least one prior systemic antilymphoma therapy. In contrast to study NHL-007, the NHL-008 study included patients who were refractory to rituximab (no response or relapsed within 6 months of rituximab treatment or who were double-refractory to rituximab and chemotherapy).</p><p>During the induction treatment period, lenalidomide 20 mg was given on Days 1-21 of repeated 28- day cycles for up to 12 cycles or until unacceptable toxicity, or withdrawal of consent or disease progression. The dose of rituximab was 375 mg/m<sup>2</sup> every week in Cycle 1 (Days 1, 8, 15, and 22) and on Day 1 of every other 28-day cycle (cycles 3, 5, 7, 9, and 11) up to 12 cycles therapy. All dosage calculations for rituximab were based on the patient body surface area (BSA) and actual weight.</p><p>The data presented are based on an interim analysis focusing on the single-arm induction treatment period. Efficacy determinations are based on ORR by best response as the primary endpoint, using a modification of the 1999 International Working Group Response Criteria (IWGRC). The secondary objective was to evaluate other parameters of efficacy, such as DoR.</p><p>Table 15: Summary of overall efficacy data (Induction Treatment Period) - Study CC- 5013- NHL-008</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="3"><p>All Subjects</p></td><td colspan="3"><p>FL Subjects</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p><p>Total N=187 ͣ</p></td><td><p>Rituximab Refractory: Yes</p><p>N=77</p></td><td><p>Rituximab Refractory:</p><p>No N=110</p></td><td><p><strong>&nbsp;</strong></p><p>Tota l N=1</p><p>48</p></td><td><p>Rituximab Refractory: Yes</p><p>N=60</p></td><td><p>Rituximab Refractory:</p><p>No N=88</p></td></tr><tr><td><p>ORR, n (%)</p></td><td><p>127 (67.9)</p></td><td><p>45 (58.4)</p></td><td><p>82 (75.2)</p></td><td><p>104</p></td><td><p>35 (58.3)</p></td><td><p>69 (79.3)</p></td></tr><tr><td><p>(CR+CRu+PR)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>(70.3)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>CRR, n (%)</p><p>(CR+Cru)</p></td><td><p>79 (42.2)</p></td><td><p>27 (35.1)</p></td><td><p>52 (47.7)</p></td><td><p>62 (41.9)</p></td><td><p>20 (33.3)</p></td><td><p>42 (48.3)</p></td></tr><tr><td><p><strong>Number of Respond ers</strong></p></td><td><p><strong>N=127</strong></p></td><td><p><strong>N=45</strong></p></td><td><p><strong>N=82</strong></p></td><td><p><strong>N=104</strong></p></td><td><p><strong>N=35</strong></p></td><td><p><strong>N=69</strong></p></td></tr><tr><td><p><strong>% of Subjects</strong></p></td><td><p><strong>93.0</strong></p></td><td><p><strong>90.4</strong></p></td><td><p><strong>94.5</strong></p></td><td><p><strong>94.3</strong></p></td><td><p><strong>96.0</strong></p></td><td><p><strong>93.5</strong></p></td></tr><tr><td><p><strong>with DoR ᵇ</strong></p><p><strong>&ge; 6 months</strong></p><p><strong>(95% CI) ᶜ</strong></p></td><td><p><strong>(85.1, 96.8)</strong></p></td><td><p><strong>(73.0, 96.8)</strong></p></td><td><p><strong>(83.9, 98.2)</strong></p></td><td><p><strong>(85.5,</strong></p><p><strong>97.9)</strong></p></td><td><p><strong>(74.8, 99.4)</strong></p></td><td><p><strong>(81.0, 97.9)</strong></p></td></tr><tr><td><p><strong>%&nbsp; of&nbsp; Subjects</strong></p></td><td><p><strong>79.1</strong></p></td><td><p><strong>73.3</strong></p></td><td><p><strong>82.4</strong></p></td><td><p><strong>79.5</strong></p></td><td><p><strong>73.9</strong></p></td><td><p><strong>81.7</strong></p></td></tr><tr><td><p><strong>with DoR ᵇ</strong></p><p><strong>&ge;&nbsp;&nbsp;&nbsp; 12&nbsp;&nbsp;&nbsp; months</strong></p><p><strong>(95% CI) ᶜ</strong></p></td><td><p><strong>(67.4, 87.0)</strong></p></td><td><p><strong>(51.2, 86.6)</strong></p></td><td><p><strong>(67.5, 90.9)</strong></p></td><td><p><strong>(65.5,</strong></p><p><strong>88.3)</strong></p></td><td><p><strong>(43.0, 89.8)</strong></p></td><td><p><strong>(64.8, 91.0)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>CI = confidence interval; DOR = duration of response; FL = follicular lymphoma</p><p>ͣ Primary Analysis Population for this study is induction efficacy evaluable (IEE) population.</p><p>ᵇ Duration of response is defined as the time (months) from the initial response (at least PR) to</p><p>documented disease progression or death, whichever occurs first.</p><p><sup>c</sup>Statistics obtained from Kaplan-Meier method. 95% CI is based on Greenwood formula.</p><p>Notes: The analysis is only performed for subjects who have achieved PR or better after the first dose date of induction therapy and prior to any Maintenance Period treatment and any subsequent anti- lymphoma therapy in Induction Period. Percentage is based on the total number of responders.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lenalidomide has an asymmetric carbon atom and can therefore exist as the optically active forms S(-) and R(+). Lenalidomide is produced as a racemic mixture. Lenalidomide is generally more soluble in organic solvents but exhibits the greatest solubility in 0.1N HCl buffer.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Lenalidomide is rapidly absorbed following oral administration in healthy volunteers, under fasting conditions, with maximum plasma concentrations occurring between 0.5 and 2 hours post-dose. In patients, as well as in healthy volunteers, the maximum concentration (Cmax) and area-under-the- concentration time curve (AUC) increase proportionally with increases in dose. Multiple dosing does not cause marked medicinal product accumulation. In plasma, the relative exposures of the S- and R- enantiomers of lenalidomide are approximately 56% and 44%, respectively.</p><p>Co-administration with a high-fat and high-calorie meal in healthy volunteers reduces the extent of absorption, resulting in an approximately 20% decrease in area under the concentration versus time curve (AUC) and 50% decrease in Cmax in plasma. However, in the main multiple myeloma and myelodysplastic syndromes registration trials where the efficacy and safety were established for lenalidomide, the medicinal product was administered without regard to food intake. Thus, lenalidomide can be administered with or without food.</p><p>Population pharmacokinetic analyses indicate that the oral absorption rate of lenalidomide is similar between MM and MDS and MCL patients.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><em>In vitro </em>(<sup>14</sup>C)-lenalidomide binding to plasma proteins was low with mean plasma protein binding at 23% and 29% in multiple myeloma patients and healthy volunteers, respectively.</p><p>Lenalidomide is present in human semen (&lt; 0.01% of the dose) after administration of 25 mg/day and the medicinal product is undetectable in semen of a healthy subject 3 days after stopping the substance (see section 4.4).</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>Results from human <em>in vitro </em>metabolism studies indicate that lenalidomide is not metabolised by cytochrome P450 enzymes suggesting that administration of lenalidomide with medicinal products that inhibit cytochrome P450 enzymes is not likely to result in metabolic medicinal product interactions in humans. <em>In vitro </em>studies indicate that lenalidomide has no inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A, or UGT1A1. Therefore, lenalidomide is unlikely to cause any clinically relevant medicinal product interactions when co-administered with substrates of these enzymes.</p><p>&nbsp;</p><p><em>In vitro </em>studies indicate that lenalidomide is not a substrate of human breast cancer resistance protein (BCRP), multidrug resistance protein (MRP) transporters MRP1, MRP2, or MRP3, organic anion transporters (OAT) OAT1 and OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), organic cation transporters (OCT) OCT1 and OCT2, multidrug and toxin extrusion protein (MATE) MATE1, and organic cation transporters novel (OCTN) OCTN1 and OCTN2.</p><p><em>In vitro </em>studies indicate that lenalidomide has no inhibitory effect on human bile salt export pump (BSEP), BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, and OCT2.</p><p>A majority of lenalidomide is eliminated through urinary excretion. The contribution of renal excretion to total clearance in subjects with normal renal function was 90%, with 4% of lenalidomide eliminated in faeces.</p><p>Lenalidomide is poorly metabolized as 82% of the dose is excreted unchanged in urine. Hydroxy- lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.</p><p>&nbsp;</p><p>The renal clearance of lenalidomide exceeds the glomerular filtration rate and therefore is at least actively secreted to some extent.</p><p>At doses of 5 to 25 mg/day, half-life in plasma is approximately 3 hours in healthy volunteers and ranges from 3 to 5 hours in patients with multiple myeloma or myelodysplastic syndromes or mantle cell lymphoma.</p><p>&nbsp;</p><p><u>Older people</u></p><p>No dedicated clinical studies have been conducted to evaluate pharmacokinetics of lenalidomide in the elderly. Population pharmacokinetic analyses included patients with ages ranging from 39 to 85 years old and indicate that age does not influence lenalidomide clearance (exposure in plasma). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it would be prudent to monitor renal function.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The pharmacokinetics of lenalidomide was studied in subjects with renal impairment due to nonmalignant conditions. In this study, two methods were used to classify renal function: the urinary creatinine clearance measured over 24 hours and the creatinine clearance estimated by Cockcroft-Gault formula. The results indicate that as renal function decreases (&lt; 50 mL/min), the total lenalidomide clearance decreases proportionally resulting in an increase in AUC. The AUC was increased by approximately 2.5, 4 and 5-fold in subjects with moderate renal impairment, severe renal impairment, and end-stage renal disease, respectively, compared to the group combining subjects with normal renal function and subjects with mild renal impairment. The half-life of lenalidomide increased from approximately 3.5 hours in subjects with creatinine clearance &gt; 50 mL/min to more than 9 hours in subjects with reduced renal function &lt; 50 mL/min. However, renal impairment did not alter the oral absorption of lenalidomide. The Cmax was similar between healthy subjects and patients with renal impairment. Approximately 30% of the medicinal product in the body was removed during a single 4- hour dialysis session. Recommended dose adjustments in patients with impaired renal function are described in section 4.2.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Population pharmacokinetic analyses included patients with mild hepatic impairment (N=16, total bilirubin &gt;1 to &le;1.5 x ULN or AST &gt; ULN) and indicate that mild hepatic impairment does not influence lenalidomide clearance (exposure in plasma). There are no data available for patients with moderate to severe hepatic impairment.</p><p>&nbsp;</p><p><u>Other intrinsic factors</u></p><p>Population pharmacokinetic analyses indicate that body weight (33- 135 kg), gender, race and type of haematological malignancy (MM or MDS or MCL) do not have a clinically relevant effect on lenalidomide clearance in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An embryofoetal development study has been conducted in monkeys administered lenalidomide at doses from 0.5 and up to 4 mg/kg/day. Findings from this study indicate that lenalidomide produced external malformations including non-patent anus and malformations of upper and lower extremities (bent, shortened, malformed, malrotated and/or absent part of the extremities, oligo and/or polydactyly) in the offspring of female monkeys who received the active substance during pregnancy.</p><p>Various visceral effects (discoloration, red foci at different organs, small colourless mass above atrio- ventricular valve, small gall bladder, malformed diaphragm) were also observed in single foetuses.</p><p>&nbsp;</p><p>Lenalidomide has a potential for acute toxicity; minimum lethal doses after oral administration were &gt; 2000 mg/kg/day in rodents. Repeated oral administration of 75, 150 and 300 mg/kg/day to rats for up to 26 weeks produced a reversible treatment-related increase in kidney pelvis mineralisation in all 3 doses, most notably in females. The no observed adverse effect level (NOAEL) was considered to be less than 75 mg/kg/day, and is approximately 25-fold greater than the human daily exposure based on AUC exposure. Repeated oral administration of 4 and 6 mg/kg/day to monkeys for up to 20 weeks produced mortality and significant toxicity (marked weight loss, reduced red and white blood cell and platelet counts, multiple organ haemorrhage, gastrointestinal tract inflammation, lymphoid, and bone marrow atrophy). Repeated oral administration of 1 and 2 mg/kg/day to monkeys for up to 1 year produced reversible changes in bone marrow cellularity, a slight decrease in myeloid/erythroid cell ratio and thymic atrophy. Mild suppression of white blood cell count was observed at 1 mg/kg/day corresponding to approximately the same human dose based on AUC comparisons.</p><p><em>In vitro </em>(bacterial mutation, human lymphocytes, mouse lymphoma, Syrian Hamster Embryo cell transformation) and <em>in vivo </em>(rat micronucleus) mutagenicity studies revealed no drug related effects at either the gene or chromosomal level. Carcinogenicity studies with lenalidomide have not been conducted.</p><p>Developmental toxicity studies were previously conducted in rabbits. In these studies, rabbits were administered 3, 10 and 20 mg/kg/day orally. An absence of the intermediate lobe of the lung was observed at 10 and 20 mg/kg/day with dose dependence and displaced kidneys were observed at 20 mg/kg/day. Although it was observed at maternotoxic levels they may be attributable to a direct effect. Soft tissue and skeletal variations in the foetuses were also observed at 10 and 20 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Microcrystalline Cellulose</p><p>Croscarmellose Sodium</p><p>Magnesium Stearate (vegetable grade)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not Store adove 30&deg;C. This medicinal product does not require any special storage conditions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu blisters</p><p>Pack size of 7 or 21 capsules. Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsules should not be opened or crushed. If powder from lenalidomide makes contact with the skin, the skin should be washed immediately and thoroughly with soap and water. If lenalidomide makes contact with the mucous membranes, they should be thoroughly flushed with water.</p><p>Healthcare professionals and caregivers should wear disposable gloves when handling the blister or capsule.</p><p>&nbsp;</p><p>Gloves should then be removed carefully to prevent skin exposure, placed in a sealable plastic polyethylene bag and disposed of in accordance with local requirements. Hands should then be washed thoroughly with soap and water. Women who are pregnant or suspect they may be pregnant should not handle the blister or capsule (see section 4.4).</p><p>&nbsp;</p><p>Any unused product or waste material should be returned to the pharmacist for safe disposal in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing authorization holder
Sudair Pharma Company (SPC)
King Fahad road, Riyadh Gallery - Building A1, Riyadh, Saudi Arabia
Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 12363 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>